

Bilag 1

Rank	Title	Study Results	Conditions	Interventions	Locations	URL
1	Talampanel for Amyotrophic Lateral Sclerosis (ALS)	Available	ALS	Drug: Talampanel Other: placebo	CA Medical Center for Movement Disorders-Forbes Norris MDA/ALS Research Center, San Francisco, California, United States University of Kansas Medical Center - Dept of Neurology, Kansas City, Kansas, United States Johns Hopkins OPC - Meyer Bldg, Baltimore, Maryland, United States Massachusetts General Hospital-Neurology Clinical Trials Unit, Charlestown, Massachusetts, United States Mayo Clinic, Rochester, Minnesota, United States Columbia University - Neurology Institute, New York, New York, United States SUNY Upstate Medical University, Syracuse, New York, United States Academic Hospital University of Leuven - ALS dept, Leuven, Belgium ALS Centre, Vancouver, British Columbia, Canada London Health Sciences Centre Motor Neuro Diseases Clinic, London, Ontario, Canada Montreal Neurological Institute, Montreal, Quebec, Canada C.H.U. La Timone - Service de Neurologie, Marseille Cedex 5, France C.H.U. de Montpellier - Hôpital Gui de Chauliac - Service des Explorations Neurologiques, Montpellier Cedex 5, France Hôpital La Pitié Salpêtrière - Fédération de Neurologie, Paris, France Universitätsklinik Berlin-Charité, Campus Virchow Klinikum, Neurologische Klinik, Berlin, Germany Berufsgenossenschaftliche Klinik Bergmannsheil, Neurologische Klinik, Bochum, Germany Universität Ulm, Ulm, Germany Semmelweis University, Department of Neurology, Budapest, Hungary Sourasky MC - EMG Unit, Tel Aviv, Israel Fondazione "S. Maugeri" Clinica della Riabilitazione IRCCS-Istituto Scientifico di Lissone, Lissone (MI), Italy Centro Clinico NEMO, Milano, Italy Azienda Ospedaliera Universitaria San Giovanni Battista di Torino - Dipartimento di Neuroscienze, Torino, Italy Universitair Medisch Centrum Utrecht, Utrecht, Netherlands Hospital Carlos III, Madrid, Spain	https://ClinicalTrials.gov/show/NCT00696332
2	Evaluation of Metabonomic Analysis in Early Diagnosis of ALS	No Results Available	ALS	Procedure: lumbar puncture	Pôle Neurosciences et Spécialisées, Service de Neurologie, CHU d'Angers, Angers, France Service de Neurologie et Pathologie du Mouvement Clinique de Neurologie, Pôle des Neurosciences et de l'Appareil Locomoteur INSERM U 837, Lille, France Service de Neurologie et Centre SLA, CHU de Limoges, EA2174 Université de Limoges - Faculté de Médecine, Limoges, France Centre SLA, CHU Gui de Chauliac, Université de Montpellier 1, Montpellier, France Centre de Recherche de l'Institut du Cerveau et de la moëlle LPMC Paris 6, Département des Maladies du Système Nerveux, Paris, France Service de neurologie, CHU La Milétrie, POITIERS, Faculté de Médecine, Poitiers, France University Hospital, Strasbourg, France CHRU - TOURS-Service de Neurologie, Tours, France	https://ClinicalTrials.gov/show/NCT01962311
3	Safety of Caprylic Triglycerides in ALS: A Pilot Study	No Results Available	ALS	Dietary Supplement: Axona	Weill Cornell Medical Center, New York, New York, United States	https://ClinicalTrials.gov/show/NCT02716662
4	A Study for Patients Who Completed VITALITY-ALS (CY 4 4031)	No Results Available	Amyotrophic Lateral Sclerosis (ALS)	Drug: tirazemtiv	St. Joseph's Hospital and Medical Center - Barrow Neurology Clinics, Phoenix, Arizona, United States Cedars-Sinai Medical Center, Los Angeles, California, United States University of California, Irvine, Orange, California, United States UC Davis Medical Center, Sacramento, California, United States Forbes Norris MDA/ALS Research Center, San Francisco, California, United States Stanford Hospital and Clinics, Stanford, California, United States University of Colorado Hospital Anschutz Outpatient Pavilion, Aurora, Colorado, United States Hospital for Special Care, New Britain, Connecticut, United States George Washington University Medical Center, Washington, District of Columbia, United States Mayo Clinic, Jacksonville, Florida, United States University of Miami, Miller School of Medicine, Miami, Florida, United States Carol & Frank Mossman Center for Advanced Health Care - University of South Florida, Tampa, Florida, United States The Emory Clinic, Atlanta, Georgia, United States Indiana University, Indianapolis, Indiana, United States University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States University of Kansas Medical Center, Kansas City, Kansas, United States Johns Hopkins University, Baltimore, Maryland, United States University of Massachusetts Medical School, Worcester, Massachusetts, United States University of Michigan Health System, Ann Arbor, Michigan, United States Henry Ford Health System, Detroit, Michigan, United States Hennepin County Medical Center, Minneapolis, Minnesota, United States St. Louis University, Department of Neurology & Psychiatry, Saint Louis, Missouri, United States Barnes-Jewish Hospital, Saint Louis, Missouri, United States Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States Hospital for Special Surgery, New York, New York, United States Neurological Institute, New York, New York, United States SUNY Upstate Medical University, Syracuse, New York, United States Neurosciences Institute, Neurology - Charlotte, Charlotte, North Carolina, United States Duke Neurological Disorders Clinic, Durham, North Carolina, United States Department of Neurology, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States The Ohio State University Wexner Medical Center, Columbus, Ohio, United States Providence Brain and Spine Inst. ALS Center, Portland, Oregon, United States Penn State Milton S. HERSHEY Medical Center, Hershey, Pennsylvania, United States Temple University School of Medicine, Philadelphia, Pennsylvania, United States Vanderbilt University Medical Center - Clinical Research Center, Nashville, Tennessee, United States Texas Neurology, PA, Dallas, Texas, United States UTHSCSA - First Outpatient Research Unit, San Antonio, Texas, United States University of Virginia Health System, Charlottesville, Virginia, United States University of Washington Medical Center, Seattle, Washington, United States West Virginia University Hospitals, Morgantown, West Virginia, United States Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States UZ Leuven, Leuven, Vlaams Brabant, Belgium University of Calgary, Calgary, Alberta, Canada University of Alberta, Edmonton, Alberta, Canada Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, Canada QE II Health Sciences, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada McMaster University Medical Centre, Hamilton, Ontario, Canada London Health Sciences Centre, London, Ontario, Canada Sunnybrook Health Sciences Center, Toronto, Ontario, Canada Hopital Notre-Dame/CHUM, Montreal, Quebec, Canada Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada CHU de Quebec - Université Laval, Quebec, Canada Hopital Dupuytren, service de neurologie, Limoges Cedex, France Hopital Gui de Chauliac, Montpellier Cedex 5, France CHU de Nice - Hôpital Pasteur 2, Nice Cedex 1, France Hopital Bretonneau, Tours cedex 9, France University of Ulm, Department of Neurology, Ulm, Baden-Wuerttemberg, Germany Hannover Medical School, Department of Neurology, Hannover, Lower Saxony, Germany Charité Campus Virchow-Klinikum, Department of Neurology, Berlin, Germany Clinical Research Centre Beaumont Hospital, Dublin, Ireland IRCCS Istituto Auxologico Italiano - U.O. Neurologia, Milan, Lombardy, Italy Centro Clinico NEMO - Fondazione Serena Onlus, ASST Grande Ospedale Metropolitano Niguarda, Ospedale Niguarda, Milan, Lombardy, Italy Dipartimento di Neuroscienze "Rita Levi Montalcini" A.O.U. Città della Salute e della Scienza di Torino P.O. "Molinette", Torino, Piemonte, Italy University Medical Center Utrecht, Utrecht, Netherlands Hospital Santa Maria - Centro Hospitalar Lisboa Norte, Lisboa, Portugal Hospital San Rafael, Madrid, Spain King's College Hospital NHS Foundation Trust, London, United Kingdom	https://ClinicalTrials.gov/show/NCT02936635
5	ALS Reversals - Lunasin 5 Regimen	Has Results	ALS (Amyotrophic Lateral Sclerosis)	Drug: Lunasin Regimen Other: Historical control	Duke Medicine / Neurology, Durham, North Carolina, United States	https://ClinicalTrials.gov/show/NCT02709930
6	Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)	Has Results	Amyotrophic Lateral Sclerosis (ALS)	Drug: Basiliximab Drug: Methylprednisolone Drug: Prednisone Drug: Tacrolimus Drug: Mycophenolate mofetil	Emory University, Atlanta, Georgia, United States Massachusetts General Hospital, Boston, Massachusetts, United States University of Massachusetts Medical School, Worcester, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT01884571
7	New Perspectives of Adaptation to NIV in ALS Phase 2, Randomized, Double Blind, Placebo Controlled	No Results Available	Amyotrophic Lateral Sclerosis (ALS)	Other: Adaptation and training to Non Invasive Ventilation (NIV)	Michele Vitacca, Lumezzane, Brescia, Italy Paolo Banfi, Milan, Italy	https://ClinicalTrials.gov/show/NCT02537132
8	Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS	No Results Available	Amyotrophic Lateral Sclerosis (ALS)	Biological: Autologous MSC-NTF cells Biological: Placebo	Massachusetts General Hospital, Boston, Massachusetts, United States UMass Medical School, Worcester, Massachusetts, United States Mayo Clinic, Rochester, Minnesota, United States	https://ClinicalTrials.gov/show/NCT02019121

A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis 9 (ALS)	No Results Available	ALS	Drug: RNS60	Massachusetts General Hospital, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT02525471
Clinical Trial Nuedexta in 10 Subjects With ALS	Has Results	Amyotrophic Lateral Sclerosis (ALS)	Drug: Nuedexta Drug: Matching Placebo	California Pacific Medical Center, San Francisco, California, United States Georgetown University Medical Center, Washington D.C., District of Columbia, United States Saint Mary's Health Care, Grand Rapids, Michigan, United States Hennepin County Medical Center, Minneapolis, Minnesota, United States Neurology Associates, P.C., Lincoln, Nebraska, United States The Cleveland Clinic, Cleveland, Ohio, United States Providence ALS Center, Portland, Oregon, United States	https://ClinicalTrials.gov/show/NCT01806857
11 PET Imaging in ALS Patients	No Results Available	Amyotrophic Lateral Sclerosis (ALS)	Other: PET Scanning	Johns Hopkins University, Baltimore, Maryland, United States	https://ClinicalTrials.gov/show/NCT02236897
A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Amyotrophic Lateral Sclerosis (ALS)	Drug: ONO-2506PO	Prof. Maloteaux, UCL Saint-Luc, Brussels, Belgium Prof. Wim Robberecht, UZ Leuven, Leuven, Belgium Prof. Alain Destee, Hopital Roger Salengro - Clinique Neurologique, Neurologie A, Lille Cedex, France Prof. Philippe Couratier, Hopital Dursuytren, Limoges Cedex, France Prof. Jan Pouget, Hopital de la Timone, Marseille, France Prof. William Camu, Hopital de Chuailaz, Montpellier cedex 5, France Prof. Claude Desnuelle, Hopital 1-Archet 1, Nice cedex 3, France Prof. Vincent Meininger, Hopital LaPitite Salpêtrière, Paris, France Dr. Thomas Meyer, Charité Campus Virchow, ALS Ambulanz, Berlin, Germany Prof. Torsten Grehl, Neurologische Ambulanz Universitätsklinik Bergmannsheil, Bochum, Germany Professor Dieter Heuss, Poliklinik der Universität Erlangen-Nürnberg, Neurologische Klinik, Erlangen, Germany Prof. Stephan Zierz, Martin Luther Universität Halle-Wittenberg, Klinikum der Medizinischen Fakultät, Universitätsklinik und Poliklinik für Neurologie, Halle, Germany Prof. Reinhard Dangler, Medizinische Hochschule Hannover, Neurologische Klinik, Hannover, Germany Prof. Gian Domenico Borasio, Interdisciplinare Zentrum für Palliativmedizin, München, Germany Prof. Albert Ludolph, Klinik und Poliklinik für Neurologie der Universität Ulm-Universitätsklinikum Ulm, Ulm, Germany Dr. Berthold Schrank, Deutsche Klinik für Diagnostik, Fachbereich Neurologie, Wiesbaden, Germany Prof. Vincenzo Silani, Dipartimento di Neurologia e Laboratorio di Neuroscienze - Università di Milano - IRCCS - Istituto Auxologico Italiano, Milano, Italy Dr. Gabriele Mora, Divisione di Neuroriabilitazione II - Fondazione Salvatore Maugeri - IRCCS, Pavia, Italy Prof. Adriano Chio, Dipartimento di Neuroscienze - Divisione di Neurologia II - Azienda Ospedaliera S. Giovanni Battista - Molinette, Torino, Italy Prof. Marianne de Visser, Academic Medical Centre (AMC) Amsterdam - Dept of Neurology, Amsterdam, Netherlands Prof. Leonard H Van Den Berg, University Medical Center Utrecht, Utrecht, Netherlands Dr. Markus Weber, Kantonsspital St. Gallen, Muskelzentrum/ALS Clinic, St. Gallen, Switzerland Prof. Nigel Leigh, Academic Neuroscience Centre, London, United Kingdom Prof. Douglas Mitchell, Royal Preston Hospital, Preston, United Kingdom Dr. Chris McDermott, Royal Hallamshire Hospital, Sheffield, United Kingdom	https://ClinicalTrials.gov/show/NCT00694941
Clinical Trial Ceftriaxone in 13 Subjects With ALS	Has Results	Amyotrophic Lateral Sclerosis ALS	Drug: ceftriaxone Other: placebo	Phoenix Neurological Associates, Phoenix, Arizona, United States University of California, Davis, Davis, California, United States University of California, San Francisco- Fresno, Fresno, California, United States Loma Linda University School of Medicine (CA), Loma Linda, California, United States Cedars-Sinai Medical Center, Los Angeles, California, United States University of California, Los Angeles, Los Angeles, California, United States University of California, Irvine - MDA ALS Neuromuscular Center, Orange, California, United States California Pacific Medical Center, San Francisco, California, United States Mayo Clinic, San Francisco, San Francisco, California, United States University of Colorado Health Sciences Center, Aurora, Colorado, United States Hospital for Special Care, New Britain, Connecticut, United States George Washington University, Washington, District of Columbia, United States Mayo Clinic Jacksonville, Jacksonville, Florida, United States University of Miami School of Medicine, Miami, Florida, United States ALS Center at Emory University, Atlanta, Georgia, United States Medical College of Georgia, Augusta, Georgia, United States Northwestern University Medical School, Chicago, Illinois, United States Indiana University (Regenstrief Health Center), Indianapolis, Indiana, United States University of Kansas Medical Center, Kansas City, Kansas, United States University of Kentucky Medical Center, Lexington, Kentucky, United States Massachusetts General Hospital, Boston, Massachusetts, United States Lahey Clinic, Burlington, Massachusetts, United States Henry Ford Health System, Detroit, Michigan, United States Saint Mary's Healthcare, Grand Rapids, Michigan, United States Hennepin County Medical Center (Berman Center), Minneapolis, Minnesota, United States St. Louis University, St. Louis, Missouri, United States Washington University, St. Louis, Missouri, United States Bryan LGH Medical Center (University of Nebraska), Lincoln, Nebraska, United States UMDNJ- Robert Wood Johnson School of Medicine, New Brunswick, New Jersey, United States Albany Medical Center, Albany, New York, United States Beth Israel Medical Center (NY), New York, New York, United States Cornell Medical Center, New York, New York, United States Columbia University, New York, New York, United States SUNY Upstate Medical University, Syracuse, New York, United States Carolinas Medical Center, Charlotte, North Carolina, United States Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States The Cleveland Clinic Foundation, Cleveland, Ohio, United States Ohio State University, Columbus, Ohio, United States Oregon Clinic (Providence Clinic), Portland, Oregon, United States Pennsylvania State University, Hershey Medical Center, Hershey, Pennsylvania, United States Drexel University College of Medicine (Hahnemann Campus), Philadelphia, Pennsylvania, United States University of Pennsylvania, Philadelphia, Pennsylvania, United States Allegheny Hospital, Pittsburgh, Pennsylvania, United States University of Pittsburgh, Pittsburgh, Pennsylvania, United States Medical University of South Carolina, Charleston, South Carolina, United States Vanderbilt University, Nashville, Tennessee, United States Texas Neurology, Dallas, Texas, United States Methodist Neurological Institute, Houston, Texas, United States University of Utah Health Sciences Center, Salt Lake City, Utah, United States University of Virginia, Charlottesville, Virginia, United States University of Calgary, Calgary, Alberta, Canada University of Alberta ALS Clinic, Edmonton, Alberta, Canada Dalhousie University, Halifax, Nova Scotia, Canada London Health Sciences Center, University Campus, London, Ontario, Canada University of Toronto, Toronto, Ontario, Canada CHUM (Centre Hospitalier de l'Université de Montréal) de Montréal, Notre-Dame Hospital, Montreal, Quebec, Canada Montreal Neurological Institute (McGill University), Montreal, Quebec, Canada Laval University, Quebec City, Quebec, Canada	https://ClinicalTrials.gov/show/NCT00349622

<p>Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)</p>	<p>No Results Available</p>	<p>Amyotrophic Lateral Sclerosis (ALS) Drug: ONO-2506PO</p>	<p>L. Boltzmann Forschungsinstitut, Neurologische Abteilung, Kaiser Franz Josef Hospital, Wien, Wien, Austria UCL Saint-Luc, Brussels, Belgium UZ Leuven, Leuven, Belgium Hopital Roger Salengro - Clinique Neurologique, Neurologie A, Lille Cedex, France Hopital Duruytren, Limoges Cedex, France Hopital de la Timone, Marseille, France Hopital de Chaullac, Montpellier cedex 5, France Hopital I-Archet 1, Nice cedex 3, France Hopital LaPitie Salpêtrière, Paris, France Charite Campus Virchow, ALS Ambulanz, Berlin, Germany Neurologische Universitätsklinik Bergmannsheil, Bochum, Germany Poliklinik der Universität Erlangen-Nürnberg, Neurologische Klinik, Erlangen, Germany Martin-Luther-Universität Halle-Wittenberg, Klinikum der Medizinischen Fakultät, Universitätsklinik und Poliklinik für Neurologie, Halle, Germany Medizinische Hochschule Hannover, Neurologische Klinik, Hannover, Germany Interdisziplinäres Zentrum für Palliativmedizin, München, Germany Klinik und Poliklinik für Neurologie der Universität Ulm - Universitätsklinikum Ulm, Ulm, Germany Deutsche Klinik für Diagnostik, Fachbereich Neurologie, Wiesbaden, Germany Dipartimento di Neurologia e Laboratorio di Neuroscienze - Università di Milano - IRCCS - Istituto Auxologico Italiano, Milano, Italy Divisione di Neuroriabilitazione II - Fondazione Salvatore Maugeri - IRCCS, Pavia, Italy Dipartimento di Neuroscienze - Divisione di Neurologia II - Azienda Ospedaliera S. Giovanni Battista - Molinette, Torino, Italy Academic Medical Centre (AMC) Amsterdam - Dept of Neurology, Amsterdam, Netherlands University Medical Center Utrecht, Utrecht, Netherlands Kantonsspital St. Gallen, Muskelzentrum/ALS Clinic, St. Gallen, Switzerland Academic Neuroscience Centre, London, United Kingdom Royal Preston Hospital, Preston, United Kingdom University of Sheffield - Academic Neurology Unit, Sheffield, United Kingdom</p>	<p>https://ClinicalTrials.gov/show/NCT00403104</p>
<p>A Study in Patients With Amyotrophic Lateral Sclerosis (ALS)</p>	<p>No Results Available</p>	<p>Amyotrophic Lateral Sclerosis (ALS) Drug: E0302 (mecobalamin) Drug: Placebo</p>	<p>Nagoya-shi, Aichi, Japan Akita-shi, Akita, Japan Aomori-shi, Aomori, Japan Chiba-shi, Chiba, Japan Touon-shi, Ehime, Japan Fukuoka-shi, Fukuoka, Japan Kitakyusyu-shi, Fukuoka, Japan Fukushima-shi, Fukushima, Japan Maebashi-shi, Gunma, Japan Higashihiroshima-shi, Hiroshima, Japan Miyoshi-shi, Hiroshima, Japan Otake-shi, Hiroshima, Japan Sapporo-shi, Hokkaido, Japan Kanazawa-shi, Ishikawa, Japan Ichinoseki-shi, Iwate, Japan Sagami-hara-shi, Kanagawa, Japan Yokohama-shi, Kanagawa, Japan Nangoku-shi, Kochi, Japan Kyoto-shi, Kyoto, Japan Tsu-shi, Mie, Japan Sendai-shi, Miyagi, Japan Watarai-gun, Miyagi, Japan Nagano-shi, Nagano, Japan Higashisonogi-gun, Nagasaki, Japan Kashiwazaki-shi, Niigata, Japan Niigata-shi, Niigata, Japan Tsukuba-gun, Okayama, Japan Ginowan-shi, Okinawa, Japan Toyonaka-shi, Osaka, Japan Hasuda-shi, Saitama, Japan Saitama-shi, Saitama, Japan Otsu-shi, Shiga, Japan Hamamatsu-shi, Shizuoka, Japan Shizuoka-shi, Shizuoka, Japan Shimotsuke-shi, Tochigi, Japan Tokushima-shi, Tokushima, Japan Yoshinogawa-shi, Tokushima, Japan Bunkyo-ku, Tokyo, Japan Kodaira-shi, Tokyo, Japan Ota-ku, Tokyo, Japan Wakayama-shi, Wakayama, Japan Yonezawa-shi, Yamagata, Japan Shimonoeki-shi, Yamaguchi, Japan Yanai-shi, Yamaguchi, Japan</p>	<p>https://ClinicalTrials.gov/show/NCT00444613</p>
<p>Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis</p>	<p>Has Results</p>	<p>Amyotrophic Lateral Sclerosis (ALS) Drug: MCI-186 Drug: Placebo Drug: MCI-186 in open label phase</p>	<p>Osaka, Japan</p>	<p>https://ClinicalTrials.gov/show/NCT01492686</p>
<p>Phase II Study Using Thalidomide for the Treatment of ALS</p>	<p>No Results Available</p>	<p>Amyotrophic Lateral Sclerosis (ALS) Drug: Thalidomide</p>	<p>Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States</p>	<p>https://ClinicalTrials.gov/show/NCT00140452</p>
<p>A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)</p>	<p>No Results Available</p>	<p>Amyotrophic Lateral Sclerosis (ALS) Drug: E0302 (mecobalamin)</p>	<p>Nagoya-shi, Aichi, Japan Aomori-shi, Aomori, Japan Chiba-shi, Chiba, Japan Touon-shi, Ehime, Japan Fukuoka-shi, Fukuoka, Japan Kitakyusyu-shi, Fukuoka, Japan Fukushima-shi, Fukushima, Japan Maebashi-shi, Gunma, Japan Higashihiroshima-shi, Hiroshima, Japan Miyoshi-shi, Hiroshima, Japan Otake-shi, Hiroshima, Japan Sapporo-shi, Hokkaido, Japan Kanazawa-shi, Ishikawa, Japan Ichinoseki-shi, Iwate, Japan Sagami-hara-shi, Kanagawa, Japan Yokohama-shi, Kanagawa, Japan Nangoku-shi, Kochi, Japan Kyoto-shi, Kyoto, Japan Tsu-shi, Mie, Japan Sendai-shi, Miyagi, Japan Watarai-gun, Miyagi, Japan Nagano-shi, Nagano, Japan Higashisonogi-gun, Nagasaki, Japan Kashiwazaki-shi, Niigata, Japan Niigata-shi, Niigata, Japan Tsukuba-gun, Okayama, Japan Ginowan-shi, Okinawa, Japan Toyonaka-shi, Osaka, Japan Hasuda-shi, Saitama, Japan Saitama-shi, Saitama, Japan Hamamatsu-shi, Shizuoka, Japan Shizuoka-shi, Shizuoka, Japan Shimotsuke-shi, Tochigi, Japan Tokushima-shi, Tokushima, Japan Yoshinogawa-shi, Tokushima, Japan Bunkyo-ku, Tokyo, Japan Kodaira-shi, Tokyo, Japan Ota-ku, Tokyo, Japan Wakayama-shi, Wakayama, Japan Yonezawa-shi, Yamagata, Japan Shimonoeki-shi, Yamaguchi, Japan Yanai-shi, Yamaguchi, Japan</p>	<p>https://ClinicalTrials.gov/show/NCT00445172</p>

19	Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)	Has Results Available	Amyotrophic Lateral Sclerosis (ALS)	Drug: rasagiline	Phoenix Neurological Institute, Phoenix, Arizona, United States California Pacific Medical Center, San Francisco, California, United States University of Iowa, Iowa City, Iowa, United States University Of Kansas Medical Center, Kansas City, Kansas, United States University of Minnesota, Minneapolis, Minnesota, United States University of Nebraska Medical Center, Omaha, Nebraska, United States University of Pennsylvania, Philadelphia, Pennsylvania, United States University of Tennessee, Memphis, Tennessee, United States The Methodist Hospital System, Houston, Texas, United States McGill University, Montreal, Quebec, Canada	https://ClinicalTrials.gov/show/NCT01232738
20	Optimizing NIPPV Use for Patients With ALS	No Results Available	ALS	Behavioral: Data Card Report	University of Pittsburgh, Pittsburgh, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT01035476
21	Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)	Has Results Available	Amyotrophic Lateral Sclerosis (ALS)	Drug: MCI-186 Drug: Placebo of MCI-186	National Hospital Organization Miyagi National Hospital, Watari-gun, Miyagi-ken, Japan	https://ClinicalTrials.gov/show/NCT00424663
22	Intravenous Injection of Adipose Derived Mesenchymal Stem Cell for ALS	No Results Available	Amyotrophic Lateral Sclerosis	Biological: mesenchymal stem cells	Royan Institute, Tehran, Iran, Islamic Republic of	https://ClinicalTrials.gov/show/NCT02492516
23	A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS	No Results Available	Amyotrophic Lateral Sclerosis (ALS)	Drug: arimoclomol	University of California, Irvine Medical Center, Irvine, California, United States University of Miami School of Medicine, Miami, Florida, United States University of Kansas Medical Center, Kansas City, Kansas, United States Massachusetts General Hospital, Boston, Massachusetts, United States Hennepin Faculty Associates/Berman Center, Minneapolis, Minnesota, United States SUNY Upstate Medical University, Syracuse, New York, United States Duke University, Durham, North Carolina, United States Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States Drexel University College of Medicine, Philadelphia, Pennsylvania, United States University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States	https://ClinicalTrials.gov/show/NCT00244244
24	Tamoxifen Therapy in Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Amyotrophic Lateral Sclerosis (ALS)	Drug: Tamoxifen	University of Wisconsin, Madison, Wisconsin, United States	https://ClinicalTrials.gov/show/NCT00214110
25	Intrathecal Transplantation of Mesenchymal Stem Cell in Patients With ALS	No Results Available	Amyotrophic Lateral Sclerosis	Biological: intrathecal injection	Royan Institute, Tehran, Iran, Islamic Republic of	https://ClinicalTrials.gov/show/NCT01771640
26	Intravenous Transplantation of Mesenchymal Stem Cell in Patients With ALS	No Results Available	Amyotrophic Lateral Sclerosis	Biological: intra venous injection of stem cell	Royan Institute, Tehran, Iran, Islamic Republic of	https://ClinicalTrials.gov/show/NCT01759797
27	Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Amyotrophic Lateral Sclerosis (ALS)	Drug: Masitinib (4.5) Drug: Riluzole Drug: Placebo Drug: Masitinib (3.0)	Hospital Carlos III, Madrid, Spain	https://ClinicalTrials.gov/show/NCT02588677
28	Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity	Has Results Available	Amyotrophic Lateral Sclerosis (ALS)	Drug: MCI-186 Drug: Placebo of MCI-186		https://ClinicalTrials.gov/show/NCT00330681
29	Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III	Has Results Available	Amyotrophic Lateral Sclerosis (ALS)	Drug: MCI-186 Drug: Placebo of MCI-186		https://ClinicalTrials.gov/show/NCT00415519
30	Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Biological: intrathecal autologous stem cell	Servicio Hematología Hospital Universitario, Monterrey, Nuevo LeA^n, Mexico	https://ClinicalTrials.gov/show/NCT01933321

A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Drug: NP001 Drug: Placebo	Mayo Clinic, Scottsdale, Scottsdale, Arizona, United States UC, Irvine, Irvine, California, United States UCLA, Los Angeles, California, United States California Pacific Med Center Forbes Norris MDA/ALS Research and Treatment Center, San Francisco, California, United States Mayo Clinic, Jacksonville, Jacksonville, Florida, United States The Emory Clinic, Atlanta, Georgia, United States University of Kansas Medical Center, Landon Center on Aging, Kansas City, Kansas, United States University of Kentucky, Department of Neurology, Lexington, Kentucky, United States Massachusetts General Hospital, Charlestown, Massachusetts, United States Columbia University, New York, New York, United States SUNY Upstate Medical University, Syracuse, Syracuse, New York, United States Carolinas Medical Center, Charlotte, North Carolina, United States Duke University, Dept of Neurology, Durham, North Carolina, United States Cleveland Clinic, Cleveland, Ohio, United States Providence ALS Center, Portland, Oregon, United States Methodist Hospital Research Institute, Methodist Neurologic Institute, Houston, Texas, United States Providence Saint Peter Hospital, Centralia, Washington, United States	https://ClinicalTrials.gov/show/NCT01281631
A Trial of Tocilizumab in ALS Subjects	No Results Available	ALS Amyotrophic Lateral Sclerosis Lou Gehrig's Disease Motor Neuron Disease	Drug: Tocilizumab Other: Placebo	Barrow Neurological Institute, Phoenix, Arizona, United States University of Kansas Medical Center, Kansas City, Kansas, United States Massachusetts General Hospital, Boston, Massachusetts, United States Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States Penn State College of Medicine Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT02469896
Neuromuscular Magnetic Stimulation in ALS Patients	No Results Available	Amyotrophic Lateral Sclerosis	Device: Neuromuscular magnetic stimulation (NMMS)		https://ClinicalTrials.gov/show/NCT03618966
Gilenya in Amyotrophic Lateral Sclerosis (ALS)	Has Results Available	Amyotrophic Lateral Sclerosis	Drug: Gilenya Other: Placebo	University of California, Irvine, Orange, California, United States Georgia Regents University, Augusta, Georgia, United States Massachusetts General Hospital, Boston, Massachusetts, United States Methodist Neurological Institute, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT01786174
Safety Study of High Doses of Zinc in ALS Patients	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Zinc and Copper	Phoenix Neurological Associates, Phoenix, Arizona, United States	https://ClinicalTrials.gov/show/NCT01259050
SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)	Has Results Available	Familial Amyotrophic Lateral Sclerosis	Drug: Pyrimethamine	Weill Cornell Medical Center/New York Presbyterian Hospital, New York, New York, United States Methodist Neurological Institute, Houston, Texas, United States Universitäts- und Rehabilitationsklinik Ulm, Ulm, Germany Milano Neurological Institute, Milan, Italy Umea University, Umea, Sweden	https://ClinicalTrials.gov/show/NCT01083667
Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Drug: GM604 Drug: Placebo comparator	Massachusetts General Hospital, Boston, Massachusetts, United States Columbia Medical Center NY, New York, New York, United States	https://ClinicalTrials.gov/show/NCT01854294
Safety and Feasibility of the EyeControl Device A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)	No Results Available	ALS (Amyotrophic Lateral Sclerosis)	Device: EyeControl device		https://ClinicalTrials.gov/show/NCT02891629
The Effect of GCSF in the Treatment of ALS Patients	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Granulocyte Colony Stimulating Factor Drug: Placebo	Iranian Neurology Research Center of Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of	https://ClinicalTrials.gov/show/NCT01825551
Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Other: Resistance Exercise Other: Endurance Exercise Other: Stretching/Range-of-Motion	Cedars-Sinai Medical Center, Los Angeles, California, United States Johns Hopkins University, Baltimore, Maryland, United States Massachusetts General Hospital, Charlestown, Massachusetts, United States Carolinas Medical Center, Charlotte, North Carolina, United States	https://ClinicalTrials.gov/show/NCT01521728
Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS	No Results Available	Amyotrophic Lateral Sclerosis	Drug: endocannabinoid palmitoylethanolamide (PEA) Drug: Riluzole		https://ClinicalTrials.gov/show/NCT02645461
Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Other: telesurveillance	Michele Vitacca, Lumezzane, BS, Italy	https://ClinicalTrials.gov/show/NCT00613899
Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis	Has Results Available	Amyotrophic Lateral Sclerosis ALS	Biological: HYNR-CS in Other: Control group	Hanyang University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01363401
Sport Therapy and Osteopathy Manipulative Treatment in ALS	No Results Available	Amyotrophic Lateral Sclerosis	Other: Sport therapy Other: Osteopathic treatment		https://ClinicalTrials.gov/show/NCT02548663

A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)	Has Results	Amyotrophic Lateral Sclerosis	Drug: Inosine	Massachusetts General Hospital, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT02288091
Developing a Discrimination Model to Diagnose ALS	No Results Available	Amyotrophic Lateral Sclerosis	Diagnostic Test: MRI(magnetic resonance imaging)	University of Michigan Hospital, Ann Arbor, Michigan, United States	https://ClinicalTrials.gov/show/NCT01995903
A New Eye-based Communication Device for ALS Patients	No Results Available	Amyotrophic Lateral Sclerosis	Device: EOL (Eye On Line)	Groupe Hospitalier Pitié Salpêtrière, Paris, France	https://ClinicalTrials.gov/show/NCT02313402
Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement	No Results Available	Amyotrophic Lateral Sclerosis	Device: noninvasive positive pressure ventilation	Johns Hopkins University School of Medicine, Baltimore, Maryland, United States	https://ClinicalTrials.gov/show/NCT00386464
Safety and Efficacy Study of Crestine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS)	Has Results	Amyotrophic Lateral Sclerosis	Drug: cretine [Drug: tamoxifen]	University of Kansas Medical Center, Kansas City, Kansas, United States Massachusetts General Hospital, Boston, Massachusetts, United States University of Massachusetts Medical Center, Worcester, Massachusetts, United States Washington University at St. Louis, St. Louis, Missouri, United States SUNY Upstate Medical University, Syracuse, New York, United States Carolinas Medical Center, Charlotte, North Carolina, United States Pennsylvania State University, Hershey Medical Center, Hershey, Pennsylvania, United States University of Washington Medical Center, Seattle, Washington, United States Medical College of Wisconsin, Milwaukee, Wisconsin, United States	https://ClinicalTrials.gov/show/NCT01257581
Memantine Therapy in Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Memantine	Phoenix Neurological Associates, LTD, Phoenix, Arizona, United States	https://ClinicalTrials.gov/show/NCT01020331
Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Device: Micro Mouth Pressure Meter [Device: Iowa Oral Performance Instrument] [Device: Electrical Impedance Myography] [Drug: Capsaicin] [Procedure: Videofluoroscopic Swallowing Study] [Procedure: Pulmonary Function Testing] [Other: Swallowing Related Quality of Life Questionnaire] [Other: Functional Oral Intake Scale] [Other: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised] [Other: Eating Assessment Tool-10] [Other: Communicative Effectiveness Survey] [Other: The Center for Neurologic Studies Bulbar Function Scale	University of Florida, Gainesville, Florida, United States	https://ClinicalTrials.gov/show/NCT02710162
Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation	No Results Available	Amyotrophic Lateral Sclerosis	Drug: NP001 [Drug: Placebo]	St. Joseph's Hospital and Medical Center - Barrow Neurology Clinics, Phoenix, Arizona, United States Mayo Clinic Arizona, Scottsdale, Arizona, United States Cedars-Sinai Medical Center, Los Angeles, California, United States University of California, Irvine, Department of Neurology, Orange, California, United States Forbes Norris MDA/ALS Research Center, CPAC, San Francisco, California, United States Mayo Clinic Florida, Jacksonville, Florida, United States University of Miami Miller School of Medicine, Miami, Florida, United States Emory University, Department of Neurology, Atlanta, Georgia, United States University of Kansas Medical Center, Kansas City, Kansas, United States University of Kentucky, Albert B. Chandler Medical Center, Lexington, Kentucky, United States Massachusetts General Hospital, Boston, Massachusetts, United States Clinical & Translational Science Institute, University of Minnesota, Minneapolis, Minnesota, United States Washington University School of Medicine, Saint Louis, Missouri, United States Columbia University Medical Center, New York, New York, United States Carolinas Medical Center, Neurosciences Institute-Neurology, Charlotte, North Carolina, United States Duke Neurological Disorders Clinic at Morreene Road, Durham, North Carolina, United States Cleveland Clinic Foundation-Cleveland Clinic Hospital, Cleveland, Ohio, United States The Ohio State University Wexner Medical Center, Columbus, Ohio, United States Providence Brain & Spine Institute, ALS Center, Portland, Oregon, United States Houston Methodist Neurological Institute, Houston, Texas, United States University of Texas Health Sciences Center San Antonio, San Antonio, Texas, United States Montreal Neurological Institute, Montreal, Quebec, Canada	https://ClinicalTrials.gov/show/NCT02794857
Ibutilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Placebo (for MN-166) [Drug: MN-166] [Drug: riluzole]	Carolinas Healthcare System, Dept. of Neurology, Charlotte, North Carolina, United States	https://ClinicalTrials.gov/show/NCT02238626
Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Biological: MSC-NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathecal injection into the CSF	Hadassah Medical Organization, Jerusalem, Israel	https://ClinicalTrials.gov/show/NCT0177646
CARE Canadian ALS Riluzole Evaluation	No Results Available	Lateral Sclerosis	Drug: Riluzole	Sanofi-Aventis, Laval, Quebec, Canada	https://ClinicalTrials.gov/show/NCT00542412
Human Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Biological: Human Neural Stem Cells	Azienda Ospedaliera Santa Maria, Terni, Italy	https://ClinicalTrials.gov/show/NCT01640057

58	Clinical Trial of Ezogabine (Retigabine) in ALS Subjects Trial of Early Noninvasive Ventilation for Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis	Drug: Ezogabine Drug: Placebo	Barrow Neurological Institute, Phoenix, Arizona, United States Cedars-Sinai, Los Angeles, California, United States UC Irvine Medical Center, Orange, California, United States Mayo Clinic in Florida, Jacksonville, Florida, United States Augusta University (Georgia Regents Medical Center), Augusta, Georgia, United States Johns Hopkins Hospital, Baltimore, Maryland, United States Massachusetts General Hospital, Boston, Massachusetts, United States Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States University of Michigan, Ann Arbor, Michigan, United States Hospital for Special Surgery, New York, New York, United States Duke University Hospital, Durham, North Carolina, United States Penn State College of Medicine Milton S. Eshelman Medical Center, Hershey, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT02450552
59	Lateral Sclerosis (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Device: BiPAP ^A S/T System Other: sham-NIPPV	University of Michigan, Ann Arbor, Michigan, United States	https://ClinicalTrials.gov/show/NCT00580593
60	Effect of Motor Rehabilitation Treatment on Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Procedure: Standard motor rehabilitation treatment Procedure: Intensive motor rehabilitation treatment	Department of Neuroscience, S. Anna Hospital, Ferrara, Italy Department of Neuroscience, S. Agostino-Estense Hospital, Modena, Italy Department of Neuroscience, IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy	https://ClinicalTrials.gov/show/NCT02306109
61	Clinical Trial of High Dose CoQ10 in ALS	Has Results	Amyotrophic Lateral Sclerosis Lou Gehrig's Disease	Drug: coenzyme Q10 Drug: Placebo	University of Arkansas for Medical Sciences, Department of Neurology, Little Rock, Arkansas, United States California Pacific Medical Center, San Francisco, California, United States University of California at San Francisco, San Francisco, California, United States University of Colorado Health Sciences, Dept of Neurology, Denver, Colorado, United States Yale University School of Medicine, Department of Neurology, New Haven, Connecticut, United States Northwestern University, Department of Neurology, Chicago, Illinois, United States University of Chicago, Department of Neurology, Chicago, Illinois, United States University of Kansas Medical Center, Kansas City, Kansas, United States University of Kentucky, Dept of Neurology, College of Medicine, Lexington, Kentucky, United States Brigham and Women's Hospital, Department of Neurology, Boston, Massachusetts, United States Baystate Medical Center, Critical Care Research, Springfield, Massachusetts, United States Minneapolis Medical Research Foundation, Minneapolis, Minnesota, United States Washington University in St. Louis School of Medicine, Department of Neurology, St. Louis, Missouri, United States Columbia Presbyterian Medical Center, The Neurological Institute, New York, New York, United States State University of New York Upstate Medical, Neurology Department, Syracuse, New York, United States Cleveland Clinic Foundation, Cleveland, Ohio, United States Drexel University, Dept of Neurology, Philadelphia, Pennsylvania, United States University of Texas, Health Science Center at San Antonio, Division of Neurology, San Antonio, Texas, United States University of Vermont, Neurology Department, Burlington, Vermont, United States	https://ClinicalTrials.gov/show/NCT00243932
62	Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-62 NTF), in ALS Patients.	No Results Available	Amyotrophic Lateral Sclerosis (IM)	Biological: MSC-NTF cells transplantation (IM) Biological: MSC-NTF cells transplantation (IT)	Hadassah Medical Organization, Jerusalem, Israel	https://ClinicalTrials.gov/show/NCT01051882
63	Safety and Efficacy of TR019622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Olesoxime Drug: Placebo Comparator	University Hospital Gasthuisberg - Dept Neurology - Herestraat 49, Leuven, Belgium HCL Hpital Neurologique et Neurochirurgical Pierre Wertheimer - Neurologie C et Laboratoire d'Electromyographie - 59, boulevard Pinel, Bron Cedex, France CHRU de LILLE - Hpital Roger Salengro - Centre SLA-MMN - Sde de Neurologie et Pathologie du Mouvement, Lille, France Centre SLA Limoges - Service de Neurologie, Limoges, France Hpital La Timone - Service Neurologie et Maladies Neuromusculaires, Marseille, France Clinique du Motoneurone - Sde d'Explorations Neurologiques - Hpital Gul de Chaillac, Montpellier, France CHU de Nice - Hpital de l'Archevtre - Centre de Rcherche pour les Maladies Neuromusculaires et la SLA, Nice, France Groupe Hospitalier PITIE-SALPTRIRE - Fdration des Maladies du Systme Nerveux, Paris, France Charit Universittsmedizin Berlin, Campus Virchow-Klinikum, Neurologische Poliklinik Ambulanz fr ALS und andere Motoneuronenerkrankungen, Berlin, Germany Universittsklinik und Poliklinik fr Neurologie - Martin-Luther-Universitt Halle-Wittenberg, Halle, Germany Neurologische Klinik Medizinische Hochschule, Hannover, Germany Universitts- und Rehabilitationsklinik Ulm (RKU) - Neurologische Universittsklinik, Ulm, Germany Hospital Carlos III - Unidad de ELA - Sinesio Delgado, 10, Madrid, Spain King's MND Care and Research Center - Academic Neurosciences Building PO Box 41 Institute of Psychiatry, London, United Kingdom Academic Neurology Unit - University of Sheffield - Section of Neuroscience - Division of Genomic Medicine - School of Medicine and Biomedical Sciences, Sheffield, United Kingdom	https://ClinicalTrials.gov/show/NCT00868166

<p>Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)</p>	<p>No Results Available</p>	<p>Amyotrophic Lateral Sclerosis</p>	<p>Drug: KNS-760704</p>	<p>University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States UCLA, Dept. of Neurology - Neuromuscular/ALS Research Center, Los Angeles, California, United States The Forbes Norris MDA/ALS Research Center, San Francisco, California, United States University of Miami Miller School of Medicine, Miami, Florida, United States University of Kansas Medical Center, Kansas City, Kansas, United States Johns Hopkins University School of Medicine, Baltimore, Maryland, United States Massachusetts General Hospital, Boston, Massachusetts, United States Washington University School of Medicine, Saint Louis, Missouri, United States Bryan LGH Medical Center East, Lincoln, Nebraska, United States Columbia University, Lou Gehrig MDA/ALS Research Center, New York, New York, United States SUNY Upstate Medical University, Syracuse, New York, United States Penn State Hershey Medical Center, Hershey, Pennsylvania, United States Drexel University College Of Medicine, Philadelphia, Pennsylvania, United States University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States Vanderbilt University Medical Center, Nashville, Tennessee, United States University of Texas Health Sciences Center of San Antonio, San Antonio, Texas, United States University of Utah, Salt Lake City, Utah, United States University of Virginia Health System, Charlottesville, Virginia, United States University of Washington, Seattle, Washington, United States</p>	<p>https://ClinicalTrials.gov/show/NCT00931944</p>
<p>Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS)</p>	<p>No Results Available</p>	<p>Amyotrophic Lateral Sclerosis</p>	<p>Drug: KNS-760704 Drug: Placebo</p>	<p>University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States UCLA, Dept. of Neurology - Neuromuscular/ALS Research Center, Los Angeles, California, United States The Forbes Norris MDA/ALS Research Center, San Francisco, California, United States University of Colorado Health Sciences Center, Aurora, Colorado, United States University of Miami Miller School of Medicine, Miami, Florida, United States University of Kansas Medical Center, Kansas City, Kansas, United States Johns Hopkins University School of Medicine, Baltimore, Maryland, United States Massachusetts General Hospital, Boston, Massachusetts, United States Washington University School of Medicine, Saint Louis, Missouri, United States Bryan LGH Medical Center East, Lincoln, Nebraska, United States Columbia University, Lou Gehrig MDA/ALS Research Center, New York, New York, United States SUNY Upstate Medical University, Syracuse, New York, United States Oregon Health Sciences University, Portland, Oregon, United States Penn State Hershey Medical Center, Hershey, Pennsylvania, United States Drexel University College Of Medicine, Philadelphia, Pennsylvania, United States University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States Vanderbilt University Medical Center, Nashville, Tennessee, United States University of Texas Health Sciences Center of San Antonio, San Antonio, Texas, United States University of Utah, Salt Lake City, Utah, United States University of Virginia Health System, Charlottesville, Virginia, United States University of Washington, Seattle, Washington, United States</p>	<p>https://ClinicalTrials.gov/show/NCT00647296</p>
<p>Safety Extension Study of TRO19622 in ALS</p>	<p>No Results Available</p>	<p>Amyotrophic Lateral Sclerosis</p>	<p>Drug: TRO19622</p>	<p>University Hospital Gasthuisberg - Dept Neurology - Herestraat 49, Leuven, Belgium HCL HÃpital Neurologique et Neurochirurgical Pierre Wertheimer - Neurologie C et Laboratoire d'Ãlctromyographie - 59, boulevard Pinel, Bron Cedex, France CHRU de LILLE - HÃpital Roger Salengro - Centre SLA-MMN - Sde de Neurologie et Pathologie du Mouvement, Lille, France Centre SLA Limoges - Service de Neurologie, Limoges, France HÃpital La Timone - Service Neurologie et Maladies Neuromusculaires, Marseille, France Clinique du Motoneurone - Sde d'Explorations Neurologiques - HÃpital Gui de Chaillac, Montpellier, France CHU de Nice - HÃpital de l'Archer 1 - Centre de RÃgÃnÃration pour les Maladies Neuromusculaires et la SLA, Nice, France Groupe Hospitalier Pitié-Salpêtrière - FÃdÃration des Maladies du SystÃme Nerveux, Paris, France CharitÃt UniversitÃtsmedizin Berlin, Campus Virchow-Klinikum, Neurologische Poliklinik Ambulanz fÃr ALS und andere Motoneuronenerkrankungen, Berlin, Germany UniversitÃtsklinik und Poliklinik fÃr Neurologie - Martin-Luther-UniversitÃt Halle-Wittenberg, Halle, Germany Neurologische Klinik Medizinische Hochschule, Hannover, Germany UniversitÃts- und Rehabilitationsklinik Ulm (RKU) - Neurologische UniversitÃtsklinik, Ulm, Germany Hospital Carlos III - Unidad de ELA - Sinecio Delgado, 10, Madrid, Spain King's MND Care and Research Center - Academic Neurosciences Building PO Box 41 Institute of Psychiatry, London, United Kingdom Academic Neurology Unit - University of Sheffield - Section of Neuroscience - Division of Genomic Medicine - School of Medicine and Biomedical Sciences, Sheffield, United Kingdom</p>	<p>https://ClinicalTrials.gov/show/NCT01285583</p>

				Barrow Neurological Institute - St. Joseph's Hospital, Phoenix, Arizona, United States University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States University of California at San Francisco - Fresno, Fresno, California, United States University of California, Irvine, Orange, California, United States University of California, Davis, Sacramento, California, United States California Pacific Medical Center, San Francisco, California, United States Hospital for Special Care, New Britain, Connecticut, United States Mayo Clinic - Jacksonville, Jacksonville, Florida, United States University of Miami Miller School of Medicine, Miami, Florida, United States University of South Florida Medical Center, Tampa, Florida, United States Emory University, Atlanta, Georgia, United States Northwestern University, Chicago, Illinois, United States Indiana University, Indianapolis, Indiana, United States University of Iowa, Iowa City, Iowa, United States University of Kansas Medical Center, Kansas City, Kansas, United States Johns Hopkins University School of Medicine, Baltimore, Maryland, United States Massachusetts General Hospital, Charlestown, Massachusetts, United States St. Mary's Health Care, Grand Rapids, Michigan, United States Hennepin County Medical Center, Minneapolis, Minnesota, United States Mayo Clinic - Rochester, Rochester, Minnesota, United States Washington University School of Medicine, Saint Louis, Missouri, United States Neurology Associates, P.C., Lincoln, Nebraska, United States University of Nevada School of Medicine, Las Vegas, Nevada, United States Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States Columbia University, New York, New York, United States Research Foundation of the State University of New York, Syracuse, New York, United States Carolinas Medical Center, Charlotte, North Carolina, United States Duke University Medical Center, Durham, North Carolina, United States Wake Forest University, Winston-Salem, North Carolina, United States The Cleveland Clinic Foundation, Cleveland, Ohio, United States Ohio State University, Columbus, Ohio, United States Providence ALS Center, Portland, Oregon, United States Penn State Hershey Medical Center, Hershey, Pennsylvania, United States ALS Center at Penn, Philadelphia, Pennsylvania, United States Drexel University College of Medicine, Philadelphia, Pennsylvania, United States University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States Vanderbilt University Medical Center, Nashville, Tennessee, United States Texas Neurology, Dallas, Texas, United States Methodist Neurological Institute, Houston, Texas, United States University of Texas Health Sciences Center, San Antonio, Texas, United States University of Utah, Salt Lake City, Utah, United States University of Virginia Health System, Charlottesville, Virginia, United States University of Washington, Seattle, Washington, United States Prince of Wales Hospital, Randwick, New South Wales, Australia Royal Brisbane and Women's Hospital, Herston, Queensland, Australia Calvary Health Care Bethlehem, Melbourne, Victoria, Australia AZ St-Lucas, Gent, Belgium UZ Leuven, Leuven, Belgium Univ of Calgary / Foothills MC, Calgary, Alberta, Canada CHUM - Hôpital Notre Dame, Montreal, Quebec, Canada McGill University, Montreal, Quebec, Canada London Health Sciences Centre, London, Canada Sunnybrook and Women's College and Health Sciences Centre, Toronto, Canada University of British Columbia, Vancouver, Canada CHRU de Lille - Hôpital Roger Salengro, Lille, France CHU de Limoges - Hôpital Dupuytren, Limoges, France Centre Hospitalier La Timone, Marseille, France CHU Gui de Chalalac, Montpellier, France CHU de Nice - Hôpital de l'Arche 1, Nice, France Hôpital La Pitié-Salpêtrière, Paris, France Charité - Universitätsmedizin Berlin, Berlin, Germany Bergmannsheil GmbH, Bochum, Germany Medizinische Hochschule Hannover (MHH), Hannover, Germany Universitätsspital Jena, Jena, Germany University of Ulm, Ulm, Germany Beaumont Hospital, Dublin, Ireland Academisch Medisch Centrum, Amsterdam, Netherlands UMC St. Radboud, Nijmegen, Netherlands Universitair Medisch Centrum Utrecht, Utrecht, Netherlands Hospital Universitario de Bellvitge, Barcelona, Spain Hospital Vall d'Hebron, Barcelona, Spain Hospital La Paz, Madrid, Spain Hospital Carlos III, Madrid, Spain Sahlgrenska Universitetssjukhuset, Göteborg, Sweden Karolinska Universitetssjukhuset, Solna, Stockholm, Sweden Queen Elizabeth Hospital, Birmingham, United Kingdom Walton Centre for Neurology & Neurosurgery, Liverpool, United Kingdom Kings College Hospital NHS Foundation Trust, London, United Kingdom Newcastle University Hospital - Clinical Ageing Research Unit, Newcastle, United Kingdom John Radcliffe Hospital, Oxford, United Kingdom Sheffield Institute for Translational Neuroscience, Sheffield, United Kingdom	Phase 3 Study of 67 Dexamipexole in ALS	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Dexamipexole Drug: Placebo		https://ClinicalTrials.gov/show/NCT01281189
				Barrow Neurology, Phoenix, Arizona, United States University of California, San Diego, La Jolla, California, United States UC Irvine ALS & Neuromuscular Center, Orange, California, United States Coordinated Clinical Research, San Diego, California, United States California Pacific Medical Center Forbes Norris MDA/ALS Research Center, San Francisco, California, United States Hospital for Special Care, New Britain, Connecticut, United States The George Washington University, Washington, District of Columbia, United States Mayo Clinic Florida Department of Neurology, Jacksonville, Florida, United States Emory University, School of Medicine, Atlanta, Georgia, United States Georgia Health Sciences University, Augusta, Georgia, United States Indiana University Department of Neurology, Indianapolis, Indiana, United States University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States University of Kansas, Kansas City, Kansas, United States Johns Hopkins University, Baltimore, Maryland, United States Massachusetts General Hospital, Boston, Massachusetts, United States University of Massachusetts Medical School, Worcester, Massachusetts, United States University of Michigan, Ann Arbor, Michigan, United States Henry Ford Hospital, Detroit, Michigan, United States St Mary's Healthcare, Grand Rapids, Michigan, United States Hennepin County Medical Center - Berman Center for Research, Minneapolis, Minnesota, United States Saint Louis University, St. Louis, Missouri, United States Washington University, St. Louis, Missouri, United States Neurology Associates, Lincoln, Nebraska, United States Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States Hospital for Special Surgery, New York, New York, United States University of Rochester, Rochester, New York, United States SUNY Upstate Medical University, Syracuse, New York, United States Carolinas Medical Center Department of Neurology, Charlotte, North Carolina, United States Duke University, Durham, North Carolina, United States Wake Forest University, School of Medicine, Winston-Salem, North Carolina, United States Ohio State University Department of Neurology, Columbus, Ohio, United States Providence ALS Center, Portland, Oregon, United States Oregon Health & Science University, Portland, Oregon, United States Penn State Hershey Neuroscience Clinics, Hershey, Pennsylvania, United States Drexel Neurology, Philadelphia, Pennsylvania, United States University of Pennsylvania, Philadelphia, Pennsylvania, United States University of Pittsburgh, Pittsburgh, Pennsylvania, United States Vanderbilt University Medical Center, Nashville, Tennessee, United States Texas Neurology, Dallas, Texas, United States Baylor College of Medicine, Houston, Texas, United States UTHSCSA Department of Neurology, San Antonio, Texas, United States University of Virginia, Charlottesville, Virginia, United States West Virginia University Department of Neurology, Morgantown, West Virginia, United States Medical College of Wisconsin, Milwaukee, Wisconsin, United States Heritage Medical Research, Calgary, Alberta, Canada University of Alberta Hospital, Edmonton, Alberta, Canada University of British Columbia, Vancouver, British Columbia, Canada Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, Canada QE II Health Sciences Centre, Halifax, Nova Scotia, Canada McMaster University Medical Centre, Hamilton, Ontario, Canada Queen's University, Kingston General, Kingston, Ontario, Canada London Health Sciences, London, Ontario, Canada Univ. of Toronto - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada Hôpital Notre Dame (CHUM) Centre Hospitalier de l'Université de Montreal, Montreal, Quebec, Canada Montreal Neurological Institute, Montreal, Quebec, Canada CHU de Quebec: Hôpital l'Enfant-Jésus, Quebec, Canada CHRU de Lille - Hôpital Roger Salengro, Lille, France CHU de Limoges - Hôpital Dupuytren, Limoges, France Hôpital La Timone Adulte, Marseille, France CHU Montpellier, Montpellier, France Hôpital Archet 1, Nice, France Hôpital de la Salpêtrière, Paris, France Hôpital Bretonneau, Tours, France Charité Universitätsmedizin, Berlin, Germany Hannover Medical School, Hannover, Germany University of Ulm, Ulm, Germany Trinity College, Beaumont Hospital, Dublin, Ireland Universitair Medisch Centrum Utrecht, Utrecht, Netherlands Hospital Carlos III, Madrid, Spain Barts and the London MND & the Centre Royal London Hospital, Whitechapel, London, United Kingdom Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom Kings College Hospital NHS Foundation Trust, London, United Kingdom John Radcliffe Hospital, Oxford, United Kingdom Plymouth Hospitals NHS Trust, Plymouth, United Kingdom Sheffield Institute for Translational Neuroscience, Sheffield, United Kingdom	Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Drug: CK-2017357 Other: Placebo tablets Drug: Riluzole		https://ClinicalTrials.gov/show/NCT01709149
				Calgary ALS Neuromuscular Clinic, Calgary, Alberta, Canada University of Alberta ALS Clinic, Edmonton, Alberta, Canada	69 (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Memantine		https://ClinicalTrials.gov/show/NCT00409721
				Mayo Clinic, Rochester, Minnesota, United States	70 (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Biological: autologous mesenchymal stem cells		https://ClinicalTrials.gov/show/NCT01142856
				California Pacific Medical Center, San Francisco, California, United States University of Kansas Medical Center - Landon Center on Aging, Kansas City, Kansas, United States Department of Neurology, University of Kentucky Medical Center, Lexington, Kentucky, United States	71 (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Drug: NP001 Drug: Placebo		https://ClinicalTrials.gov/show/NCT01091142
				PEREZ, Lille, France Pôle des maladies respiratoires et service EFR- Centre hospitalier Régional Universitaire, Lille, France	72 (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Device: PtCCO2		https://ClinicalTrials.gov/show/NCT00879593
				California Pacific Medical Center, San Francisco, California, United States Mayo Florida, Jacksonville, Florida, United States University of Arkansas, Kansas City, Kansas, United States Johns Hopkins Hospital, Baltimore, Maryland, United States Columbia University Medical Center, New York, New York, United States SUNY Upstate Medical Center, Syracuse, New York, United States Carolinas Neuromuscular ALS-MND Center, Charlotte, North Carolina, United States Penn State Hershey Medical Center, Hershey, Pennsylvania, United States Drexel University College of Medicine, Philadelphia, Pennsylvania, United States	73 (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Placebo Drug: CK-2017357		https://ClinicalTrials.gov/show/NCT01378676

74	Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial	Has Results	Amyotrophic Lateral Sclerosis	Drug: Insulin like growth factor, type 1 [Drug: Placebo]	Mayo Clinic in Scottsdale, Scottsdale, Arizona, United States California Pacific Medical Center, San Francisco, California, United States Mayo Clinic in Jacksonville, Jacksonville, Florida, United States Emory University, Atlanta, Georgia, United States Indiana University, Indianapolis, Indiana, United States University of Michigan Medical Center, Ann Arbor, Michigan, United States Henry Ford Hospital, Detroit, Michigan, United States Hennepin County Medical Center, Minneapolis, Minnesota, United States Mayo Clinic, Rochester, Minnesota, United States University of Mississippi, Jackson, Mississippi, United States Beth Israel Medical Center, New York, New York, United States University of Rochester Medical Center, Rochester, New York, United States University of Cincinnati, Cincinnati, Ohio, United States Cleveland Clinic, Cleveland, Ohio, United States Ohio State University, Columbus, Ohio, United States University of Pennsylvania, Pennsylvania Hospital, Philadelphia, Pennsylvania, United States Methodist Hospital, Houston, Texas, United States West Virginia University, Morgantown, West Virginia, United States Froedtert and Medical College Clinics, Milwaukee, Wisconsin, United States University of Puerto Rico, San Juan, Puerto Rico	https://ClinicalTrials.gov/show/NCT0035815
75	Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Drug: CK-2017357 Drug: Placebo	University of California at San Francisco, Fresno Campus, Central California Neurological Institute, Fresno, California, United States Coordinated Clinical Research, La Jolla, California, United States University of California at Irvine, ALS and Neuromuscular Center, Orange, California, United States Hospital for Special Care, New Britain, Connecticut, United States Massachusetts General Hospital, Neurology Clinical Trials Unit, Charlestown, Massachusetts, United States Washington University, St. Louis, Missouri, United States Cornell Faculty, Hospital for Special Surgery, New York, New York, United States Duke University School of Medicine, Division of Neurology, Durham, North Carolina, United States Ohio State University, Department of Neurology, Columbus, Ohio, United States Providence ALS Center, Portland, Oregon, United States University of Texas Health Science Center, Department of Neurology, San Antonio, Texas, United States	https://ClinicalTrials.gov/show/NCT01486849
76	Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis)	No Results Available	ALS (Amyotrophic Lateral Sclerosis) Iron Overload	Drug: Deferiprone	HÃpital Roger Salengro, CHRU de Lille, Lille, France	https://ClinicalTrials.gov/show/NCT02164253
77	A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Placebo Drug: 250 mg CK-2017357 Drug: 500 mg CK-2017357	Phoenix Neurological Associates, Ltd., Phoenix, Arizona, United States University Neurology Associates, Fresno, California, United States California Pacific Medical Center, San Francisco, California, United States Mayo Clinic Florida, Jacksonville, Florida, United States University of Kentucky, Lexington, Kentucky, United States Johns Hopkins Hospital, Baltimore, Maryland, United States Massachusetts General Hospital, Boston, Massachusetts, United States Washington University, St. Louis, Missouri, United States SUNY Upstate Medical Center, Syracuse, New York, United States Duke University, Durham, North Carolina, United States Providence ALS Center, Portland, Oregon, United States Drexel University College of Medicine, Dept of Neurology, Philadelphia, Pennsylvania, United States Penn State, University Park, Pennsylvania, United States The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States University of Vermont, Burlington, Vermont, United States	https://ClinicalTrials.gov/show/NCT01089010
78	Study of Standard Noninvasive Positive Pressure Ventilation (NIPPV) and Low Expiratory Pressure NIPPV in ALS Patients	Has Results	Amyotrophic Lateral Sclerosis	Device: ViasysÂ® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)	University of Michigan, Ann Arbor, Michigan, United States	https://ClinicalTrials.gov/show/NCT01154283

			Muscle Cramps in Amyotrophic Lateral Sclerosis	Drug: Mexiletine Drug: Placebo	UCD Telehealth Network - Lake Almanor Clinic, Chester, California, United States UCSD Department of Neurosciences ALS Clinical Trials (ACT) Program, La Jolla, California, United States UCLA Neuromuscular Research Program, Los Angeles, California, United States UCD Telehealth Network, Multiple Locations, California, United States UC Irvine Health ALS & Neuromuscular Center, Orange, California, United States UC, Davis Medical Center ALS Clinic, Sacramento, California, United States	https://ClinicalTrials.gov/show/NCT01811355
79	Mexiletine for the Treatment of Muscle Cramps in ALS	Has Results				
			Amyotrophic Lateral Sclerosis	Drug: SB-509	Coordinated Clinical Research, La Jolla, California, United States University of California, Irvine; MDA ALS and Neuromuscular Center,, Orange, California, United States California Pacific Medical Center (CPMC), The Forbes Norris MDA/ALS Research Center, San Francisco, California, United States The University of Kansas Medical Center (KU), Kansas City, Kansas, United States Johns Hopkins University, Baltimore, Maryland, United States Nerve and Muscle Center of Texas, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT00748501
80	Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)	No Results Available				
			Amyotrophic Lateral Sclerosis	Drug: TCH346	Novartis USA, East Hanover, New Jersey, United States Novartis Belgium, Vilvoorde, Belgium Novartis CANADA, Dorval, Quebec, Canada Novartis France, Rueil-Malmaison, France Novartis Germany, Nuernberg, Germany Novartis Italy, Saronno, Italy Novartis Netherlands, Arnhem, Netherlands Novartis Switzerland, Bern, Switzerland Novartis UK, Frimley, United Kingdom	https://ClinicalTrials.gov/show/NCT00072709
81	Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)	No Results Available				
			Amyotrophic Lateral Sclerosis	Drug: 40 mg glatiramer acetate Drug: Placebo	Teva Benelux, Leuven, Belgium Teva France, Paris, France Teva Germany, Morfelden-Walldorf, Germany Teva Israel, Tel Aviv, Israel Teva Italy, Milano, Italy Teva UK, Aylesbury, United Kingdom	https://ClinicalTrials.gov/show/NCT00326625
82	Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)	No Results Available				
			Alorhea Amyotrophic Lateral Sclerosis	Drug: Botox injection Drug: Placebo injection	DÃ©partement de Neurologie, HÃ´pital de l'HÃ´tel-Dieu, CHU d'Angers, Angers cedex 9, France Centre SLA, Groupement Hospitalier Est, HÃ´pital Neurologie Pierre Wertheimer, Hospices Civils de Lyon, Bron, France Service de Neurologie Vastel, HÃ´pital CÃ´te de Nacre, CHU de Caen, Caen cedex 9, France Service de Neurologie, HÃ´pital Gabriel Montpied, CHU de Clermont-Ferrand, Clermont-Ferrand cedex 1, France Centre SLA, Service de Neurologie A et pathologies du mouvement, HÃ´pital Roger Salengro, CHU de Lille, Lille, France Service de Neurologie, HÃ´pital Dupuytren, CHU de Limoges, Limoges, France Service de Neurologie, HÃ´pital de la Timone, CHU de Marseille, Marseille cedex 5, France Service de Neurologie, HÃ´pital Central, CHU de Nancy, Nancy, France Centre de RÃ©adaptation maladies Neuromusculaires, Service de MÃ©decine Physique et RÃ©adaptation, HÃ´pital de Nice, CHU de Nice, Nice cedex 3, France FÃ©dÃ©ration des Maladies du SystÃ©me Nerveux, Groupement Hospitalier PitiÃ© SalpÃ©trier, AP-HP, Paris cedex 13, France Service de Neurologie, CHU de Saint-Etienne, Saint-Etienne cedex 2, France DÃ©partement de Neurologie, HÃ´pital de Haute-pierre, CHRU de Strasbourg, Strasbourg, France Service d'Explorations Fonctionnelles Neuro-Musculaires, HÃ´pital Rangueil, CHU de Toulouse, Toulouse, France	https://ClinicalTrials.gov/show/NCT01551940
83	Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea	No Results Available				
			Amyotrophic Lateral Sclerosis	Other: EH301 Other: Placebo	Universidad CatÃ³lica de Valencia San Vicente MÃ¡rtir, Valencia, Spain	https://ClinicalTrials.gov/show/NCT03489200
84	EH301 for the Treatment of ALS Exercise and Disease Progression in Amyotrophic Lateral Sclerosis Patients	No Results Available		Other: standard care Other: moderate exercise		https://ClinicalTrials.gov/show/NCT03326622
85	Combination Therapy in Amyotrophic Lateral Sclerosis (ALS)	No Results Available		Drug: Pioglitazone and Tretinoin Drug: Tretinoin and Pioglitazone HCL Drug: Placebo	Phoenix Neurological Associates, LTD, Phoenix, Arizona, United States	https://ClinicalTrials.gov/show/NCT00919555
86						

87	Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Rasagiline Drug: Placebo	Department of Neurology, University of Ulm, Ulm, Baden-Württemberg, Germany Department of Neurology, Technische Universität München, Muenchen, Bayern, Germany Department of Neurology, University of Regensburg, Regensburg, Bayern, Germany Department of Neurology, University of Wuerzburg, Wuerzburg, Bayern, Germany Department of Neurology, Deutsche Klinik für Diagnostik, Wiesbaden, Hessen, Germany Department of Neurology, University of Rostock, Rostock, Mecklenburg-Vorpommern, Germany Department of Neurology, Goettingen, Niedersachsen, Germany Department of Neurology, Medical School Hannover, Hannover, Niedersachsen, Germany Neurologische Universitätsklinik Bergmannsheil, Bochum, Nordrhein-Westfalen, Germany Department of Neurology, University of Muenster, Muenster, Nordrhein-Westfalen, Germany Department of Neurology, University of Bonn, Bonn, Nordrhein-Westfalen, Germany Department of Neurology, University of Halle-Wittenberg, Halle/Saale, Sachsen-Anhalt, Germany Department of Neurology, TU Dresden, Dresden, Sachsen, Germany Department of Neurology, University of Jena, Jena, Thuringen, Germany Department of Neurology, Humboldt University, Berlin, Germany	https://ClinicalTrials.gov/show/NCT01879241
88	Muscle Training of Patients With Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Other: Muscle training	Department of Clinical Research, Odense University Hospital, University of Southern Denmark, Odense C, Fyn, Denmark	https://ClinicalTrials.gov/show/NCT01504009
89	Trial of Sodium Valproate in Amyotrophic Lateral Sclerosis Study of the Effects	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Sodium Valproate	UMC Utrecht, Utrecht, Netherlands	https://ClinicalTrials.gov/show/NCT00136110
90	Strengthening Exercises in Individuals With ALS	No Results Available	Amyotrophic Lateral Sclerosis	Procedure: Exercise	Cleveland Clinic Foundation, Cleveland, Ohio, United States	https://ClinicalTrials.gov/show/NCT00204464
91	Safety, Tolerability, and Activity Study of ISIS SOD1x to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations	No Results Available	Familial Amyotrophic Lateral Sclerosis	Drug: ISIS 333611	Johns Hopkins University, Baltimore, Maryland, United States Massachusetts General Hospital-East, Neurology Clinical Trials Unit, Charlestown, Massachusetts, United States Washington University School of Medicine, St. Louis, Missouri, United States Methodist Neurological Institute, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT01041222
92	Safety and Biomarker Study of EPI-589 in Subjects With ALS Clinical Trial of Vitamin E to	No Results Available	Amyotrophic Lateral Sclerosis	Drug: EPI-589	Cedar's Sinai, Los Angeles, California, United States California Pacific Medical Center, San Francisco, California, United States Providence Brain and Spine Institute ALS Center, Portland, Oregon, United States	https://ClinicalTrials.gov/show/NCT02460679
93	Treat Muscular Cramps in Patients With ALS Controlled Crossover Trial With THC (Delta 9-Tetrahydrocannabinol) for the Treatment of Cramps in Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Dietary Supplement: Vitamin E	London Health Sciences Centre, London, Ontario, Canada	https://ClinicalTrials.gov/show/NCT00372879
94	Cramps Amyotrophic Lateral Sclerosis	No Results Available	Cramps Amyotrophic Lateral Sclerosis	Drug: Dronabinol	Kantonsspital St.Gallen, St.Gallen, Switzerland	https://ClinicalTrials.gov/show/NCT00812851
95	Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis)	No Results Available	Amyotrophic Lateral Sclerosis	Drug: sodium phenylbutyrate	VA Medical Center, Iowa City, Iowa, United States VA Medical Center, Lexington, Lexington, Kentucky, United States VA Maryland Health Care System, Baltimore, Baltimore, Maryland, United States Edith Nourse Rogers Memorial Veterans Hospital, Bedford, Bedford, Massachusetts, United States VA Medical Center, Jamaica Plain Campus, Boston, Massachusetts, United States VA Medical Center, Syracuse, Syracuse, New York, United States VA Medical Center, Durham, Durham, North Carolina, United States VA Medical Center, Cincinnati, Cincinnati, Ohio, United States VA Pittsburgh Health Care System, Pittsburgh, Pennsylvania, United States Michael E. DeBakey VA Medical Center (152), Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT00107770
96	Placebo-controlled Trial of Arimodolom in SOD1 Positive Familial Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Arimodolom Drug: Placebo	University of Miami Miller School of Medicine, Miami, Florida, United States Massachusetts General Hospital, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT00706147
97	Impact of Early Non Invasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) Patients	No Results Available	Amyotrophic Lateral Sclerosis	Device: Home pressure ventilator model Vvo 40 (BREAS Medical AB)	Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain	https://ClinicalTrials.gov/show/NCT01641965
98	R(+)-JPPX High Dose Treatment of ALS	No Results Available	Amyotrophic Lateral Sclerosis	Drug: R(+)-pramipexole dihydrochloride monohydrate	University of Virginia, Charlottesville, Virginia, United States	https://ClinicalTrials.gov/show/NCT00600873
99	Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis Repetitive Transcranial	No Results Available	Amyotrophic Lateral Sclerosis	Genetic: VM202	Northwestern University, Chicago, Illinois, United States	https://ClinicalTrials.gov/show/NCT02039401
100	Magnetic Stimulation (rTMS) in Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Procedure: Real rTMS of the brain Procedure: Sham rTMS of the brain	Institute of neurology Università Cattolica, Rome, Italy	https://ClinicalTrials.gov/show/NCT00833820

Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Drug: ODM-109 Drug: Placebo for ODM-109	Charite Universitätsmedizin Berlin, Berlin, Germany Medical School Hannover, Hannover, Germany University Clinical Jena, Jena, Germany University Hospital of Ulm, Ulm, Germany Beaumont Hospital, Dublin, Ireland University Medical Centre Utrecht, Utrecht, Netherlands Royal Sussex County Hospital, Brighton, United Kingdom The Walton Centre, Liverpool, United Kingdom London Kings College Hospital, London, United Kingdom Royal London Hospital, London, United Kingdom University of Sheffield, Sheffield, United Kingdom	https://ClinicalTrials.gov/show/NCT02487407
101 and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Drug: TCH346	Neurological Institute, New York, New York, United States	https://ClinicalTrials.gov/show/NCT00036413
102					
First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Drug: PLACEBO Drug: GSK1223249	GSK Investigational Site, Baltimore, Maryland, United States GSK Investigational Site, New York, New York, United States GSK Investigational Site, Syracuse, New York, United States GSK Investigational Site, Charlotte, North Carolina, United States GSK Investigational Site, Winston-Salem, North Carolina, United States GSK Investigational Site, Columbus, Ohio, United States GSK Investigational Site, Paris, France GSK Investigational Site, Verona, Veneto, Italy GSK Investigational Site, Birmingham, United Kingdom GSK Investigational Site, Cambridge, United Kingdom GSK Investigational Site, London, United Kingdom GSK Investigational Site, London, United Kingdom	https://ClinicalTrials.gov/show/NCT00875446
103					
104 Creatine for the Treatment of Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Drug: creatine monohydrate	California Pacific Medical Center, San Francisco, California, United States Rush-Presbyterian St. Luke's Medical Center, Chicago, Illinois, United States University of Kansas Medical Center, Kansas City, Kansas, United States University of New Mexico - Medical Center, Albuquerque, New Mexico, United States University of Texas Health and Science Center, San Antonio, Texas, United States University of Virginia Health System, Charlottesville, Virginia, United States	https://ClinicalTrials.gov/show/NCT00070993
105 Exploratory Study of Biotelemetry in Amyotrophic Lateral Sclerosis	Has Results	Amyotrophic Lateral Sclerosis	Device: Faros Sensor (FS) and Lifesight Hub Device: Fast Fix electrode patch Procedure: Quantitative Measure of Speech (Core Phase Only)	GSK Investigational Site, London, United Kingdom GSK Investigational Site, Oxford, United Kingdom	https://ClinicalTrials.gov/show/NCT02447952
106 Brain and Nerve Stimulation for Hand Muscles in Spinal Cord Injury and ALS	No Results Available	Spinal Cord Injury Amyotrophic Lateral Sclerosis (ALS)	Device: Transcranial magnetic stimulation Device: Median nerve stimulation Device: Cervical transcutaneous stimulation	James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States	https://ClinicalTrials.gov/show/NCT02469675
107					
A Study to Explore the Safety and Tolerability of Achar in Patients With Amyotrophic Lateral Sclerosis	Has Results	Amyotrophic Lateral Sclerosis	Drug: Repository corticotropin injection	Questcor Investigational Site, Birmingham, Alabama, United States Questcor Investigational Site, Phoenix, Arizona, United States Questcor Investigational Site, San Francisco, California, United States Questcor Investigational Site, Stanford, California, United States Questcor Investigational Site, Jacksonville, Florida, United States Questcor Investigational Site, Miami, Florida, United States Questcor Investigational Site, Tampa, Florida, United States Questcor Investigational Site, Atlanta, Georgia, United States Questcor Investigational Site, Kansas City, Kansas, United States Questcor Investigational Site, Rochester, Minnesota, United States Questcor Investigational Site, Lincoln, Nebraska, United States Questcor Investigational Site, Hershey, Pennsylvania, United States Questcor Investigational Site, Pittsburgh, Pennsylvania, United States Questcor Investigational Site, Memphis, Tennessee, United States Questcor Investigational Site, Dallas, Texas, United States Questcor Investigational Site, Houston, Texas, United States Questcor Investigational Site, San Antonio, Texas, United States	https://ClinicalTrials.gov/show/NCT01906658
108 Rehabilitative Trial With tDCS in Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Device: Anodal bilateral motor cortex and cathodal spinal tDCS Device: Sham bilateral motor cortex and sham spinal tDCS	AO Spedali Civili, Brescia, BS, Italy	https://ClinicalTrials.gov/show/NCT03293394
109 Exploratory Clinical Trial to Assess Treatment of Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Procedure: Autologous Adipose-Tissue Derived Stem Cells	China Medical University Beigang Hospital, Beigang, Yunlin, Taiwan	https://ClinicalTrials.gov/show/NCT02383654
110 Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls	No Results Available	Amyotrophic Lateral Sclerosis	Drug: SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM	Salpêtrière Hospital, Paris, France Bretonneau Hospital, Tours, France	https://ClinicalTrials.gov/show/NCT01160263

111	Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS	No Results Available	Amyotrophic Lateral Sclerosis	Drug: AVP-923	Loma Linda University Dept. of Neurology, Loma Linda, California, United States UCLA School of Medicine Dept. of Neurology, Los Angeles, California, United States University of California, San Francisco, San Francisco, California, United States University of Colorado Health Sciences, Denver, Colorado, United States University of Miami Dept. of Neurology, Miami, Florida, United States Northwestern Medical School, Chicago, Illinois, United States Johns Hopkins University, Baltimore, Maryland, United States Massachusetts General Hospital, Boston, Massachusetts, United States Columbia-Presbyterian Center Neurological Institute, New York, New York, United States State University of New York, Syracuse, New York, United States Carolinas Medical Center Carolinas Neuromuscular/ALS-MDA Center, Charlotte, North Carolina, United States Wake Forest University, Winston-Salem, North Carolina, United States Cleveland Clinic Foundation, Cleveland, Ohio, United States MCP-Hahnemann University Dept. of Neurology, Philadelphia, Pennsylvania, United States Penn Neurological Institute, Philadelphia, Pennsylvania, United States University of Texas Health Science Center @ San Antonio, San Antonio, Texas, United States University of Wisconsin ALS Clinical Research Center, Madison, Wisconsin, United States	https://ClinicalTrials.gov/show/NCT00021697
112	Growth Hormone in Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Growth Hormone (Somatropin) Drug: Placebo	Dipartimento di Scienze Neurologiche, Naples, Italy Istituto Biostrutture e Bioimmagini, Consiglio Nazionale delle Ricerche, Naples, Italy	https://ClinicalTrials.gov/show/NCT00635960
113	Virtual Task in Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Device: Acquisition on TouchScreen Device: Acquisition on Kinect Device: Acquisition on LeapMotion Device: Acquisition on TouchScreen Control Group Device: Acquisition on Kinect Control Group Device: Acquisition on LeapMotion Control Group	Escola de Artes, Ciências e Humanidades da Universidade d Sao Paulo, Sao Paulo, Brazil	https://ClinicalTrials.gov/show/NCT03113630
114	Influence of the Vitamin D Blood Levels on the Amyotrophic Lateral Sclerosis Effects of Nocturnal Non-invasive Ventilation in Patients With Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Procedure: Blood test	UH Montpellier, Montpellier, France	https://ClinicalTrials.gov/show/NCT01823380
115	Effect of Lithium Carbonate in Patients With Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Device: non-invasive ventilation	Pellin Lee, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT00958048
116	Neuromuscular Transmission in Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Drug: lithium	Piti�-Salp�tri�re Hospital, Paris, France	https://ClinicalTrials.gov/show/NCT00925847
117	Neuromuscular Transmission in Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Procedure: Anconeus Muscle biopsy	Bruneteau Gaelle, Paris, France	https://ClinicalTrials.gov/show/NCT00847847
118	Study of Ozanezumab (GSK123249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis	Has Results	Amyotrophic Lateral Sclerosis	Drug: Ozanezumab Drug: Placebo	GSK Investigational Site, Boston, Massachusetts, United States GSK Investigational Site, Grand Rapids, Michigan, United States GSK Investigational Site, Syracuse, New York, United States GSK Investigational Site, Columbus, Ohio, United States GSK Investigational Site, Randwick, New South Wales, Australia GSK Investigational Site, Herston, Queensland, Australia GSK Investigational Site, Leuven, Belgium GSK Investigational Site, Calgary, Alberta, Canada GSK Investigational Site, London, Ontario, Canada GSK Investigational Site, Toronto, Ontario, Canada GSK Investigational Site, Montreal, Quebec, Canada GSK Investigational Site, Montreal, Quebec, Canada GSK Investigational Site, Lille cedex, France GSK Investigational Site, Limoges cedex, France GSK Investigational Site, Montpellier cedex 5, France GSK Investigational Site, Nice cedex 3, France GSK Investigational Site, Paris cedex 13, France GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany GSK Investigational Site, Muenchen, Bayern, Germany GSK Investigational Site, Hannover, Niedersachsen, Germany GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany GSK Investigational Site, Jena, Thuringen, Germany GSK Investigational Site, Berlin, Germany GSK Investigational Site, Torino, Piemonte, Italy GSK Investigational Site, Verona, Veneto, Italy GSK Investigational Site, Kanagawa, Japan GSK Investigational Site, Miyagi, Japan GSK Investigational Site, Osaka, Japan GSK Investigational Site, Seoul, Korea, Republic of GSK Investigational Site, Seoul, Korea, Republic of GSK Investigational Site, Utrecht, Netherlands GSK Investigational Site, Preston, Lancashire, United Kingdom GSK Investigational Site, Brighton, United Kingdom GSK Investigational Site, Edgbaston, United Kingdom	https://ClinicalTrials.gov/show/NCT01753076

119	High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis	Has Results	Amyotrophic Lateral Sclerosis	Dietary Supplement: Oxepea [Dietary Supplement: Jevity 1.5] Dietary Supplement: Jevity 1.0	Barrow Neurological Institute/St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States University of California at Irvine, Irvine, California, United States California Pacific Medical Center, University of California at San Francisco, San Francisco, California, United States Sarasota Memorial Hospital, Sarasota, Florida, United States Emory University School of Medicine, Atlanta, Georgia, United States Neurology Clinical Trials Unit, Massachusetts General Hospital, Boston, Massachusetts, United States Saint Mary's Health Care, Grand Rapids, Michigan, United States Columbia Presbyterian Medical Center, New York, New York, United States Carolinas Medical Center Neuromuscular/ALS-MDA Center, Charlotte, North Carolina, United States Oregon Health and Science University, Portland, Oregon, United States Drexel University, Philadelphia, Pennsylvania, United States Methodist Neurological Institute, Houston, Texas, United States University of Vermont, Burlington, Vermont, United States	https://ClinicalTrials.gov/show/NCT00983983
120	G-CSF Treatment for Amyotrophic Lateral Sclerosis: A RCT Study Assessing Clinical Response	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Granulocyte Colony Stimulating Factor [Drug: NS	Dongsheng Fan, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT00397423
121	Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Amyotrophic Lateral Sclerosis Sialorrhea	Drug: Botulinum toxin type B [Myobloc] Procedure: Injection of salivary glands	University of Kansas Medical Center/Neurology, 1008 Wescoe, Kansas City, Kansas, United States Carolinas MDA Neuromuscular/ALS Center; Carolinas Medical System; 1540 Garden Terrace, Charlotte, North Carolina, United States	https://ClinicalTrials.gov/show/NCT00125203
122	Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS)	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Memantine (Ebixa) [Drug: riluzole] [Drug: Placebo	Department of Neurology - Hospital de Santa Maria, Lisbon, Portugal	https://ClinicalTrials.gov/show/NCT00353665
123	Clinical Trial on the Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis (Extension CMN/ELA)	No Results Available	Amyotrophic Lateral Sclerosis	Procedure: Laminectomy and bone marrow stem cells transplantation Procedure: Intrathecal infusion of autologous bone marrow stem cells Procedure: Intrathecal infusion of placebo (saline solution).	Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain	https://ClinicalTrials.gov/show/NCT01254539
124	R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Drug: R(+) pramipexole dihydrochloride monohydrate	David Lacomis MD, Pittsburgh, Pennsylvania, United States University of Virginia, Charlottesville, Virginia, United States	https://ClinicalTrials.gov/show/NCT00140218
125	Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Celecoxib [Drug: Ceftriaxone] [Drug: Minocycline	Phoenix Neurological Associates, Phoenix, Arizona, United States UCLA, Los Angeles, California, United States University of California Irvine, Orange, California, United States California Pacific Medical Center, San Francisco, California, United States Mayo Clinic Florida, Jacksonville, Florida, United States Medical College of Georgia, Augusta, Georgia, United States University of Illinois, Chicago, Illinois, United States University of Kansas, Kansas City, Kansas, United States Mayo Clinic Rochester, Rochester, Minnesota, United States Washington University, St. Louis, Missouri, United States UMDNJ, New Brunswick, New Jersey, United States University of New Mexico, Albuquerque, New Mexico, United States Beth Israel, New York, New York, United States Columbia University, New York, New York, United States Duke University, Durham, North Carolina, United States Oregon Health and Science University, Portland, Oregon, United States University of Pennsylvania, Philadelphia, Pennsylvania, United States UT Southwestern Medical Center, Dallas, Texas, United States University of Vermont, Burlington, Vermont, United States	https://ClinicalTrials.gov/show/NCT00355576
126	Transplantation of Autologous Peripheral Blood Mononuclear Cells for Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Biological: PBMC autotransplantation	The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China	https://ClinicalTrials.gov/show/NCT03085706
127	Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS	No Results Available	Amyotrophic Lateral Sclerosis [ALS] Lou Gehrig Disease Lou Gehrig's Disease Lou-Gehrigs Disease Motor Neuron Disease, Amyotrophic Lateral Sclerosis	Drug: BHV-0223	Holy Cross Neuroscience Research Institute, Fort Lauderdale, Florida, United States Sommos/Neurology Associates Clinical Research, Lincoln, Nebraska, United States Neurosciences Institute, Neurology - Charlotte, Charlotte, North Carolina, United States Wesley Neurology Clinic, Cordova, Tennessee, United States Texas Neurology, Dallas, Texas, United States	https://ClinicalTrials.gov/show/NCT03520517

A Safety and Tolerability Study of Intracerebroventricular Administration of sNNO029 to Patients With Amyotrophic Lateral Sclerosis		No Results Available	Amyotrophic Lateral Sclerosis	Drug: sNNO029 Drug: Placebo	University Hospital Leuven, Department of Neurology, Leuven, Belgium	https://ClinicalTrials.gov/show/NCT00800501
128	Clinical Trial on the Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Procedure: Laminectomy and bone marrow stem cells transplantation Procedure: Autologous bone marrow cells collection	Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain	https://ClinicalTrials.gov/show/NCT00855400
129	Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis	Has Results	Amyotrophic Lateral Sclerosis	Drug: tauroursodeoxycholic acid [TUDCA] Drug: Placebo	Fondazione IRCCS Istituto neurologico Carlo Besta, Milan, Italy	https://ClinicalTrials.gov/show/NCT00877604
130	Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Biological: Albumin	Hospital Universitari Bellvitge, Hospital de Llobregat, Barcelona, Spain	https://ClinicalTrials.gov/show/NCT02479802
131	Nighttime NIV Initiation in Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Procedure: Nighttime NIV initiation		https://ClinicalTrials.gov/show/NCT02759003
132	An Outpatient Setting in Immuno-modulation in Amyotrophic Lateral Sclerosis - a Phase II Study of Safety and Activity of Low Dose Interleukin-2	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Placebo Drug: 1.0 MIU IL-2 per day Drug: 2.0 MIU IL-2 per day	CHRU de Montpellier - H�pital Gui de Chauliac, Montpellier, France	https://ClinicalTrials.gov/show/NCT02059759
133	Creation of a Bank of Fibroblast From Patients With Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Procedure: skin biopsy	Centre r����rent maladies rares SLA, Paris, France	https://ClinicalTrials.gov/show/NCT01639391
134	Mexiletine in Sporadic Amyotrophic Lateral Sclerosis [SALS]	Has Results	Sporadic Amyotrophic Lateral Sclerosis	Drug: Mexiletine Drug: Placebo	UCLA, Neuromuscular Research Center, Los Angeles, California, United States University of Iowa, Iowa City, Iowa, United States University of Kansas Medical Center, Kansas City, Kansas, United States Massachusetts General Hospital, Boston, Massachusetts, United States University of Massachusetts (Worcester) Memorial Medical Center, Worcester, Massachusetts, United States Washington University Medical School, Saint Louis, Missouri, United States SUNY Upstate Medical Center, Syracuse, New York, United States Penn State Hershey Medical Center, Hershey, Pennsylvania, United States University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States University of Washington Medical Center, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT01849770
135	A P300 Brain Computer Interface Keyboard to Control Assistive Technology For Use by People With Amyotrophic Lateral Sclerosis	Has Results	Amyotrophic Lateral Sclerosis	Device: P300 Brain Computer Interface Keyboard	University of Michigan, Ann Arbor, Michigan, United States	https://ClinicalTrials.gov/show/NCT01139001
136	Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Creatinine	University of Vermont, Burlington, Vermont, United States	https://ClinicalTrials.gov/show/NCT00005766
137	Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS	Has Results	Pseudobulbar Affect (PBA)	Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg Drug: Placebo	St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States Neuromuscular Research Center, Scottsdale, Arizona, United States South Coast Clinical Trials, Anaheim, California, United States UCI Medical Center, Irvine, California, United States Center for Neurologic Study, La Jolla, California, United States UCLA School of Medicine, Los Angeles, California, United States The Forbes Norris MDA/ALS Research Center - California Pacific Medical Center, San Francisco, California, United States The ALS Center at UCSF, San Francisco, California, United States University of Colorado at Denver & Health Science Center, Aurora, Colorado, United States Neuroscience Center, Ft. Lauderdale, Florida, United States Mayo Clinic, Jacksonville, Florida, United States University of Miami, Miami, Florida, United States Suncoast Neuroscience Associates, St. Petersburg, Florida, United States The ALS Center at Emory University, Atlanta, Georgia, United States Neurology Specialists of Decatur of Decatur, Decatur, Georgia, United States Northwestern University, Chicago, Illinois, United States Consultants in Neurology, Northbrook, Illinois, United States University of Kentucky Health Care - Dept. of Neurology, Lexington, Kentucky, United States The Johns Hopkins University, Baltimore, Maryland, United States Massachusetts General Hospital, Boston, Massachusetts, United States Baystate Medical Center, Springfield, Massachusetts, United States University of Michigan, Ann Arbor, Michigan, United States Henry Ford Hospital, Detroit, Michigan, United States St. Louis University - Neuromuscular Clinic, St. Louis, Missouri, United States Advanced Neurology Specialists, Great Falls, Montana, United States Neurology Associates, Lincoln, Nebraska, United States University of Nevada, Las Vegas, Nevada, United States Upstate Clinical Research, Albany, New York, United States Jacobs Neurological Institute, Buffalo, New York, United States Mount Sinai Medical Center, New York, New York, United States Neurological Institute - Columbia Presbyterian Center, New York, New York, United States Carolinas Medical Center, Charlotte, North Carolina, United States Duke University Medical Center, Durham, North Carolina, United States Department of Neurology - The Cleveland Clinic Foundation, Cleveland, Ohio, United States Ohio State University, Columbus, Ohio, United States Oregon Health Science University, Portland, Oregon, United States Drexel University - Department of Neurology, Philadelphia, Pennsylvania, United States The ALS Center - Penn Neurological Institute - The University of Pennsylvania, Philadelphia, Pennsylvania, United States Vanderbilt University, Nashville, Tennessee, United States The Methodist Hospital - Baylor College of Medicine, Houston, Texas, United States Department of Neuropsychiatry - Texas Tech University, Lubbock, Texas, United States University of Texas Health Science Center, San Antonio, Texas, United States University of Vermont, Burlington, Vermont, United States West Virginia University, Morgantown, West Virginia, United States Dean Foundation, Madison, Wisconsin, United States FACENE, Buenos Aires, Ciudad de Buenos Aires, Argentina IADIN, Buenos Aires, Ciudad de Buenos Aires, Argentina Hospital Italiano, Buenos Aires, Ciudad de Buenos Aires, Argentina NEBA, Buenos Aires, Ciudad de Buenos Aires, Argentina Hospital Ramos Mejia, Buenos Aires, Ciudad de Buenos Aires, Argentina Hospital Britanico, Buenos Aires, Ciudad de Buenos Aires, Argentina Policlinico Bancario, Buenos Aires, Ciudad de Buenos Aires, Argentina FLENI, Buenos Aires, Ciudad de Buenos Aires, Argentina Instituto Medico Rodriguez Alfici, Godoy Cruz, Mendoza, Argentina Instituto de Neurociencias Rosario, Rosario, Santa Fe, Argentina Hospital Militar Regional de C�rdoba, C�rdoba, Argentina Santa Casa de Miseric�rdia de Belo Horizonte, Belo Horizonte, M G, Brazil Hospital da Restaurac�o, Recife, PE, Brazil Hospital de C�-nicas-UFPR, Curitiba, PR, Brazil Hospital Universit�rio Clementino Fraga Filho, Rio de Janeiro, RJ, Brazil Hospital Moimhos de Vento, Porto Alegre, RS, Brazil Hospital das C�-nicas da Faculdade de Medicina da Universidade S�o Paulo, Sao Paulo, SP, Brazil	https://ClinicalTrials.gov/show/NCT00573443

				St. Joseph's Hospital & Medical Center - Barrow Neurology Clinics, Phoenix, Arizona, United States University of California San Diego, La Jolla, California, United States Cedars-Sinai Medical Center, Los Angeles, California, United States University of California, Irvine, Orange, California, United States University of California Davis Medical Center, Sacramento, California, United States Forbes Norris MDA/ALS Research Center, San Francisco, California, United States Stanford Hospital and Clinics, Stanford, California, United States University of Colorado Hospital Anschutz Outpatient Pavilion, Aurora, Colorado, United States Hospital for Special Care, New Britain, Connecticut, United States George Washington University Medical Center, Washington, District of Columbia, United States Mayo Clinic, Jacksonville, Florida, United States University of Miami, Miami, Florida, United States Carol and Frank Morsani Center for Advanced Health Care - University of South Florida, Tampa, Florida, United States The Emory Clinic, Atlanta, Georgia, United States Georgia Regents University, Augusta, Georgia, United States Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States Indiana University, Indianapolis, Indiana, United States University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States University of Kansas Medical Center, Kansas City, Kansas, United States Johns Hopkins University, Baltimore, Maryland, United States Massachusetts General Hospital, Boston, Massachusetts, United States University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States University of Michigan Hospital and Health System, Ann Arbor, Michigan, United States Henry Ford Health System, Detroit, Michigan, United States Hennepin County Medical Center, Minneapolis, Minnesota, United States Saint Louis University, Saint Louis, Missouri, United States Barnes-Jewish Hospital, Saint Louis, Missouri, United States Neurology Associates, Lincoln, Nebraska, United States Dartmouth Hitchcock Medical Center Dept of Neurology, Lebanon, New Hampshire, United States Hospital for Special Surgery, New York, New York, United States Neurological Institute Columbia University Medical Center, New York, New York, United States SUNY Upstate Medical University, Syracuse, New York, United States Neurosciences Institute: Neurology - Charlotte, Charlotte, North Carolina, United States Duke Neurological Disorders Clinic, Durham, North Carolina, United States Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States The Ohio State University Wexner Medical Center, Columbus, Ohio, United States Providence Brain and Spine Institute ALS Center, Portland, Oregon, United States Oregon Health and Science Center, Portland, Oregon, United States Penn State Milton S. Eisenhower Medical Center, Hershey, Pennsylvania, United States The Penn Comprehensive Neuroscience Center, Philadelphia, Pennsylvania, United States Temple University School of Medicine, Philadelphia, Pennsylvania, United States Vanderbilt University Medical Center, Nashville, Tennessee, United States Texas Neurology, Dallas, Texas, United States Baylor College of Medicine, Houston, Texas, United States University of Texas Health Science Center, San Antonio, Texas, United States University of Virginia Health System, Charlottesville, Virginia, United States University of Washington Medical Center, Seattle, Washington, United States West Virginia University Department of Neurology, Morgantown, West Virginia, United States Froedtert Memorial Lutheran Hospital, Department of Neurology, Milwaukee, Wisconsin, United States UZ Leuven - Campus Gasthuisberg, Leuven, Vlaams Brabant, Belgium University of Calgary, Calgary, Alberta, Canada Edmonton Kaye Clinic, Edmonton, Alberta, Canada Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, Canada QE II Health Sciences Centre, NHI Site, Halifax, Nova Scotia, Canada McMaster University Medical Centre, Hamilton, Ontario, Canada London Health Sciences Centre, London, Ontario, Canada Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada Notre-Dame Hospital/CHUM, Montreal, Quebec, Canada Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada CHU de Quebec - Universite Laval Hospital de l'Erifant-Jesus, Quebec, Canada Hopital R. Sakengro, CHRU Lille, Lille Cedex, France CHU Dupuytren, Limoges cedex, France Hopital de la Timone, Marseille, France Hopital Gui de Chauliac, Montpellier, France CHU de Nice - Hospital Pasteur 2, Nice Cedex 1, France Hopital de la Salpêtrière, Paris, France Bretagne University Hospital, Tours Cedex 9, France University of Ulm, Department of Neurology, Ulm, Baden-Wuerttemberg, Germany Hannover Medical School, Department of Neurology, Hannover, Lower Saxony, Germany Charité Campus Virchow-Klinikum, Neurology Department, Berlin, Germany Clinical Research Centre, Beaumont Hospital, Dublin, Ireland IRCCS Istituto Auxologico Italiano - U.O. Neurologia, Milan, Italy Centro Clinico NEMO - Fondazione Serena Onlus, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy Dipartimento di Neuroscienze "Rita Levi Montalcini" A.O.U. Città della Salute e della Scienza di Torino P.O. "Molinette", Torino, Italy University Medical Center Utrecht, Utrecht, Netherlands Hospital Santa Maria-Centro Hospitalar Lisboa Norte, Lisboa, Portugal Hospital San Rafael, Madrid, Spain Derriford Hospital, Plymouth, Devon, United Kingdom Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom Clinical Research Centre, Royal London Hospital, London, United Kingdom Kings College Hospital, London, United Kingdom	https://ClinicalTrials.gov/show/NCT02496767
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year	No Results Available	Amyotrophic Lateral Sclerosis	Drug: tirasemtiv Drug: Placebo tablets Drug: Riluzole 50 MG		https://ClinicalTrials.gov/show/NCT0005674
Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS]	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Creatine	Washington University, St. Louis, Missouri, United States	https://ClinicalTrials.gov/show/NCT0005674
Minocycline to Treat Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Drug: minocycline	Mayo Clinic, Scottsdale, Arizona, United States University of California, Irvine, Irvine, California, United States University of California Department of Neurology, Los Angeles, California, United States California Pacific Medical Center, San Francisco, California, United States Univ. of Colorado Health Sciences Center, Denver, Colorado, United States Mayo Clinic, Jacksonville, Florida, United States University of Illinois, Chicago, Illinois, United States Indiana University School of Medicine, Indianapolis, Indiana, United States University of Iowa, Iowa City, Iowa, United States University of Kansas Medical Center, Kansas City, Kansas, United States University of Kentucky, Lexington, Kentucky, United States Hennepin County Med Center, Minneapolis, Minnesota, United States University of Minnesota, Minneapolis, Minnesota, United States Washington University, St. Louis, Missouri, United States UMDNJ/Robert Wood Johnson Medical Center, New Brunswick, New Jersey, United States University of New Mexico, Albuquerque, New Mexico, United States Columbia University, Eleanor and Los Gehrig MDA/ALS Center, New York, New York, United States Carolinas Medical Center, Charlotte, North Carolina, United States Duke University, Durham, North Carolina, United States Wake Forest University, Winston-Salem, North Carolina, United States Metro Health Clinic, Cleveland, Ohio, United States Oregon Health & Science University, Portland, Oregon, United States University of Pennsylvania, Philadelphia, Pennsylvania, United States Drexel University College of Medicine, Hahnemann Campus, Philadelphia, Pennsylvania, United States University of Texas Southwestern, Dallas, Texas, United States Methodist Hospital, Houston, Texas, United States University of Texas Health Sciences Center, San Antonio, Texas, United States University of Utah, Salt Lake City, Utah, United States University of Vermont, Burlington, Vermont, United States Virginia Mason Medical Center, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT0047723
Escitalopram (Lexapro) for Depression MS or ALS	Has Results	Major Depression Multiple Sclerosis Amyotrophic Lateral Sclerosis	Drug: escitalopram	University of South Carolina School of Medicine, Columbia, South Carolina, United States	https://ClinicalTrials.gov/show/NCT00965497
Modafinil for Treatment of Fatigue in ALS Patients	Has Results	Fatigue	Drug: Modafinil Drug: Placebo	New York State Psychiatric Institute-Columbia University, New York, New York, United States	https://ClinicalTrials.gov/show/NCT00614926
Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease	No Results Available	Motor Neuron Disease Amyotrophic Lateral Sclerosis (ALS)	Drug: Cannabis Sativa extract Oromucosal spray	San Raffaele Scientific Institute, Milan, Italy Fondazione Salvatore Maugeri IRCCS, Istituto Scientifico, Milan, Italy NEuroMuscular Omnicentre (NEMO), Fondazione Serena - H CÀ granda, Milan, Italy Universita' Degli Studi Di Padova, Azienda Ospedaliera Di Padova, Neurologic Department, Padova, Italy	https://ClinicalTrials.gov/show/NCT01776970
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Participants	No Results Available	Respiratory Infections	Drug: ALS-008176 (250 mg) Drug: ALS-008176 (500 mg) Drug: ALS-008176 (750 mg) Other: Placebo	Fukuoka, Japan	https://ClinicalTrials.gov/show/NCT02487833
Escalated Application of Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis Patients	No Results Available	Motor Neuron Disease	Biological: Autologous Mesenchymal stem cells (MSCs)	Hospital e Maternidade Dr Christovao da Gama, Santo Andre, Sao Paulo, Brazil Instituto de Ensino e Pesquisas - IEP-SÃo Lucas, Sao Paulo, SP, Brazil	https://ClinicalTrials.gov/show/NCT02987413
Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Reference capsule GDC-0134 Drug: Prototype capsule GDC-0134 Drug: rabeprazole	Quotient Clinical Ltd, Clinical Research Unit, Nottingham, United Kingdom	https://ClinicalTrials.gov/show/NCT03237741
Differential Study of Muscle Transcriptome	No Results Available	ALS[SMA]SB MA	Procedure: Muscle biopsy	Centre d'Ãvaluation THÃ©rapeutique, Dr LACOMBLEZ, Paris, France	https://ClinicalTrials.gov/show/NCT01984957
Dexramipexole and Cimetidine Drug-Drug Interaction (DDI)	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Dexramipexole Drug: Cimetidine plus Dexramipexole	Research Site, Overland Park, Kansas, United States	https://ClinicalTrials.gov/show/NCT01536249

	Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexramipexole (QTC = Electrocardiogram [ECG] Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Dexramipexole [Drug: Dexramipexole Placebo] [Drug: Moxifloxacin	Research Site, Overland Park, Kansas, United States	https://ClinicalTrials.gov/show/NCT01511029
	Dexramipexole SAD/MAD 151 Study	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Dexramipexole [Drug: Dexramipexole Placebo	Research Site, Overland Park, Kansas, United States	https://ClinicalTrials.gov/show/NCT01449578
	Dexramipexole Japanese PK 152 Study	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Single dose reduced standard [Drug: Multiple Dose	Research Site, London, United Kingdom	https://ClinicalTrials.gov/show/NCT01424163
	An In-home Study of Brain Computer Interfaces 153	Has Results	Amyotrophic Lateral Sclerosis	Device: Brain Computer Interface for Wheelchair Tilt Control	University of Michigan, Ann Arbor, Michigan, United States	https://ClinicalTrials.gov/show/NCT01123200

Children's of Alabama, Birmingham, Alabama, United States|Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States|Long Beach Memorial Medical Center/Miller Children's and Women's Hospital of Long Beach, Long Beach, California, United States|Children's Hospital of Orange County, Orange, California, United States|The University of California at San Diego, San Diego, California, United States|LSU Health Sciences Center, Shreveport, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|The Children's Mercy, Kansas City, Missouri, United States|University of Rochester, Rochester, New York, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States|Children's Hospital/University of Tennessee, Memphis, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, United States|The University of Utah, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States|The Canberra Hospital, Canberra, Australia|Monash Medical Center, Melbourne, Australia|Women's and Children's Hospital, North Adelaide, Australia|The Royal Children's Hospital Melbourne, Parkville, Australia|Princess Margaret Hospital, Perth, Australia|The Children's Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada|Canadian Centre for Vaccinology IWK Health Centre, Halifax, Nova Scotia, Canada|McMaster Children's Hospital, Hamilton, Ontario, Canada|McGill University Health Centre, Montreal, Quebec, Canada|Hospital Dr. Ezequiel Gonzalez Cortes, San Miguel, Santiago, Chile|Complejo Asistencial Dr. Sotero del Rio, Santiago, Chile|Hospital Padre Hurtado, Santiago, Chile|Fundacion Cardio Infantil Instituto de Cardiologia, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|CHI Pellegrin / Pneumologie pediatrique, Bordeaux, France|Hospital Necker, Paris, France|Hirocaki National Hospital, Hirocaki-shi, Aomori, Japan|Chiba Children's Hospital, Chiba-shi, Chiba, Japan|Ota Memorial Hospital, Ota, Gunma, Japan|Gunma Children's Medical Center, Shikakawa-shi, Gunma, Japan|NHO Fukuyama Medical Center, Fukuyama, Hiroshima, Japan|Hokkaido P.W. F.A.C. Asahikawa-Kosei General Hospital, Asahikawa-shi, Hokkaido, Japan|NHO Kanazawa Medical Center, Kanazawa, Ishikawa, Japan|NHO Shikoku Medical Center for Children and Adults, Takamatsu, Kagawa, Japan|Okinawa Chubu Hospital, Urumi, Okinawa, Japan|Nakanawa Children's Hospital, Osaka-city, Osaka, Japan|National Hospital Organization Saitama National Hospital, Wako, Saitama, Japan|Tokyo Metropolitan Children's Medical Center, Fuchu-shi, Tokyo, Japan|National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan|Fukuoka Children's Hospital, Fukuoka, Japan|NHO Fukuoka Hospital, Fukuoka, Japan|Kochi Health Sciences Center, Kochi, Japan|Saitama Children's Medical Center, Saitama, Japan|Christchurch Clinical Study Trust, Christchurch, New Zealand|Hawke's Bay Hospital, Hastings, New Zealand|Wellington Hospital, Wellington, New Zealand|Hospital Materno Infantil Jose Domingo de Obaldia, David, Chiriqui, Panama|Hospital de Especialidades Pediatricas "Omar Torrijos Herrera", Panama City, Panama|Hospital del Nino, Panama City, Panama|Institute for Mother and Child Care "Alfred Ruesescu", Bucharest, Romania|2 Military Hospital, Cape Town, South Africa|Kingsbury Hospital, Cape Town, South Africa|Tygerberg Academic Hospital, Cape Town, South Africa|Linkou Chang Gung Medical Hospital, Taipei, Taiwan|MacKay Memorial Hospital, Taipei, Taiwan|Chulalongkorn University Department of Pediatrics, Bangkok, Thailand|Phramongklotkiao Hospital Department of Pediatrics, Bangkok, Thailand|Siriraj Hospital, Mahidol University Department of Pediatrics, Bangkok, Thailand|Khon Kaen University Department of Pediatrics, Khon Kaen, Thailand|Bristol Royal Hospital for Children, Bristol, England, United Kingdom|Alder Hey Children's Hospital, Liverpool, England, United Kingdom|St. George's University of London, London, England, United Kingdom|University Hospital Southampton NHS Foundation Trust, Southampton, England, United Kingdom|Royal Hospital for Sick Children, Edinburgh, Scotland, United Kingdom|Children's Hospital of Wales, Cardiff, Wales, United Kingdom|Birmingham Children's Hospital, Birmingham, United Kingdom|Royal Alexandra Children's Hospital, Brighton, United Kingdom|Royal Manchester Children's Hospital, Manchester, United Kingdom|Queens Medical Center, Nottingham, United Kingdom|University of Oxford, Oxford, United Kingdom

	A Study of ALS-008176 in 154 Infants Hospitalized With RSV	No Results Available	Respiratory Infections	Drug: ALS-008176 [Drug: Placebo Drug: Formulation A (ALS-008176) [Drug: Formulation B (ALS-008176) [Drug: Formulation C (ALS-008176) [Drug: Formulation D (ALS-008176) [Drug: Formulation E (ALS-008176) [Drug: Formulation F (ALS-008176) [Drug: Formulation G1 (ALS-008176) [Drug: Formulation G2 (ALS-008176) [Drug: Formulation G3 (ALS-008176) [Drug: Formulation H1 (ALS-008176) [Drug: Formulation H2 (ALS-008176) [Drug: Formulation H3 (ALS-008176)	Nottingham, United Kingdom	https://ClinicalTrials.gov/show/NCT02813460
	Study to Assess the Taste Profile of Different ALS-008176 Oral Liquid Formulations in 155 Healthy Adult Participants	No Results Available	Healthy	Formulation H3 (ALS-008176)	Nottingham, United Kingdom	https://ClinicalTrials.gov/show/NCT02813460
	Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in 156 Healthy Participants	No Results Available	Healthy	Drug: ALS-008176 [Drug: Placebo] [Drug: Moxifloxacin	Tempe, Arizona, United States	https://ClinicalTrials.gov/show/NCT02833831
	A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176 157	No Results Available	Respiratory Syncytial Virus Infections	Drug: ALS-008176 [Drug: ALS-008112	Quotient Clinical, Nottingham, United Kingdom	https://ClinicalTrials.gov/show/NCT02231671
	A Phase 2a Study to Evaluate ALS-008176 in the Virus 158 Challenge Model	No Results Available	Respiratory Syncytial Virus Infections	Drug: ALS-008176 [Drug: vehicle	Retroscreen Virology Ltd, London, United Kingdom	https://ClinicalTrials.gov/show/NCT02094365
	Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With 159 Amyotrophic Lateral Acclerosis	No Results Available	Amyotrophic Lateral Sclerosis Mot or Neuron Disease Lou Gehrig's Disease	Behavioral: Treadmill Exercise	Carolinas ALS Clinical Research Center, Charlotte, North Carolina, United States	https://ClinicalTrials.gov/show/NCT00956488
	Study of Single and Multiple Doses of ALS-008176 in Healthy 160 Volunteers	No Results Available	Respiratory Syncytial Virus Infections	Drug: ALS-008176 [Drug: Placebo	Investigational Site, Rennes, France	https://ClinicalTrials.gov/show/NCT01906164

161	A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus	No Results Available	Respiratory Syncytial Virus Infections	Drug: ALS-008176 Drug: Placebo	Lake Internal Med. Assoc., Eustis, Florida, United States The Research Center, Inc., Hialeah, Florida, United States JDH Medical Group LLC, Miami, Florida, United States St Lucie Medical Center, Port Saint Lucie, Florida, United States Tampa General Hospital, Tampa, Florida, United States Infectious Disease Specialists of Atlanta, Atlanta, Georgia, United States Kentucky Lung Clinic, PSC, Hazard, Kentucky, United States Bronson Methodist Hosp. Fed, Kalamazoo, Michigan, United States William Beaumont Hospital, Troy, Michigan, United States University of Missouri-Clinical Research Center, Columbia, Missouri, United States Washington Univ School of Med, Saint Louis, Missouri, United States Westmead Hospital, Northmead, New South Wales, Australia Cairns Hospital, Cairns, Queensland, Australia Mater Adult Hospital, South Brisbane, Queensland, Australia Princess Alexandra Hospital, Woolloongabba, Queensland, Australia The Queen Elizabeth Hospital, Woodville South, South Australia, Australia Monash Heal.-Monash Lung&Sleep, Clayton, Victoria, Australia The Royal Melbourne Hospital, Parkville, Victoria, Australia Wellington Regional Hospital, Newtown, Wellington, New Zealand Raffles Hospital, Singapore, Singapore Taipei Med. Uni-Shuang Ho Hosp, New Taipei City, Taiwan	https://ClinicalTrials.gov/show/NCT02673476
162	First in Human Study of ALS-002200: Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1	No Results Available	Hepatitis C, Chronic	Drug: ALS-002200 Drug: Placebo	Biotrial, Rennes, Brittany, France Biotrial, Paris, France Arensis, Chisinau, Moldova, Republic of Arensis, Bucharest, Romania	https://ClinicalTrials.gov/show/NCT01590407
163	A P300 Brain Computer Interface to Operate Power Wheelchair Tilt	Has Results	Healthy Amyotrophic Lateral Sclerosis	Device: Using a BCI to control wheelchair tilt		https://ClinicalTrials.gov/show/NCT01123148
164	Influence of G-CSF and EPO on Associative Learning and Motor Skills	No Results Available	Chronic Stroke Amyotrophic Lateral Sclerosis	Drug: granulocyte - colony stimulating factor (G-CSF) Drug: erythropoetin (EPO)	Department of neurology, University Hospital of Muenster, Muenster, Nordrhein-Westfalen, Germany	https://ClinicalTrials.gov/show/NCT00298597
165	Evaluation of a Tongue Operated Assistive Technology for Individuals With Severe Paralysis	Has Results	Quadriplegia Spinal Cord Injury ALS	Procedure: Tongue Piercing Device: Usability assessment	Georgia Institute of Technology, Atlanta, Georgia, United States Shepherd Center, Atlanta, Georgia, United States Northwestern University, Chicago, Illinois, United States Rehabilitation Institute of Chicago, Chicago, Illinois, United States	https://ClinicalTrials.gov/show/NCT01124292
166	Dexrampipexole Renal PK Study	No Results Available	Amyotrophic Lateral Sclerosis Renal Insufficiency	Drug: Dexrampipexole (dose 1) Drug: Dexrampipexole (dose 2)	Research Site, Orlando, Florida, United States Research Site, Brooklyn Center, Minnesota, United States	https://ClinicalTrials.gov/show/NCT01424176
167	Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome	No Results Available	Myelodysplastic Syndrome	Drug: Antithymocyte globulin Drug: Cyclosporine	Hospital de Cabueñes, Asturias, Spain Hospital Germans Trias i Pujol, Badalona, Spain Hospital de Basurto, Bilbao, Spain Hospital Ntra Sra del Rosell, Cartagena, Spain Hospital Materno Infantil de Las Palmas, Las Palmas de Gran Canaria, Spain Hospital Virgen de la Victoria, Malaga, Spain Hospital Morales Meseguer, Murcia, Spain Hospital de Navarra, Pamplona, Spain Hospital Arnau de Vilanova, Valencia, Spain Hospital Dr Pesset, Valencia, Spain Hospital Clinico Universitario, Zaragoza, Spain	https://ClinicalTrials.gov/show/NCT00488436
168	Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA)	No Results Available	Cytopaenia	Biological: Eltrombopag Biological: Rabbit ATG Biological: CsA	Novartis Investigative Site, Aichi, Japan Novartis Investigative Site, Aichi, Japan Novartis Investigative Site, Ibaraki, Japan Novartis Investigative Site, Ishikawa, Japan Novartis Investigative Site, Miyagi, Japan Novartis Investigative Site, Okayama, Japan Novartis Investigative Site, Osaka, Japan Novartis Investigative Site, Osaka, Japan Novartis Investigative Site, Osaka, Japan Novartis Investigative Site, Tochigi, Japan Novartis Investigative Site, Tokyo, Japan	https://ClinicalTrials.gov/show/NCT02404025
169	Allogeneic Hematopoietic Stem Cell Transplantation Using a Non-meloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-thymocyte Globulin for Older Patients With Relapsed Lymphoid Malignancies	No Results Available	Haemato-lymphoid Malignancies or Syndromes in Whom Allogeneic Stem Cell Transplantation is Warranted	Drug: total lymphoid irradiation and anti-thymocyte globulin	Besançon University Hospital, Besançon, France Lille University Hospital, Lille, France Lyon University Hospital, Lyon, France Nantes University Hospital, Nantes, France	https://ClinicalTrials.gov/show/NCT01566656
170	Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia	Has Results	Aplastic Anemia	Drug: cyclosporine Biological: anti-thymocyte globulin	Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States	https://ClinicalTrials.gov/show/NCT01231841

171	Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma	No Results Available	Drug/Agent Toxicity by Tissue/Organ Multiple Myeloma and Plasma Cell Neoplasm	Biological: anti-thymocyte globulin Drug: sirolimus	James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States	https://ClinicalTrials.gov/show/NCT00317798
172	Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia	Has Results	Myelodysplastic Syndrome	Drug: Antithymocyte globulin Drug: Cyclosporine	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT0005937
173	Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation	No Results Available	Type 1 Diabetes Mellitus Hypoglycemia	Biological: Allogeneic Islets of Langerhans Drug: Everolimus Drug: anti-thymocyte globulin Drug: Cyclosporine	University of Minnesota, Minneapolis, Minnesota, United States	https://ClinicalTrials.gov/show/NCT00286624
174	Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in Anew Kidney Transplant	No Results Available	De Novo Kidney Transplant	Drug: ATG-F	Beijing, China Changchun, China Chengdu, China Guangzhou, China Hangzhou, China Jinan, China Nanjing, China Shanghai, China Shenyang, China Tianjin, China Wenzhou, China Wuhan, China Xi'an, China Zhengzhou, China	https://ClinicalTrials.gov/show/NCT02267512
175	Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndromes	No Results Available	Myelodysplastic Syndromes	Drug: ATG + CSA Behavioral: Supportive care	Universitaetsspital-Baseel, Basel, Switzerland	https://ClinicalTrials.gov/show/NCT00004208
176	Prospective Phase II Study of Rabbit Antithymocyte Globulin (ATG, ThymoglobulinA*, Genzyme) With Cyclosporin for Patients With Acquired Aplastic Anemia	No Results Available	Acquired Aplastic Anaemia	Drug: Rabbit ATG, Thymoglobuline (Genzyme)		https://ClinicalTrials.gov/show/NCT01530555
177	Study of APN201 (Liposomal Recombinant Human Cu/Zn-Superoxide Dismutase) for the Prevention of Radiation-Induced Dermatitis in Women With Breast Cancer	No Results Available	Radiation Induced Dermatitis	Drug: APN201 Drug: Placebo	Medical University Graz; Department of Therapeutic Radiology and Oncology, Graz, Austria	https://ClinicalTrials.gov/show/NCT01513278
178	A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome	No Results Available	Hematologic Diseases Myelodysplastic Syndromes	Drug: Antithymocyte globulin Drug: Cyclosporine	Warren G. Magnuson Clinical Center (CC), Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT0001839
179	Cyclophosphamide and Antithymocyte Globulin Followed by Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant	Has Results	Aplastic Anemia	Drug: cyclophosphamide Biological: anti-thymocyte globulin Drug: cyclosporine Procedure: allogeneic bone marrow transplantation Drug: methotrexate Genetic: DNA analysis Other: flow cytometry Genetic: polymorphism analysis Other: laboratory biomarker analysis	Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States	https://ClinicalTrials.gov/show/NCT00343785
180	Donor Stem Cell Transplant After Busulfan, Fludarabine, Methyprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome	No Results Available	Leukemia Myelodysplastic Syndromes Nonmalignant Neoplasm Pancytopenia Nocturnal Hemoglobinuria	Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation	Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT00731328
181	Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic Syndrome	No Results Available	Leukemia Myelodysplastic Syndromes	Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation Procedure: peripheral blood stem cell transplantation	Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT00732316
182	Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies	Has Results	Blood Cancer Leukemia	Drug: Cyclosporine Drug: Anti-Thymocyte Globulin Drug: mycophenolate mofetil Drug: Granulocyte-Colony Stimulating Factor Radiation: Total Lymphoid Irradiation	Stanford University School of Medicine, Stanford, California, United States	https://ClinicalTrials.gov/show/NCT00185640
183	Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease	No Results Available	Graft Vs Host Disease	Drug: ABX-CBL	Abgenix, Inc, Fremont, California, United States	https://ClinicalTrials.gov/show/NCT00035880
184	Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)	No Results Available	Myelodysplastic Syndromes	Drug: Daclizumab	National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT00072969
185	Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia	No Results Available	Aplastic Anemia	Drug: Anti-thymocyte globulin Drug: Cyclophosphamide Procedure: Bone marrow transplantation	Roswell Park Cancer Institute, Buffalo, New York, United States University of Texas - MD Anderson Cancer Center, Houston, Texas, United States Medical College of Wisconsin, Milwaukee, Wisconsin, United States Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States	https://ClinicalTrials.gov/show/NCT00004474

IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency	No Results Available	T-Cell Immune Deficiency Diseases Severe Combined Immunodeficiency	Drug: Busulfan, Fludarabine and ATG	Children's Healthcare of Atlanta, Atlanta, Georgia, United States	https://ClinicalTrials.gov/show/NCT00228852
186					
Trial of Ascertaining Individual Preferences for Loved One's Role in End-of-Life	No Results Available	Amyotrophic Lateral Sclerosis Glioma Pancreatic Cancer Pancreatic Cancer Making Other: standard of care	Other: TAILORED Patient Family Decision Making Other: standard of care	Johns Hopkins University, Baltimore, Maryland, United States	https://ClinicalTrials.gov/show/NCT01160367
187					
ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis	No Results Available	Hematopoietic Stem Cell Transplantation Antithymocyte Globulin Viral Infection	Drug: ATG	Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT01883180
188					
Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease	No Results Available	Spinal Muscular Atrophy Amyotrophic Lateral Sclerosis Spinobulbar Muscular Atrophy	Drug: leuprolide Drug: testosterone		https://ClinicalTrials.gov/show/NCT00004771
189					
Pupilligraphy as Screening Tool for Brain Insulin Resistance	No Results Available	Obesity	Drug: human insulin Drug: placebo Diagnostic Test: Pupilligraphy	University of Tuebingen, Department of Internal Medicine IV, TÄxibingen, Germany	https://ClinicalTrials.gov/show/NCT03651661
190					
Cluster Randomized Trial of Stepped Care Intervention vs. Treatment as Usual for Patients With Depression	No Results Available	Depression	Behavioral: Active monitoring Behavioral: Bibliotherapy Behavioral: Online self-help Behavioral: Outpatient psychotherapy Procedure: Psychiatric treatment Behavioral: Combined psychotherapy and psychopharmacological treatment Other: Control group: treatment as usual	Centre for Psychosocial Medicine, Department of Medical Psychology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany	https://ClinicalTrials.gov/show/NCT01731717
191					
Home Use of Cupping Massage in Chronic Neck Pain	No Results Available	Neck Pain	Procedure: cupping massage Procedure: Progressive muscle relaxation	Klinik fÄxir Naturheilkunde, Essen, Germany	https://ClinicalTrials.gov/show/NCT01500330
192					
Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease	No Results Available	Motor Neuron Disease Amyotrophic Lateral Sclerosis Primary Lateral Sclerosis Prog ressive Muscular Atrophy	Biological: Levetiracetam	Duke University ALS Clinic - 932 Morreene Road, Durham, North Carolina, United States	https://ClinicalTrials.gov/show/NCT00324454
193					
Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple Myeloma	No Results Available	Multiple Myeloma and Plasma Cell Neoplasm	Biological: anti-thymocyte globulin	Fred Hutchinson Cancer Research Center, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT00378768
194					
Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes	No Results Available	Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Diseases	Biological: anti-thymocyte globulin Biological: etanercept	St. Joseph Cancer Center, Bellingham, Washington, United States Olympic Medical Center, Port Angeles, Washington, United States Seattle Cancer Care Alliance, Seattle, Washington, United States Fred Hutchinson Cancer Research Center, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT00217386
195					
Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia	Has Results	Aplastic Anemia	Drug: Campath-1H Drug: r-ATG Drug: CSA	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT00652620
196					
The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation	No Results Available	Patients Active and Listed for Lung Transplantation	Drug: Zenapax	Johns Hopkins University Hospital, Baltimore, Maryland, United States	https://ClinicalTrials.gov/show/NCT00181142
197					
Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation	Has Results	Graft Rejection	Drug: Alemtuzumab Drug: Anti-Thymocyte Globulin	Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States	https://ClinicalTrials.gov/show/NCT00331162
198					
Combination Therapy of Cord Blood and G-CSF for Patients With Brain Injury or Neurodegenerative Disorders	No Results Available	Brain Injury Cerebral Palsy Amyotrophic Lateral Sclerosis Parkinson's Disease	Procedure: Umbilical cord blood therapy Biological: Filgrastim	CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02236065
199					
Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to Treatment	No Results Available	Multiple Myeloma and Plasma Cell Neoplasm	Biological: anti-thymocyte globulin Drug: busulfan Drug: fludarabine phosphate Procedure: allogeneic bone marrow transplantation Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation	Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille, France	https://ClinicalTrials.gov/show/NCT00802568
200					

201	Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer	No Results Available	Chronic Myeloproliferative Disorders Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms	Biological: therapeutic immune globulin Drug: busulfan Drug: fludarabine phosphate Procedure: allogeneic hematopoietic stem cell transplantation	Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille, France	https://ClinicalTrials.gov/show/NCT00806767
202	Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer	No Results Available	Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms	Biological: anti-thymocyte globulin Drug: busulfan Drug: fludarabine phosphate Drug: leucovorin calcium Drug: methotrexate Procedure: allogeneic bone marrow transplantation Procedure: allogeneic hematopoietic stem cell transplantation Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation	Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT00627666
203	Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer	Has Results	Graft Versus Host Disease Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Diseases Secondary Myelofibrosis	Biological: anti-thymocyte globulin Drug: busulfan Drug: cyclophosphamide Drug: mycophenolate mofetil Drug: tacrolimus Genetic: polymerase chain reaction Genetic: polymorphism analysis Other: flow cytometry Other: laboratory biomarker analysis Other: pharmacogenomic studies Other: pharmacological study Procedure: allogeneic bone marrow transplantation Procedure: allogeneic hematopoietic stem cell transplantation Procedure: peripheral blood stem cell transplantation		https://ClinicalTrials.gov/show/NCT00611351
204	Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders	No Results Available	Anemia, Aplastic Hematologic Diseases Pancytopenia Blood Disease	Drug: antilymphocyte serum Drug: nandrolone		https://ClinicalTrials.gov/show/NCT00000597
205	Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer	Has Results	Chronic Myeloproliferative Disorders Graft Versus Host Disease Infection Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms Precancerous stem cell conditions Secondary Myelofibrosis Small Intestine Cancer	Biological: anti-thymocyte globulin Drug: cyclophosphamide Drug: etoposide Drug: fludarabine phosphate Drug: melphalan Drug: methotrexate Drug: sirolimus Drug: tacrolimus Procedure: allogeneic hematopoietic stem cell transplantation Procedure: hematopoietic stem cell transplantation Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation Procedure: peripheral blood stem cell transplantation Radiation: total-body irradiation	Banner Good Samaritan Medical Center, Phoenix, Arizona, United States City of Hope Comprehensive Cancer Center, Duarte, California, United States	https://ClinicalTrials.gov/show/NCT00589563

			Chronic Myeloproliferative Disorders Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative			
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant	Has Results	Neoplasms	Biological: rituximab Drug: busulfan Drug: carmustine Drug: cyclophosphamide Drug: cytarabine Drug: etoposide Drug: fludarabine phosphate Drug: melphalan Radiation: total body irradiation	(TBI) Drug: anti-thymocyte globulin IV	Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States	https://ClinicalTrials.gov/show/NCT00691015
Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies	No Results Available	Phase Chronic Myelogenous Leukemia Adult Acute Myeloid Leukemia in Remission Adult Acute Myeloid Leukemia With t(11q23 [ML1] Abnormalities) Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13,q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q13) analysis	Drug: fludarabine phosphate Drug: busulfan Biological: anti-thymocyte globulin Drug: tacrolimus Drug: methotrexate Procedure: peripheral blood stem cell transplantation Procedure: allogeneic hematopoietic stem cell transplantation Other: laboratory biomarker analysis		Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT01056614
Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission	No Results Available	Congenital Amegakaryocytic Thrombocytopenia Diamond-blackfan Anemia Fanconi Anemia Severe Congenital Neutropenia Thrombocytopenia	Biological: anti-thymocyte globulin Drug: busulfan Drug: fludarabine phosphate Procedure: allogeneic bone marrow transplantation Procedure: peripheral blood stem cell transplantation Procedure: umbilical cord blood transplantation Radiation: radiation therapy		UCSF Comprehensive Cancer Center, San Francisco, California, United States	https://ClinicalTrials.gov/show/NCT00305708
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer	No Results Available	Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes	Biological: anti-thymocyte globulin Biological: sargramostim Drug: busulfan Drug: fludarabine phosphate Drug: mycophenolate mofetil Drug: tacrolimus Procedure: umbilical cord blood transplantation		UCSF Comprehensive Cancer Center, San Francisco, California, United States	https://ClinicalTrials.gov/show/NCT00301951
Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer	No Results Available	Chronic Myeloproliferative Disorders Graft Versus Host Disease Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Diseases	Biological: anti-thymocyte globulin Drug: busulfan Drug: fludarabine phosphate Drug: methotrexate Drug: tacrolimus Procedure: allogeneic hematopoietic stem cell transplantation Procedure: peripheral blood stem cell transplantation		Fred Hutchinson Cancer Research Center, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT00346359
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease	Has Results	Chronic Myeloproliferative Disorders Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes	Biological: anti-thymocyte globulin Biological: sargramostim Biological: therapeutic allogeneic lymphocytes Drug: busulfan Drug: fludarabine phosphate Drug: methotrexate Drug: tacrolimus Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation Procedure: peripheral blood stem cell transplantation		Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States	https://ClinicalTrials.gov/show/NCT00448201

212	With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)	No Results Available	MDS AML ALL BAL	Drug: Clofarabine in combination with IV busulfan and ATG	HÃpital Edouard Herriot, Lyon, France Institut Paoli Calmettes, Marseille, France Nantes University hospital, Nantes, France HÃpital Saint Louis, Paris, France CHU Haut-LÃ©vÃ©, Pessac, France CHRU Hauteperiere, Strasbourg, France	https://ClinicalTrials.gov/show/NCT00863148
213	Phase II Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis	No Results Available	Systemic Sclerosis	Drug: anti-thymocyte globulin Drug: cyclophosphamide	University of Colorado Cancer Center, Denver, Colorado, United States Duke University Medical Center, Durham, North Carolina, United States Fred Hutchinson Cancer Research Center, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT00016458
214	Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder	No Results Available	Chronic Myeloproliferative Disorders Graft Versus Host Disease Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Diseases	Biological: anti-thymocyte globulin Drug: busulfan Drug: cyclophosphamide Drug: cyclosporine Drug: methotrexate Procedure: allogeneic bone marrow transplantation Procedure: peripheral blood stem cell transplantation	Fred Hutchinson Cancer Research Center, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT00054340
215	Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis	No Results Available	Multiple Sclerosis	Drug: anti-thymocyte globulin Drug: cyclophosphamide Drug: flglrastim Drug: prednisone Procedure: peripheral blood stem cell transplantation Procedure: irradiation	City of Hope National Medical Center, Duarte, California, United States University of Colorado Cancer Center, Denver, Colorado, United States Washington University Barnard Cancer Center, Saint Louis, Missouri, United States University of Nebraska Medical Center, Omaha, Nebraska, United States Duke University Medical Center, Durham, North Carolina, United States Fred Hutchinson Cancer Research Center, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT00014755
216	Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders	No Results Available	Systemic Sclerosis Systemic Lupus Erythematosus Dermatomyositis Juvenile Rheumatoid Arthritis Autoimmune Diseases	Procedure: Stem Cell Transplantation Device: CD34 selection	Fred Hutchinson Cancer Research Center, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT00010335
217	Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists	Has Results	End Stage Renal Disease	Drug: Rabbit Antithymocyte globulin Drug: Daclizumab	Medical University of South Carolina, Charleston, South Carolina, United States	https://ClinicalTrials.gov/show/NCT00859131
218	Biological Therapy in Treating Patients With Myelodysplastic Syndromes	No Results Available	Myelodysplastic Syndromes	Biological: anti-thymocyte globulin Biological: etanercept	Fred Hutchinson Cancer Research Center, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT00005853
219	Medical Treatment for Diamond Blackfan Anemia	No Results Available	Fanconi's Anemia HematoLogic Disease	Drug: Antithymocyte globulin Drug: Cyclosporine	National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT00001749
220	50020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome	No Results Available	Leukemia Myelodysplastic Syndromes	Biological: anti-thymocyte globulin Drug: cyclosporine	MBCCOP - Gulf Coast, Mobile, Alabama, United States CCOP - Greater Phoenix, Phoenix, Arizona, United States Veterans Affairs Medical Center - Phoenix (Carl T. Hayden), Phoenix, Arizona, United States Veterans Affairs Medical Center - Tucson, Tucson, Arizona, United States Arizona Cancer Center, Tucson, Arizona, United States University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States Veterans Affairs Medical Center - Little Rock (McClellan), Little Rock, Arkansas, United States City of Hope Comprehensive Cancer Center, Duarte, California, United States USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States Veterans Affairs Medical Center - West Los Angeles, Los Angeles, California, United States Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States CCOP - Bay Area Tumor Institute, Oakland, California, United States Chao Family Comprehensive Cancer Center, Orange, California, United States University of California Davis Cancer Center, Sacramento, California, United States CCOP - Santa Rosa Memorial Hospital, Santa Rosa, California, United States David Grant Medical Center, Travis Air Force Base, California, United States University of Colorado Cancer Center, Denver, Colorado, United States MBCCOP - Howard University Cancer Center, Washington, District of Columbia, United States CCOP - Atlanta Regional, Atlanta, Georgia, United States Dwight David Eisenhower Army Medical Center, Fort Gordon, Georgia, United States Cancer Research Center of Hawaii, Honolulu, Hawaii, United States Tripler Army Medical Center, Honolulu, Hawaii, United States MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States CCOP - Central Illinois, Decatur, Illinois, United States Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital), Hines, Illinois, United States Loyola University Medical Center, Maywood, Illinois, United States Genesis Medical Center, Davenport, Iowa, United States University of Kansas Medical Center, Kansas City, Kansas, United States CCOP - Wichita, Wichita, Kansas, United States Veterans Affairs Medical Center - Wichita, Kansas, United States Veterans Affairs Medical Center - Lexington, Lexington, Kentucky, United States Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States MBCCOP - LSU Medical Center, New Orleans, Louisiana, United States Tulane University School of Medicine, New Orleans, Louisiana, United States Louisiana State University Health Sciences Center - Shreveport, Shreveport, Louisiana, United States Veterans Affairs Medical Center - Shreveport, Shreveport, Louisiana, United States Boston Medical Center, Boston, Massachusetts, United States Veterans Affairs Medical Center - Boston (Jamaica Plain), Jamaica Plain, Massachusetts, United States Veterans Affairs Medical Center - Ann Arbor, Ann Arbor, Michigan, United States CCOP - Ann Arbor Regional, Ann Arbor, Michigan, United States University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States Veterans Affairs Medical Center - Detroit, Detroit, Michigan, United States Henry Ford Hospital, Detroit, Michigan, United States CCOP - Grand Rapids, Grand Rapids, Michigan, United States CCOP - Beaumont, Royal Oak, Michigan, United States Providence Hospital - Southfield, Southfield, Michigan, United States Veterans Affairs Medical Center - Biloxi, Biloxi, Mississippi, United States University of Mississippi Medical Center, Jackson, Mississippi, United States Veterans Affairs Medical Center - Jackson, Jackson, Mississippi, United States Keesler Medical Center - Keesler AFB, Keesler AFB, Mississippi, United States Veterans Affairs Medical Center - Kansas City, Kansas City, Missouri, United States CCOP - Kansas City, Kansas City, Missouri, United States St. Louis University Health Sciences Center, Saint Louis, Missouri, United States CCOP - St. Louis-Cape Girardeau, Saint Louis, Missouri, United States CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States CCOP - Montana Cancer Consortium, Billings, Montana, United States Veterans Affairs Medical Center - Albuquerque, Albuquerque, New Mexico, United States MBCCOP - University of New Mexico HSC, Albuquerque, New Mexico, United States Veterans Affairs Medical Center - Albany, Albany, New York, United States Herbert Irving Comprehensive Cancer Center, New York, New York, United States University of Rochester Medical Center, Rochester, New York, United States CCOP - Southeast Cancer Control Consortium, Winston-Salem, North Carolina, United States Veterans Affairs Medical Center - Cincinnati, Cincinnati, Ohio, United States Barrett Cancer Center, Cincinnati, Ohio, United States Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States CCOP - Columbus, Columbus, Ohio, United States Veterans Affairs Medical Center - Dayton, Dayton, Ohio, United States CCOP - Dayton, Dayton, Ohio, United States University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States Veterans Affairs Medical Center - Oklahoma City, Oklahoma City, Oklahoma, United States Veterans Affairs Medical Center - Portland, Portland, Oregon, United States CCOP - Columbia River Program, Portland, Oregon, United States Oregon Cancer Institute, Portland, Oregon, United States Veterans Affairs Medical Center - Charleston, Charleston, South Carolina, United States Medical University of South Carolina, Charleston, South Carolina, United States CCOP - Greenville, Greenville, South Carolina, United States CCOP - Spartanburg, Spartanburg, South Carolina, United States Brooke Army Medical Center, Fort Sam Houston, Texas, United States University of Texas Medical Branch, Galveston, Texas, United States Veterans Affairs Medical Center - Houston, Houston, Texas, United States University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States Veterans Affairs Medical Center - San Antonio (Murphy), San Antonio, Texas, United States Veterans Affairs Medical Center - Temple, Temple, Texas, United States CCOP - Scott and White Hospital, Temple, Texas, United States Huntsman Cancer Institute, Salt Lake City, Utah, United States Veterans Affairs Medical Center - Salt Lake City, Salt Lake City, Utah, United States CCOP - Virginia Mason Research Center, Seattle, Washington, United States Veterans Affairs Medical Center - Seattle, Seattle, Washington, United States CCOP - Northwest, Tacoma, Washington, United States Madigan Army Medical Center, Tacoma, Washington, United States	https://ClinicalTrials.gov/show/NCT00016419

221	Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer	Has Results	Myeloproliferative Disorders Kidney Cancer Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myeloid Leukemia Myeloid Malignancies Myeloid Neoplasms Myeloid Disorders	Biological: anti-thymocyte globulin Drug: busulfan Drug: cyclophosphamide Drug: fludarabine phosphate Drug: methotrexate Drug: tacrolimus Procedure: nonmyeloablative allogeneic HSCT	Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States	https://ClinicalTrials.gov/show/NCT0078761
222	Phase 2 Study of Autologous Transplantation Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG	Has Results	Transplantation Autologous Transplantation Allogeneic Transplantation Peripheral Blood Stem Cell Transplantation Hematopoietic Stem Cell Transplantation	Procedure: Autologous peripheral blood stem cells (auto-PBSC) transplantation Procedure: Allogeneic peripheral blood stem cells (allo-PBSC) transplantation Drug: Filgrastim Drug: Cyclophosphamide Drug: Melphalan Drug: Cyclosporine Radiation: Total lymphoid irradiation Biological: Rabbit anti-thymocyte globulin Drug: Mycophenolate Mofetil Drug: Solumedrol Drug: Diphenhydramine Drug: Hydrocortisone	Stanford University School of Medicine, Stanford, California, United States	https://ClinicalTrials.gov/show/NCT0089847
223	Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation	Has Results	Kidney Transplantation	Drug: Sirolimus Drug: Tacrolimus	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT0076570
224	Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic Anemia	No Results Available	Aplastic Anemia	Biological: anti-thymocyte globulin Biological: filgrastim Drug: Fludarabine Drug: Cyclophosphamide Procedure: CD34 ⁺ CD19 ⁻ depleted hematopoietic stem cell transplantation	Asan Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01105273
225	Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients With Hematopoietic Stem Cell Support in Systemic Sclerosis	No Results Available	Implant or Graft; Rejection	Drug: Belatacept Drug: Tacrolimus Drug: Mycophenolate Drug: rATG Drug: Methylprednisolone Procedure: Renal transplant	Columbia University Medical Center, New York, New York, United States	https://ClinicalTrials.gov/show/NCT02152345
226	Support in Systemic Sclerosis	Has Results	SYSTEMIC SCLERODERMA	Drug: standard of care Procedure: stem cell transplantation	Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States	https://ClinicalTrials.gov/show/NCT00278525
227	Comparing Therapies for the Treatment of Severe Aplastic Anemia	No Results Available	Severe Aplastic Anemia	Drug: antithymocyte globulin Drug: cyclophosphamide Drug: cyclosporine	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT0001626
228	Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT	No Results Available	Bone Marrow Failure Syndromes	Drug: Cyclophosphamide-fludarabine-anti thymocyte globulin	Asan Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT0074527
229	Improved Induction and Maintenance Immunosuppression in Kidney Transplantation	Has Results	End-stage Renal Disease	Drug: rabbit anti-thymocyte globulin Drug: mycophenolate mofetil Drug: sirolimus Drug: tacrolimus	The Nebraska Medical Center, Omaha, Nebraska, United States	https://ClinicalTrials.gov/show/NCT0056933
230	TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD	No Results Available	Myeloproliferative Disorders Blood Cancer Myeloid Dysplastic Syndromes	Procedure: Total Lymphoid Irradiation (TLI) Procedure: Anti-Thymocyte Globulin as Conditioning (ATG)	Stanford University School of Medicine, Stanford, California, United States	https://ClinicalTrials.gov/show/NCT00185796
231	Combination Therapy of Severe Aplastic Anemia	No Results Available	Severe Aplastic Anemia	Drug: Cyclosporine	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT00001964
232	Delayed Mycophenolate Mofetil in Single-Donor Islet Allograft Transplantation in Type 1 Diabetes	No Results Available	Type 1 Diabetes	Biological: Allogeneic Islets of Langerhans	University of Minnesota, Minneapolis, Minnesota, United States	https://ClinicalTrials.gov/show/NCT00285233
233	Evaluate Effects and Safety of Pre-load Myfortic [®] in Kidney Transplant Recipients	Has Results	Kidney Transplant Recipients	Drug: mycophenolic acid	University of Cincinnati Medical Center, Cincinnati, Ohio, United States	https://ClinicalTrials.gov/show/NCT01336296
234	P300 Brain Computer Interface Keyboard to Operate Assistive Technology	Has Results	Healthy Amyotrophic Lateral Sclerosis Neuromuscular Disease Spinal Cord Injury Cerebral Palsy	Device: Brain Computer Interface Keyboard	University of Michigan Direct Brain Interface Project, Ann Arbor, Michigan, United States Wadsworth Center, Albany, New York, United States	https://ClinicalTrials.gov/show/NCT00860951

EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection	Has Results	Chronic Obstructive Pulmonary Idiopathic Pulmonary Fibrosis Cystic Fibrosis Bronchiectasis Pulmonary Vascular Disease Biological: Placebo Biological: EZ-2053 Biological: EZ-2053 5mg/kg	Cedars-Sinai Medical Center, Los Angeles, California, United States University of California, San Francisco, San Francisco, California, United States Stanford University, Stanford, California, United States Mayo Clinic, Jacksonville, Florida, United States Emory University School of Medicine, Atlanta, Georgia, United States University of Iowa Hospital & Clinics, Iowa City, Iowa, United States University of Kentucky Medical Center, Lexington, Kentucky, United States Barnes-Jewish Hospital, St. Louis, Missouri, United States Cleveland Clinic, Cleveland, Ohio, United States INTEGRIS Baptist Medical Center, Oklahoma City, Oklahoma, United States University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States Temple University Hospital, Philadelphia, Pennsylvania, United States Vanderbilt University, Nashville, Tennessee, United States Baylor College of Medicine, Houston, Texas, United States University of Texas Health Sciences Center, San Antonio, Texas, United States The Alfred Hospital, Melbourne, Victoria, Australia Medical University of Vienna, Vienna, Austria University of Alberta, Edmonton, Alberta, Canada Toronto General Hospital, Toronto, Canada	https://ClinicalTrials.gov/show/NCT00105183
236 Immunological Risk	Has Results	Kidney Transplantation Drug: Rabbit Antithymocyte Globulin Drug: Velcade Drug: Rituxan	The Christ Hospital, Cincinnati, Ohio, United States The University Hospital, Cincinnati, Ohio, United States	https://ClinicalTrials.gov/show/NCT00782821
237 Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients	Has Results	Kidney Transplantation Drug: basiliximab Drug: rabbit antithymocyte globulin Drug: tacrolimus Drug: alemtuzumab Drug: mycophenolate mofetil Drug: steroids	Birmingham, Alabama, United States Los Angeles, California, United States Palo Alto, California, United States San Diego, California, United States San Francisco, California, United States San Francisco, California, United States Denver, Colorado, United States Washington, District of Columbia, United States Washington, District of Columbia, United States Miami, Florida, United States Tampa, Florida, United States Chicago, Illinois, United States Chicago, Illinois, United States Livingston, New Jersey, United States New Brunswick, New Jersey, United States Hawthorne, New York, United States New York, New York, United States New York, New York, United States Chapel Hill, North Carolina, United States Durham, North Carolina, United States Cincinnati, Ohio, United States Portland, Oregon, United States Danville, Pennsylvania, United States Harrisburg, Pennsylvania, United States Charleston, South Carolina, United States San Antonio, Texas, United States Salt Lake City, Utah, United States Madison, Wisconsin, United States Milwaukee, Wisconsin, United States	https://ClinicalTrials.gov/show/NCT00113269
238 Scleroderma: Cyclophosphamide or Transplantation (SCOT)	Has Results	Scleroderma, Systemic Sclerosis Autoimmune Disease Biological: mHSC1 Drug: cyclophosphamide	City of Hope National Medical Center, Duarte, California, United States UCLA Medical School, Los Angeles, California, United States University of Kentucky, Lexington, Kentucky, United States Massachusetts General Hospital, Boston, Massachusetts, United States Boston University School of Medicine, Boston, Massachusetts, United States University of Michigan, Ann Arbor, Michigan, United States Washington University School of Medicine, Saint Louis, Missouri, United States Duke University, Durham, North Carolina, United States University of Toledo Health Science Campus, Toledo, Ohio, United States University of Pittsburgh, Pittsburgh, Pennsylvania, United States Medical University of South Carolina, Charleston, South Carolina, United States University of Texas-Houston Medical School, Houston, Texas, United States MD Anderson Cancer Center, Houston, Texas, United States Fred Hutchinson Cancer Research Center (FHCR), Seattle, Washington, United States Medical College of Wisconsin, Milwaukee, Wisconsin, United States University of Calgary, Calgary, Alberta, Canada Dr. Markland Medical Professional Corporation, Saskatoon, Saskatchewan, Canada	https://ClinicalTrials.gov/show/NCT00114530
239 ECoG Direct Brain Interface for Individuals With Upper Limb Paralysis	Has Results	Tetraplegia Spinal Cord Injury Brachial Plexus Injury Muscular Dystrophy ALS Brainstem Stroke Device: Implantation of ECoG sensors on the brain surface	University of Pittsburgh, Pittsburgh, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT01393444

				Neurodegenerative Disease Weight Loss Amyotrophic Lateral Sclerosis Parkinson's Disease Huntington's Disease Cacheuxia	Behavioral: In-Person Nutritional Counseling by a Registered Dietitian Behavioral: Nutritional counseling using an e-Health Application	Massachusetts General Hospital, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT02418546
240	Electronic Health Application To Measure Outcomes Remotely	No Results Available					
				Alzheimer's Disease Amyotrophic Lateral Sclerosis Brain Injury Huntington's Disease Multiple Sclerosis Parkinson's Disease Stroke Spinal Cord Injury	Other: Laughter Therapy	Evergreen Healthcare, Kirkland, Washington, United States	https://ClinicalTrials.gov/show/NCT02750982
241	Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.	No Results Available					
	Open-Label and Single-Arm Study of MYOBLOCA® in the Treatment of Troublesome Sialorrhea in Adults	No Results Available	Sialorrhea	Drug: MYOBLOC		Phoenix, Arizona, United States Scottsdale, Arizona, United States Scottsdale, Arizona, United States Loma Linda, California, United States Los Angeles, California, United States Aurora, Colorado, United States Atlanta, Florida, United States Boca Raton, Florida, United States Orlando, Florida, United States Port Charlotte, Florida, United States Atlanta, Georgia, United States Kansas City, Kansas, United States Overland Park, Kansas, United States Elkridge, Maryland, United States Farmington Hills, Michigan, United States Saint Louis, Missouri, United States Las Vegas, Nevada, United States Edison, New Jersey, United States Centerville, Ohio, United States Tulsa, Oklahoma, United States Greenville, South Carolina, United States Cordova, Tennessee, United States San Antonio, Texas, United States Kirklund, Washington, United States Spokane, Washington, United States Tacoma, Washington, United States Grodno, Belarus Dnipropetrovsk, Ukraine Ivano-Frankivsk, Ukraine Kharkiv, Ukraine Lviv, Ukraine Odesa, Ukraine Rivne, Ukraine Uzhgorod, Ukraine Zaporizhzhya, Ukraine	https://ClinicalTrials.gov/show/NCT02610868
242	Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CSA	No Results Available	Sialorrhea	Drug: MYOBLOC			
	243 Treatment	Has Results	Anemia, Aplastic Anemia, Hypoplastic	Drug: h-ATG (ATGAM) Drug: Cyclosporine (Gengraf)		National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT00944749
	Efficacy and Safety Study of MYOBLOCA® Followed by Open-Label Multiple-Treatment With MYOBLOCA® in the Treatment of Troublesome Sialorrhea in Adult Subjects	No Results Available	Sialorrhea	Drug: MYOBLOC Other: PLACEBO		Loma Linda, California, United States Los Angeles, California, United States National City, California, United States Aurora, Colorado, United States Washington, District of Columbia, United States Boca Raton, Florida, United States Port Charlotte, Florida, United States Carmel, Indiana, United States Baltimore, Maryland, United States Elkridge, Maryland, United States Detroit, Michigan, United States Saint Louis, Missouri, United States Edison, New Jersey, United States Albany, New York, United States New York, New York, United States Cincinnati, Ohio, United States Tulsa, Oklahoma, United States Port Royal, South Carolina, United States Cordova, Tennessee, United States Houston, Texas, United States San Antonio, Texas, United States Salt Lake City, Utah, United States Kirklund, Washington, United States Tacoma, Washington, United States Irkutsk Region, Russian Federation Vsevolozhsk, Leningrad Region, Russian Federation St.Petersburg, Petrodvorets, Russian Federation Krasnoyarsk, Russian Federation Dnipropetrovsk, Ukraine Ivano-Frankivsk, Ukraine Kharkiv, Ukraine Lviv, Ukraine Rivne, Ukraine Uzhgorod, Ukraine	https://ClinicalTrials.gov/show/NCT01994109
244	Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia	No Results Available	Severe Aplastic Anemia	Drug: cyclosporine Drug: Rapamune Drug: ATG		National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT00061360
245	Telemedicine for Patients With Chronic Respiratory Insufficiency	No Results Available	Chronic Respiratory Failure	Device: telemedicine program		Telemedicine Service, Fondazione S. Maugeri, IRCCS, Lumezzane, Brescia, Italy	https://ClinicalTrials.gov/show/NCT00563745

247	Safety Study of AVP-923 in the Treatment of IED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)	No Results Available	Alzheimer's Disease Stroke Parkinson's Disease Traumatic Brain Injury	Drug: AVP-923	Barrow Neurological Institute, Phoenix, Arizona, United States Center for Neurologic Study, La Jolla, California, United States UCLA School of Medicine, Los Angeles, California, United States UCSF, San Francisco, California, United States Research Center for Clinical Studies, Inc., Darien, Connecticut, United States George Washington University Medical Faculty Assoc., Washington, District of Columbia, United States Neurological Associates, Ft. Lauderdale, Florida, United States University of Miami Dept. of Neurology, Miami, Florida, United States Miami Jewish Home & Hospital for the Aged, Miami, Florida, United States Allied Clinical Trials, Miami, Florida, United States Renstar Medical Research, Plantation, Florida, United States Suncoast Neuroscience Associates Inc., St. Petersburg, Florida, United States Tampa, Florida, United States Neurology & Headache Specialist of Atlanta, L.L.C., Decatur, Georgia, United States Consultants in Neurology LTD, Northbrook, Illinois, United States Advanced Neurology Specialists, Great Falls, Montana, United States Neurological Associates, P.C., Lincoln, Nebraska, United States Upstate Clinical Research, Albany, New York, United States DENT Neurologic Group L.L.P., Amherst, New York, United States Hospital for Joint Diseases MS Care Center, New York, New York, United States SUNY Upstate Medical University, Syracuse, New York, United States Carolinas Medical Center, Charlotte, North Carolina, United States Raleigh Neurology Associates, PA, Raleigh, North Carolina, United States NeuroCare Center, Inc., Canton, Ohio, United States MetroHealth Medical Center, Cleveland, Ohio, United States University Memory and Aging Center, Cleveland, Ohio, United States The Cleveland Clinic Foundation, Cleveland, Ohio, United States Clinical Pharmaceutical Trials, Inc., Tulsa, Oklahoma, United States Lehigh Valley Neurosciences and Pain Research Center, Allentown, Pennsylvania, United States Westmoreland Neurology, Greensburg, Pennsylvania, United States Jenkintown, Pennsylvania, United States MCP-Hahnemann University, Philadelphia, Pennsylvania, United States Penn Neurological Institute, Philadelphia, Pennsylvania, United States Neurological Associates of Delaware Valley, Upland, Pennsylvania, United States Claghorn-Lesem Research Clinic, Bellaire, Texas, United States Methodist Neurological Institute, Houston, Texas, United States Fletcher Allen Health Care, Burlington, Vermont, United States Neurology and Neurosurgery Associates of Tacoma, Tacoma, Washington, United States University of Wisconsin, Madison, Wisconsin, United States	https://ClinicalTrials.gov/show/NCT0056524
248	Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation in Aplastic Anemia	No Results Available	Aplastic Anemia	Drug: Antithymocyte Globulin Drug: Cyclophosphamide Drug: Fludarabine Radiation: Total Body Irradiation (TBI) Procedure: Bone Marrow Transplant	University of Texas MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT00474747
249	Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease	Has Results	Hodgkin's Disease	Drug: Gemcitabine Drug: Fludarabine Drug: Melphalan Drug: Antithymocyte Globulin Procedure: Allogeneic Stem Cell Infusion Drug: Tacrolimus Drug: Filgrastim (G-CSF) Drug: Methotrexate	University of Texas MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT00385788
250	Intrabone Infusion of Cord Blood in Adults With Hematological Malignancies	No Results Available	Hematological Malignancies	Procedure: Intrabone cord blood infusion	Hematology Institute "L. and A. SerÀ gnoli", S. Orsola-Malpighi University Hospital, Bologna, Italy	https://ClinicalTrials.gov/show/NCT0086522
251	Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies	No Results Available	Blood And Marrow Transplantation Leukemia Lymphoma Transplantation Infection Transplantation, Bone Marrow	Drug: Melphalan Drug: Fludarabine Drug: Mycophenolate mofetil Drug: Tacrolimus Procedure: Cord Blood Infusion Drug: ATG Drug: Busulfan Drug: Clofarabine Radiation: Total Body Irradiation (TBI)	University of Texas MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT01471067
252	Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation 19 (CD19)-Specific T Cells	Has Results	Leukemia Chronic Myelogenous Leukemia	Drug: Fludarabine Drug: Busulfan Procedure: NK cell infusion Drug: Interleukin-2 Drug: Anti-Thymocyte Globulin Procedure: Allogeneic related Stem Cell Transplant Drug: Tacrolimus Drug: Methotrexate Drug: G-CSF	University of Texas MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT01390402
253	Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML) Allogeneic Stem Cell Transplantation for Myelofibrosis and Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia	No Results Available	Leukemia Lymphoma	Genetic: T-Cell Infusion Procedure: Cord Blood Infusion	University of Texas MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT01362452
254	Fludarabine and Thymoglobulin Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML) Allogeneic Stem Cell Transplantation for Myelofibrosis and Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia	Has Results	Stem Cell Transplantation Leukemia	Drug: Plerixafor Drug: Filgrastim Drug: Fludarabine Drug: Busulfan Procedure: Allogeneic blood stem cell transplant Drug: ATG (Thymoglobulin)	UT MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT00822770
255	Fludarabine and Thymoglobulin Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML) Allogeneic Stem Cell Transplantation for Myelofibrosis and Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia	No Results Available	Stem Cell Transplantation Leukemia	Drug: Fludarabine Drug: Busulfan Drug: Thymoglobulin Drug: Azacitidine Procedure: Stem Cell Transplant	University of Texas MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT00813124
256	Fludarabine and Thymoglobulin Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML) Allogeneic Stem Cell Transplantation for Myelofibrosis and Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia	Has Results	Myelofibrosis	Drug: Busulfan Drug: Fludarabine Drug: Thymoglobulin (ATG)	University of Texas MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT00475020
257	Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)	No Results Available	Aplastic Anemia	Drug: Fludarabine Drug: Cyclophosphamide Drug: Antithymocyte Globulin	U.T.M.D. Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT00427336
258	Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)	No Results Available	Myelodysplastic Syndrome Leukemia	Drug: Thymoglobulin Drug: Busulfan Drug: Fludarabine Procedure: Alloreactive NK Infusion Drug: G-CSF Drug: Tacrolimus Drug: Methotrexate Drug: Interleukin-2	UT MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT00402558
259	Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS	No Results Available	Acute Myelogenous Leukemia Myelodysplastic Syndrome Chronic Lymphocytic Leukemia	Drug: Mylotarg Drug: Fludarabine Drug: Melphalan Drug: Anti-thymocyte globulin Procedure: Stem cell transplant	MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT00038831

Ongoing Rank	Title	Study Results	Conditions	Interventions	Locations	URL
1	Non-invasive Brain Stimulation for the Treatment of Depression Symptoms in ALS	No Results Available	ALS	Device: rTMS	Hospital for Special Surgery, New York, New York, United States	https://ClinicalTrials.gov/show/NCT03373981

T Cell Phenotypes in Amyotrophic Lateral Sclerosis	No Results Available	ALS	Other: phenotyping Tcells Other: Supplementation in vitamin D	University Hospital of Montpellier, Montpellier, France	https://ClinicalTrials.gov/show/NCT02756104
2 (ALS) Influence of Vitamin D Spiral Interneuron Excitability	No Results Available	ALS	Device: Electrophysiology	Hopital Pitie Salpetriere, Paris, France	https://ClinicalTrials.gov/show/NCT02429492
3 in ALS Development and Needs Assessment and Efficiency of Smart Communication System	No Results Available	ALS (Amyotrophic Lateral Sclerosis)	Other: communication system	Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT03787420
4 for Patients With ALS	No Results Available	Amyotrophic Lateral Sclerosis ALS	Drug: AMX0035	Massachusetts General Hospital, Boston, Massachusetts, United States University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT03488524
5 AMX0035 in Patients With ALS	No Results Available	Amyotrophic Lateral Sclerosis (ALS)	Biological: NurOwn [®] (MSC-NTF cells) Other: Placebo	University of California Irvine Alpha Stem Cell Clinic, Irvine, California, United States Cedars-Sinai Medical Center, Los Angeles, California, United States California Pacific Medical Center, San Francisco, California, United States Massachusetts General Hospital, Boston, Massachusetts, United States University of Massachusetts Medical School, Worcester, Massachusetts, United States Mayo Clinic, Rochester, Minnesota, United States	https://ClinicalTrials.gov/show/NCT03280056
6 in ALS Patients A Study to Evaluate Transplantation of Astrocytes Derived From Human Embryonic Stem Cells, in Patients With Amyotrophic Lateral Sclerosis (ALS)	No Results Available	ALS (Amyotrophic Lateral Sclerosis)	Biological: AstroRx	Hadassah Ein Kerem Medical Center, Jerusalem, Israel	https://ClinicalTrials.gov/show/NCT03482050
7 Lateral Sclerosis (ALS)	No Results Available	ALS	Drug: Ranolazine 500 MG [Drug: Ranolazine 1000 MG]	University of Kansas Medical Center, Kansas City, Kansas, United States	https://ClinicalTrials.gov/show/NCT03472950
8 Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis (ALS)	Device: Non-invasive home ventilation	Montreal Chest Institute, Montreal, Quebec, Canada	https://ClinicalTrials.gov/show/NCT01746381
9 (ALS) Using the IVAPS Mode ALS Study Determining Various Biomarkers and Strength	No Results Available	Amyotrophic Lateral Sclerosis	Other: Resistance Exercise Program	University of Kansas Medical Center, Kansas City, Kansas, United States	https://ClinicalTrials.gov/show/NCT03201991
10 Comparison After Exercise	No Results Available	ALS Amyotrophic Lateral Sclerosis	Drug: Pimozide 2mg/day (current) or 4 mg/day (study initiation) Drug: Placebo Oral Tablet	Dr. Lawrence Korgut - South Health Campus, Calgary, Alberta, Canada Dr. Wendy Johnston, Edmonton, Alberta, Canada Dr. Colleen O'Connell - Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, Canada Dr. John Turnbull McMaster University/Hamilton Health Services, Hamilton, Ontario, Canada Dr. Christen Shoemith, London, Ontario, Canada Dr. Lorne Zinman Sunnybrook Research Institute, Toronto, Ontario, Canada Dr. Sandrine Larue - Reserche Sepmus Inc., Greenfield Park, Quebec, Canada Dr. Genevieve Matte, MontréAl, Quebec, Canada	https://ClinicalTrials.gov/show/NCT03272503
11 Lateral Sclerosis (ALS)	No Results Available	ALS (Amyotrophic Lateral Sclerosis)	Drug: Autologous Adipose-derived Mesenchymal Stromal Cells	Mayo Clinic in Rochester, Rochester, Minnesota, United States	https://ClinicalTrials.gov/show/NCT03268603
12 Sclerosis (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Device: Custom Mask Interface	Michigan Medicine, Ann Arbor, Michigan, United States	https://ClinicalTrials.gov/show/NCT03519880
13 Printed Masks for ALS Subjects	No Results Available				
A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Drug: CK-2127107 Drug: Placebo	St. Joseph's Hospital and Medical Center - Barrow Neurological Clinics, Phoenix, Arizona, United States Cedars-Sinai Medical Center, Los Angeles, California, United States University of California Irvine, Orange, California, United States Forbes Norris MDA/ALS Research Center, San Francisco, California, United States Stanford Hospital and Clinics, Stanford, California, United States University of Colorado Hospital Anschutz Outpatient Pavilion, Aurora, Colorado, United States Hospital for Special Care, New Britain, Connecticut, United States George Washington University Medical Faculty Associates, Washington, District of Columbia, United States University of Florida, Gainesville, Florida, United States Mayo Clinic, Jacksonville, Florida, United States Caro & Frank Morsani Center for Advanced Healthcare - University of South Florida, Tampa, Florida, United States Emory Clinic, Atlanta, Georgia, United States Duchessos Center for Advanced Medicine, Chicago, Illinois, United States IU Health Neuroscience Center of Excellence, Indianapolis, Indiana, United States University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States University of Kansas Medical Center, Kansas City, Kansas, United States Johns Hopkins University - Outpatient Center, Baltimore, Maryland, United States University of Massachusetts Memorial Medical Center/University of Massachusetts Medical School, Worcester, Massachusetts, United States Michigan Medicine, Ann Arbor, Michigan, United States Henry Ford Health System, Detroit, Michigan, United States Hennepin County Medical Center, Minneapolis, Minnesota, United States Mayo Clinic, Rochester, Minnesota, United States Saint Louis University, Department of Neurology, Saint Louis, Missouri, United States Washington University School of Medicine, Saint Louis, Missouri, United States Neurology Associates, P. C., Lincoln, Nebraska, United States Hospital For Special Surgery, New York, New York, United States Neurological Institute, Columbia University Medical Center, New York, New York, United States SUNY Upstate Medical University, Syracuse, New York, United States Neurosciences Institute, Neurology - Charlotte, Charlotte, North Carolina, United States Duke Neurological Disorders Clinic, Durham, North Carolina, United States Wake Forest School of Medicine, Winston-Salem, North Carolina, United States Cleveland Clinic, Cleveland, Ohio, United States The Ohio State University Wexner Medical Center, Columbus, Ohio, United States Providence Brain and Spine Institute ALS Center, Portland, Oregon, United States Oregon Health & Science University, Portland, Oregon, United States Penn State Milton S. Eisenhower Medical Center, Hershey, Pennsylvania, United States Temple University School of Medicine, Philadelphia, Pennsylvania, United States Vanderbilt University Medical Center - Clinical Research Center, Nashville, Tennessee, United States Texas Neurology, Dallas, Texas, United States Houston Methodist Hospital, Houston, Texas, United States UTHSCSA Medical Arts and Research Center, San Antonio, Texas, United States Vermont Medical Center, Burlington, Vermont, United States University of Virginia Health System, Charlottesville, Virginia, United States VCU Health - Ambulatory Care Center (ACC), Richmond, Virginia, United States University of Washington Medical Center, Seattle, Washington, United States West Virginia University, Dept. of Neurology, Morgantown, West Virginia, United States Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States Brain and Mind Centre, The University of Sydney, Camperdown, New South Wales, Australia Department of Neurology, Westmead Hospital, Westmead, New South Wales, Australia Royal Brisbane and Women's Hospital, Herston, Queensland, Australia Flinders Medical Centre, Bedford Park, South Australia, Australia The Perron Institute for Neurological and Translation Science, Nedlands, Western Australia, Australia University of Calgary, Heritage Medical Research Center, Calgary, Alberta, Canada Edmonton Kaye Clinic, Edmonton, Alberta, Canada McMaster University Medical Centre, Hamilton, Ontario, Canada London Health Sciences Centre University Hospital, London, Ontario, Canada Sunnybrook Health Science Centre, Toronto, Ontario, Canada Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada Centre de recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada Saskatoon City Hospital, Saskatoon, Saskatchewan, Canada CHU de Québec-Université Laval, Hôpital de l'Enfant Jésus, Québec, Canada Beaumont Hospital, Dublin, Ireland University Medical Center Utrecht, Utrecht, Netherlands Hospital San Rafael Servicio de Neurología, Madrid, Spain	https://ClinicalTrials.gov/show/NCT03160898
14 (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Biological: Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients	Medical University of Warsaw, Warsaw, Poland	https://ClinicalTrials.gov/show/NCT03296501
15 Patients	No Results Available	Amyotrophic Lateral Sclerosis	Device: CES at rest Device: CES plus active hand or wrist movements	James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States	https://ClinicalTrials.gov/show/NCT03411863
16 for ALS	No Results Available				
The Effect of RNS60 on ALS Biomarkers	No Results Available	Amyotrophic Lateral Sclerosis	Drug: RNS60	Massachusetts General Hospital, Boston, Massachusetts, United States Azienda Ospedaliera Universitaria Consorziale Policlinico - Università degli studi di Bari, Bari, Italy Spedali civili di Brescia, Brescia, Italy ASST Valle Olona Presidio ospedaliero Gallarate, Gallarate, Italy IRCCS Azienda Ospedaliera Universitaria San Martino IST, Genova, Italy Ospedale San Raffaele, Milano, Italy Centro Clinico NEMO - Fondazione Serena Onlus, Milano, Italy Presidio Ospedaliero Provinciale - Nuovo Ospedale Civile "S. Agostino Estense", Modena, Italy Azienda Ospedaliera Universitaria della Seconda Univ. Degli Studi di Napoli (AOU-SUN), Napoli, Italy Azienda Ospedaliera Universitaria Maggiore della Carità, Novara, Italy Azienda Ospedaliera di Padova-Università degli studi di Padova, Padova, Italy Azienda Ospedaliera Universitaria Policlinico "P. Giaccone", Palermo, Italy Istituto Neurologico Nazionale "C. Mondino", Pavia, Italy Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy POLICLINICO UMBERTO I - Università di Roma "La Sapienza", Roma, Italy IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy Azienda Ospedaliera Universitaria Senese (AOUS), Siena, Italy Azienda Ospedaliera "Santa Maria" di Terni, Terni, Italy Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy Azienda Ospedaliera "Card. G. Panico", Tricase, Italy	https://ClinicalTrials.gov/show/NCT03456882
17 Biomarkers	No Results Available				

				Phoenix Neurological Associates, Phoenix, Arizona, United States Neuromuscular Research Center and Neuromuscular Clinic of Arizona, Phoenix, Arizona, United States University of California San Diego, La Jolla, California, United States Cedars-Sinai Medical Center, Los Angeles, California, United States University of California Irvine, Orange, California, United States California Pacific Medical Center, San Francisco, California, United States Colorado Springs Neurological Associates, Colorado Springs, Colorado, United States Hospital for Special Care, New Britain, Connecticut, United States Georgetown University, Washington, District of Columbia, United States The George Washington Medical Faculty Associates - Foggy Bottom North Pavilion, Washington, District of Columbia, United States Providence Holy Cross Medical Center, Fort Lauderdale, Florida, United States University of Florida, Gainesville, Florida, United States University of Florida Health - Jacksonville, Jacksonville, Florida, United States Mayo Clinic - Jacksonville, Jacksonville, Florida, United States University of South Florida, Tampa, Florida, United States Emory University School of Medicine, Atlanta, Georgia, United States Augusta University, Augusta, Georgia, United States Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States Kentucky Neuroscience Research, Louisville, Kentucky, United States The Johns Hopkins Hospital, Baltimore, Maryland, United States Massachusetts General Hospital, Boston, Massachusetts, United States University of Michigan, Kalamazoo, Michigan, United States Mayo Clinic - Rochester, Rochester, Minnesota, United States HealthPartners Specialty Center, Saint Paul, Minnesota, United States Washington University School of Medicine, Saint Louis, Missouri, United States Neurology Associates, Lincoln, Nebraska, United States Mount Sinai Beth Israel, New York, New York, United States Hospital for Special Surgery, New York, New York, United States Columbia Presbyterian Hospital, New York, New York, United States Neurosciences Institute - Neurology Charlotte, Charlotte, North Carolina, United States Duke University Medical Center, Durham, North Carolina, United States Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States The Ohio State University, Columbus, Ohio, United States Oregon Health and Science University, Portland, Oregon, United States Providence Brain and Spine Institute, Portland, Oregon, United States Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States Temple University School of Medicine, Philadelphia, Pennsylvania, United States Allegheny General Hospital, Pittsburgh, Pennsylvania, United States University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States Texas Neurology, Dallas, Texas, United States Nerve and Muscle Center of Texas, Houston, Texas, United States University of Utah - Imaging & Neurosciences Center, Salt Lake City, Utah, United States University of Vermont Medical Center, Burlington, Vermont, United States Swedish Neuroscience Institute, Seattle, Washington, United States University of Washington Medical Center, Seattle, Washington, United States Froedert Hospital, Milwaukee, Wisconsin, United States Brain and Mind Center, Camperdown, New South Wales, Australia Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia Flinders Medical Centre, Bedford Park, South Australia, Australia Calvary Health Care Bethlehem, Cauffman South, Victoria, Australia Perron Institute for Neurological and Translational Science, Murdoch, Western Australia, Australia Universität Innsbruck, Innsbruck, Tyrol, Austria Salzkammergut-Klinikum Vöcklabruck, Vöcklabruck, Upper Austria, Austria Medizinische Universität Wien, Wien, Austria Universitaire Ziekenhuis Leuven, Leuven, Flemish Brabant, Belgium Centre Hospitalier Régional de la Citadelle, Liège, Liège, Belgium Algemeen Ziekenhuis St. Lucas Gent, Gent, Oost-Vlaanderen, Belgium Alberta Health Services - Neuromuscular Clinic, Calgary, Alberta, Canada University of Alberta, Edmonton, Alberta, Canada Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, Canada Moncton Hospital, Southeast Regional Health Authority, Moncton, New Brunswick, Canada McMaster University Medical Centre, Hamilton, Ontario, Canada Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada Centre De Recherche Du Centre Hospitalier de l'Université de Montreal - Hôpital Notre-Dame, Montréal, Québec, Canada Montreal Neurological Institute and Hospital, Montréal, Québec, Canada Centre Hospitalier Affilié Universitaire de Québec, Québec, Québec, Canada Neurologian Poliklinikka - Mellahden Tornisaara 3, Helsinki, Finland Etelä-Karjalainen keskussairaala, Lappeenranta, Finland Turku University Hospital, Turku, Finland Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany Deutsche Klinik für Diagnostik, Wiesbaden, Hessen, Germany Universitätsmedizin Rostock, Rostock, Mecklenburg-westerpommern, Germany Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany Alfried Krupp Krankenhaus Rätterscheid, Essen, Nordrhein-westfalen, Germany Universitätsklinikum MÄnster, MÄnster, Nordrhein-westfalen, Germany Universitätsklinikum Carl Gustav Carus, Dresden, Sachsen, Germany Universitätsklinikum Jena, Jena, Thüringen, Germany Charité Universitätsmedizin Berlin - Campus Virchow-Klinikum, Berlin, Germany Beaumont Hospital - Ireland, Dublin, Ireland Azienda Ospedaliera Universitaria-Maggiore della Città di Novara, Novara, Italy ICS Mangiù Spa S8, Pavia, Italy Azienda Ospedaliera Universitaria Pavia Ospedale Santa Chiara, Pavia, Italy Poliniclinico Umberto I di Roma, Roma, Italy Azienda Ospedaliera - Universitaria Città della Salute e della Scienza di Torino, Torino, Italy Academisch Medisch Centrum, Amsterdam, Noord-Holland, Netherlands Universitair Medisch Centrum Utrecht - Rudolf Magnus Instituut voor Neurowetenschappen, Utrecht, Netherlands Hospital de Basurto, Bilbao, Vizcaya, Spain Hospital Universitario de Bellvitge, Barcelona, Spain Hospital Universitario Reina Sofia, Córdoba, Spain Hospital San Rafael - Madrid, Madrid, Spain Hospital Universitario y Politécnico de La Fe, Valencia, Spain Norrlands Universitetssjukhus, Umeå, Västerbotten, Sweden Centralk sjukhuset Karlstad, Karlstad, Sweden Karolinska Universitetssjukhuset, Stockholm, Sweden Barts Health NHS Trust, London, England, United Kingdom King's College Hospital NHS Foundation Trust, London, England, United Kingdom The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom	https://ClinicalTrials.gov/show/NCT03505021					
Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS	No Results Available	Amotrophic Lateral Sclerosis	Drug: Levosimendan Drug: Placebo for levosimendan							https://ClinicalTrials.gov/show/NCT03168711
Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Amotrophic Lateral Sclerosis	Drug: Inosine Drug: Placebo	Holy Cross Hospital, Fort Lauderdale, Florida, United States Massachusetts General Hospital, Boston, Massachusetts, United States University of Minnesota, Minneapolis, Minnesota, United States						
An Online Mindfulness Intervention for People With ALS and Their Caregivers	No Results Available	Amotrophic Lateral Sclerosis	Behavioral: Mindfulness	Penn State Hershey Medical Center, Hershey, Pennsylvania, United States						https://ClinicalTrials.gov/show/NCT03095989
Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study	No Results Available	Familial Amyotrophic Lateral Sclerosis	Drug: Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days	University of Kentucky Medical Center, Lexington, Kentucky, United States						https://ClinicalTrials.gov/show/NCT03707795
Lung Volume Recruitment Combined With Expiratory Muscle Strength Training (EMST) Procedure: EMST + Lung Volume Recruitment (LVR)	No Results Available	Amotrophic Lateral Sclerosis	Procedure: Expiratory Muscle Strength Training (EMST) Procedure: EMST + Lung Volume Recruitment (LVR)	University of Florida, Gainesville, Florida, United States University of Minnesota, Minneapolis, Minnesota, United States						https://ClinicalTrials.gov/show/NCT03202017
Muscle Strength Training in ALS	No Results Available	Amotrophic Lateral Sclerosis	Drug: Darunavir Drug: Ritonavir Drug: Raltegravir Drug: Zidovudine	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States						https://ClinicalTrials.gov/show/NCT02437110
HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Amotrophic Lateral Sclerosis	Drug: Darunavir Drug: Ritonavir Drug: Raltegravir Drug: Zidovudine	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States						https://ClinicalTrials.gov/show/NCT02437110
Cycle Treatment After 6 Months of 1st Cycle HLA-haplo Matched Allogeneic Bone Marrow Derived Stem Cell	No Results Available	Amotrophic Lateral Sclerosis	Biological: HYNRC5-Allo Inj	Hanyang University Seoul Hospital, Cell Therapy Center for Neurologic Disorders, Seoul, Haengdang-dong, Seongdong-gu, Korea, Republic of						https://ClinicalTrials.gov/show/NCT03214146
A Study of IPL344 in the Treatment of ALS Patients	No Results Available	Amotrophic Lateral Sclerosis	Drug: IPL344	Hadassah Medical Center - Motor Neuron Disease Clinic, Jerusalem, Israel						https://ClinicalTrials.gov/show/NCT03652805
Clinical Trial of Ultra-high Dose Methylcobalamin for ALS	No Results Available	Amotrophic Lateral Sclerosis	Drug: methylcobalamin Drug: saline solution	Nagoya University Hospital, Nagoya, Aichi, Japan Miyoshi Neurological Clinic, Miyoshi, Hiroshima, Japan Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan Kobe Central Municipal Medical center, Kobe, Hyogo, Japan Ioh National Hospital, Kanazawa, Ishikawa, Japan Kitasato University East Hospital, Sagami-hara, Kanagawa, Japan Shiga Medical University Hospital, Otsu, Shiga, Japan Chiba University Hospital, Chiba, Japan Murakami Karindo Hospital, Fuukuoka, Japan Okayama University Hospital, Okayama, Japan Tokushima University Hospital, Tokushima, Japan Juntendo University Hospital, Tokyo, Japan Toho University Hospital, Tokyo, Japan Teikyo University Hospital, Tokyo, Japan Tokyo Metropolitan Neurological Hospital, Tokyo, Japan Wakayama Medical University Hospital, Wakayama, Japan						https://ClinicalTrials.gov/show/NCT03548311
CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS	No Results Available	Amotrophic Lateral Sclerosis	Drug: CC100 Drug: Placebos	Indiana University, IU Health Physicians Neurology, Indianapolis, Indiana, United States						https://ClinicalTrials.gov/show/NCT03049046
Rapamycin Treatment for ALS	No Results Available	Amotrophic Lateral Sclerosis	Drug: Rapamycin Drug: Placebo Oral Tablet	Centro Sia, Irccs A.O.U. S.Martino Ist, Genova, Genova, Italy Centro Clinico Nemo, Fondazione Serena Onlus, Milano, Milano, Italy Centro Sia, Irccs Fondazione Salvatore Maugeri, Milano, Milano, Italy Centro Sia, Irccs Istituto Carlo Besta, Milano, Milano, Italy Centro Sia, Ospedale Civile S. Agostino Estense, A.O.U. Modena, Modena, Italy Centro Sia, A.O.U. Maggiore Della Carità - Novara, Novara, Italy Centro Sia, Univerista Di Padova, Padova, Italy Centro Sia, Univerista Di Torino, Torino, Italy						https://ClinicalTrials.gov/show/NCT03359538
MIROCALs: Modifying Immune Response and Outcomes in ALS	No Results Available	Amotrophic Lateral Sclerosis	Drug: Riluzole Drug: IL-2 Drug: 5% glucose water solution	CHRU de Lille - HÂpital Roger Salengro, Lille, France CHU de Limoges - HÂpital Dupuytren, Limoges, France HCL - HÂpital Neurologique P. Wertheimer, Lyon, France APHM - HÂpital de la Timone, Marseille, France CHRU de Montpellier - HÂpital Gui de Chauliac, Montpellier Cedex 5, France CHU de Nice - HÂpital Pasteur, Nice, France APHP - Groupe Hospitalier Pitié-Salpêtrière, Paris Cedex 13, France CENTRE HOSPITALIER DE SAINT BRIEUC - HÂpital Yves Le Foll, Saint Brieuc, France CHU de Strasbourg - HÂpital de Hautepierre, Strasbourg, France CHRU de Tours - HÂpital Bretonneau, Tours, France Trafford Centre for Biomedical Research, Brighton, United Kingdom Institute of Neurological Sciences, Queen Elizabeth Hospital Glasgow, United Kingdom North-East London and Essex MND Regional Care Centre, London, United Kingdom King's MND Care and Research Centre, London, United Kingdom Centre for Neuromuscular Diseases - National Hospital of Neurology, London, United Kingdom Salford Royal NHS Foundation Trust, Neurology Dept, Manchester, United Kingdom Sheffield Care and Research Centre, Sheffield, United Kingdom						https://ClinicalTrials.gov/show/NCT03039673
Long-Term Evaluation of BIIB067	No Results Available	ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation	Drug: BIIB067	Research Site, Phoenix, Arizona, United States Research Site, La Jolla, California, United States Research Site, San Francisco, California, United States Research Site, Orlando, Florida, United States Research Site, Atlanta, Georgia, United States Research Site, Baltimore, Maryland, United States Research Site, Boston, Massachusetts, United States Research Site, Saint Louis, Missouri, United States Research Site, Knoxville, Tennessee, United States Research Site, Leuven, Belgium Research Site, Toronto, Ontario, Canada Research Site, Montreal, Quebec, Canada Research Site, Ulm, Baden Wuerttemberg, Germany Research Site, Sheffield, South Yorkshire, United Kingdom						https://ClinicalTrials.gov/show/NCT03070119
ALS Treatment Extension Study	No Results Available	Amotrophic Lateral Sclerosis	Drug: Cu UJATSM	Macquarie University, Sydney, New South Wales, Australia						https://ClinicalTrials.gov/show/NCT03136809
A Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in the Treatment of Subjects With Amyotrophic Lateral Sclerosis	No Results Available	Amotrophic Lateral Sclerosis	Drug: Acthar Drug: Placebo	Neuromuscular Research Center, Phoenix, Arizona, United States Mayo Clinic - Arizona, Scottsdale, Arizona, United States University of California San Diego, La Jolla, California, United States Loma Linda University Health System, Department of Neurology, Loma Linda, California, United States Keeck School of Medicine, University of Southern California, Los Angeles, California, United States University of California Los Angeles, Los Angeles, California, United States University of California Irvine Medical Center, Orange, California, United States California Pacific Medical Center, San Francisco, California, United States University of California San Francisco, San Francisco, California, United States Colorado Springs Neurological Associates, Colorado Springs, Colorado, United States Georgetown University, Washington, District of Columbia, United States George Washington University, Washington, District of Columbia, United States University of Florida - McKnight Brain Institute, Gainesville, Florida, United States University of South Florida, Tampa, Florida, United States Emory University, Atlanta, Georgia, United States Augusta University, Augusta, Georgia, United States Indiana University-Neuroscience Center of Excellence/Goodman Hall, Indianapolis, Indiana, United States University of Kansas Medical Center, Kansas City, Kansas, United States University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States John Hopkins Outpatient Center, Baltimore, Maryland, United States University of Massachusetts Medical School, Worcester, Massachusetts, United States Mercy Health - Saint Mary's, Grand Rapids, Michigan, United States Neurology Associates, Lincoln, Nebraska, United States University of Nebraska Medical Center - Physicians Clinical Neurosciences Center, Omaha, Nebraska, United States Las Vegas Clinic, Las Vegas, Nevada, United States Jersey Shore University Medical Center, Neptune, New Jersey, United States Columbia Presbyterian Hospital, New York, New York, United States Providence ALS Center, Portland, Oregon, United States Penn State Health Milton S. Eisenhower Medical Center, Hershey, Pennsylvania, United States Temple University School of Medicine, Philadelphia, Pennsylvania, United States Allegheny General Hospital, Pittsburgh, Pennsylvania, United States Wesley Neurology Clinic, Cordova, Tennessee, United States Austin Neuromuscular Center, Austin, Texas, United States Texas Neurology, P.A., Dallas, Texas, United States The Methodist Hospital, Houston, Texas, United States University of Vermont Medical Center, Colchester, Vermont, United States VCU Medical Center, Richmond, Virginia, United States Swedish Neuroscience Institute, Seattle, Washington, United States Medical College of Wisconsin/Froedert Hospital, Milwaukee, Wisconsin, United States Edmonton Kaye Clinic, Edmonton, Alberta, Canada Recherche Supras Inc, Greenfield Park, Quebec, Canada Centre de rechercheAD du Centre Hospitalier de l'Université de Montreal (CRCHUM), Montréal, Québec, Canada Montreal Neurological Institute & Hospital, Montréal, Québec, Canada Centro de Trastornos del Movimiento (CETRAM), Santiago, Metropolitana, Chile Biomedica Research Group AV Salvador 149, oficina 1101, Santiago, Chile Centro de Investigaciones CÍA-nicas SAS, Cali, Colombia						https://ClinicalTrials.gov/show/NCT03068754

33	Open-label Clinical Trial of Lacosamide in ALS	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Lacosamide	Chiba University Hospital, Chiba, Japan	https://ClinicalTrials.gov/show/NCT03186040
34	Brain Excitability and Connectivity in Sensory-motor Pathways in ALS	No Results Available	Amyotrophic Lateral Sclerosis	Device: functional MRI Device: structural MRI [Device: EEG/MEG]	Hopital Pitie-Salpetriere, Paris, France	https://ClinicalTrials.gov/show/NCT03694132
35	The Use of Airway Clearance Devices in ALS	No Results Available	Amyotrophic Lateral Sclerosis	Device: High Frequency Chest Compression Device (HFCC) [Device: Cough Assist]	Cedars-Sinai Medical Center, Los Angeles, California, United States	https://ClinicalTrials.gov/show/NCT02682030
36	Riluzole Oral Soluble Film Swallowing Safety in Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Riluzole Oral Soluble film (ROSF) 50 mg	University of Florida Center for Movement Disorders & Neuroscience, Gainesville, Florida, United States	https://ClinicalTrials.gov/show/NCT03679975
37	Trial of Amivita in Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Amivita	Wujing People's Hospital, Changzhou, Jiangsu, China	https://ClinicalTrials.gov/show/NCT03103815
38	Therapy in Amyotrophic Lateral Sclerosis (TAME)	No Results Available	Amyotrophic Lateral Sclerosis [Frontal Temporal Dementia]	Drug: Memantine [Drug: Placebo (for Memantine)]	Phoenix Neurological Associates, Phoenix, Arizona, United States [UC Irvine, Irvine, California, United States] University of Florida, Jacksonville, Florida, United States [University of Kansas Medical Center, Kansas City, Kansas, United States] [University of Kansas School of Medicine - Wichita, Wichita, Kansas, United States] [University of Kentucky, Lexington, Kentucky, United States] [University of Missouri, Columbia, Missouri, United States] [Columbia University, New York, New York, United States] [University of Texas Southwestern, Dallas, Texas, United States] [Nerve & Muscle Center of Texas, Houston, Texas, United States] [University of Washington, Seattle, Washington, United States]	https://ClinicalTrials.gov/show/NCT02118727
39	Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Amyotrophic Lateral Sclerosis [Possible]	Drug: L-Serine	Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States	https://ClinicalTrials.gov/show/NCT03580616
40	Predict to Prevent Frontotemporal Lobar Degeneration (FDT) and Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Amyotrophic Lateral Sclerosis [Frontotemporal Lobar Degeneration] [Amyotrophic Lateral Sclerosis]	Behavioral: characterization	Groupe Hospitalier Pitie-Salpetriere - Charles Fok, Paris, France	https://ClinicalTrials.gov/show/NCT02590276
41	Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND	No Results Available	Amyotrophic Lateral Sclerosis [Motor Neuron Disease]	Drug: Cu(II)ATSM	Macquarie University, Sydney, New South Wales, Australia [Calvary Health Care Bethlehem, Cauffield, Victoria, Australia]	https://ClinicalTrials.gov/show/NCT02870634
42	Muscular Biomarkers in Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Other: Samples	Service de chirurgie orthopedique et traumatologique, CHRU de TOURS, Tours, France [Service de Neurologie, CHRU de TOURS, Tours, France]	https://ClinicalTrials.gov/show/NCT02670226
43	Epidemiology and Genetics of Sclerosis in the French West	No Results Available	Amyotrophic Lateral Sclerosis	Dietary Supplement: Blood sample and environmental survey	Hospital University Center of Pointe-à-Pitre, Pointe-à-Pitre, Guadeloupe [Hospital University Center of Martinique, Fort-de-France, Martinique]	https://ClinicalTrials.gov/show/NCT03367650
44	Pharyngeal Electrical Stimulation in Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Device: Pharyngeal Electrical Stimulation	University of Ulm, Ulm, Germany	https://ClinicalTrials.gov/show/NCT03481348
45	Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis Patients	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Fycompa	Johnny S. Salameh, Beirut, Lebanon	https://ClinicalTrials.gov/show/NCT03377309
46	Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Perampanel [Other: Placebo]	Mayo Clinic, Jacksonville, Florida, United States	https://ClinicalTrials.gov/show/NCT03793868
47	Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Drug: DNL747 [Drug: Placebo]	CHDR, Leiden, South Holland, Netherlands	https://ClinicalTrials.gov/show/NCT03757351
48	SSRIs vs. TCAs for Depression in ALS Patients	No Results Available	Depression [Amyotrophic Lateral Sclerosis]	Drug: Tricyclic Antidepressants ("TCA") [Drug: Selective Serotonin Uptake Inhibitors ("SSRI")]	Monteleone Hall, Saint Louis University, 1438 South Grand Blvd., Saint Louis, Missouri, United States	https://ClinicalTrials.gov/show/NCT02851914
49	A Study to Evaluate the Safety, Tolerability and Efficacy of ILB in Patients With Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Drug: ILB	Sahlgrenska University Hospital, Gothenburg, Sweden	https://ClinicalTrials.gov/show/NCT03613571
50	Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Drug: BIIB078 [Drug: Placebo]	Research Site, La Jolla, California, United States [Research Site, Baltimore, Maryland, United States] [Research Site, Boston, Massachusetts, United States] [Research Site, Cambridge, Massachusetts, United States] [Research Site, Knoxville, Tennessee, United States]	https://ClinicalTrials.gov/show/NCT03626012
51	Efficacy and Safety of Plasma Exchange With Albutein® 5% in Patients With Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Biological: Albutein 5%	Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States	https://ClinicalTrials.gov/show/NCT02872142
52	Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Drug: GDC-0134 [Drug: Placebo] [Drug: Rabeprazole] [Drug: Midazolam] [Drug: Caffeine]	Forbes Norris Mda/als Ctr; Research Center, San Francisco, California, United States [Mayo Clinic Hospital - Florida, Jacksonville, Florida, United States] [University of Miami Miller School of Medicine, Miami, Florida, United States] [Bioclinica Research, Orlando, Florida, United States] [The Emory ALS Clinic, Atlanta, Georgia, United States] [Johns Hopkins University School of Medicine, Baltimore, Maryland, United States] [Massachusetts General Hospital, Boston, Massachusetts, United States] [Wake Research Associates, Raleigh, North Carolina, United States] [New Orleans Center for Clinical Research, Knoxville, Tennessee, United States] [Methodist Neurological Institute, Houston, Texas, United States] [MUCH - Montreal Neurological Institute & Hospital, Montreal, Quebec, Canada] [UMC Utrecht, Utrecht, Netherlands]	https://ClinicalTrials.gov/show/NCT02655614
53	A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Perampanel [Drug: Placebo Oral Tablet]	Stony Brook University Medical Center, Stony Brook, New York, United States	https://ClinicalTrials.gov/show/NCT03020797
54	Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)	No Results Available	Neuromuscular Diseases	Drug: Edaravone [Drug: Riluzole]	EMG Department, Alzahra Hospital, Isfahan, Iran, Islamic Republic of	https://ClinicalTrials.gov/show/NCT03272802
55	Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis	No Results Available	AMYOTROPHIC LATERAL SCLEROSIS	Other: Two intrathecal MSC injections	University of Sao Paulo School of Medicine Clinics Hospital, Sao Paulo, SP, Brazil	https://ClinicalTrials.gov/show/NCT02917681

					Amyotrophic Lateral Sclerosis Motor Disease Neuro muscular Diseases Neurodegenerative Diseases Spinal Cord Diseases TDP-43 Proteinopathies Nervous System Diseases Central Nervous System Diseases	Barrow Neurological Institute, Phoenix, Arizona, United States UC Irvine Medical Center, Orange, California, United States Forbes Norris MDA/ALS Research Center - California Pacific Medical Center, San Francisco, California, United States University of Florida Medical Center, Gainesville, Florida, United States Carol and Frank Marsini Center for Advanced Health Care - University of South Florida, Tampa, Florida, United States Emory University Hospital, Atlanta, Georgia, United States University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States University of Kentucky Medical Center, Lexington, Kentucky, United States Ochsner Neuroscience Institute, New Orleans, Louisiana, United States Johns Hopkins Hospital, Baltimore, Maryland, United States Massachusetts General Hospital, Boston, Massachusetts, United States University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States University of Michigan Medical Center, Ann Arbor, Michigan, United States Hennepin County Medical Center, Minneapolis, Minnesota, United States Washington University Medical Center, Saint Louis, Missouri, United States Neurology Associates P.C., Lincoln, Nebraska, United States Mount Sinai Beth Israel, New York, New York, United States Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States The Ohio State University Wexner Medical Center, Columbus, Ohio, United States Oregon Health & Science University, Portland, Oregon, United States The Penn Comprehensive ALS Center, Philadelphia, Pennsylvania, United States Temple University Hospital, Philadelphia, Pennsylvania, United States Texas Neurology, P.A., Dallas, Texas, United States University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States ALS Center at the Swedish Neuroscience Institute, Seattle, Washington, United States		
AMX0035 in Patients With Amyotrophic Lateral Sclerosis	No Results Available		Drug: AMX0035 Other: Placebo					
56 Predictive Factors for the Diagnosis of Early Noninvasive Ventilation Equipment	No Results Available	Amyotrophic Lateral Sclerosis	Diagnostic Test: diagnosis variables			University Hospital Toulouse, Toulouse, France	https://ClinicalTrials.gov/show/NCT03127514	
57								
						St. Joseph's Hospital and Medical Center (SIHMC) - Barrow Neurological Institute (BNI) - The Gregory W. Fulton ALS and Neuromuscular Disease Center, Phoenix, Arizona, United States HonorHealth Neurology, Phoenix, Arizona, United States UC Irvine Health ALS and Neuromuscular Center, Orange, California, United States University of Miami, Miami, Florida, United States University of Kansas Medical Center (KUMC) - Landon Center on Aging, Kansas City, Kansas, United States Hospital for Special Surgery, New York, New York, United States Providence Brain & Spine Institute, Portland, Oregon, United States University of Pennsylvania, Perelman Center for Advanced Medicine - Penn Neuroscience Center, Philadelphia, Pennsylvania, United States University of Texas Southwestern Medical Center, Dallas, Texas, United States University of Virginia Health System, Charlottesville, Virginia, United States Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada Montreal Neurological Institute and Hospital, Montr�al, Quebec, Canada Centre Hospitalier Regional Universitaire (CHRU) Montpellier - Hpital Gui De Chauiac, Montpellier, France Groupe Hospitalier Pite-Salpetriere - Centre d'Investigation Clinique Neurosciences 1422, Paris, France Istituto Clinica Scientifica Maugeri - IRCCS, Milano, Italy Azienda Ospedaliera Universitaria (AOU) di Torino - Citta' della Salute e della Scienza di Torino, Torino, Italy University Medical Center Utrecht, Utrecht, Netherlands Hospital Universitario Vall d'Hebron ALS Unit. Consultas Externas; Office: 9-10-11, Barcelona, Spain Hospital Carlos III - Hospital Universitario La Paz, ALS Unit, Madrid, Spain Ume�v University Hospital, Ume�v, Sweden		
58 Arimodol in Amyotrophic Lateral Sclerosis	No Results Available	Amyotrophic Lateral Sclerosis	Drug: Arimodolol Drug: Placebo oral capsule				https://ClinicalTrials.gov/show/NCT03491462	
					Healthy Subjects, Patients With Amyotrophic Lateral Sclerosis, Patients With Shoulder Surgery	Device: Videogames	Hopital PITIE SALPETRIERE, Paris, France	https://ClinicalTrials.gov/show/NCT03545451
59 Neurofeedback Rehabilitation Based on Motor Imaging in Patients in the Immobilization Phase	No Results Available							
					Amyotrophic Lateral Sclerosis (ALS) Neuromuscular Diseases	Other: Acute Intermittent Hypoxia Other: Sham Acute Intermittent Hypoxia	UF Clinical Research Center, Gainesville, Florida, United States University of Florida, Gainesville, Florida, United States	https://ClinicalTrials.gov/show/NCT03645031
60 Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease	No Results Available							
					Age-Related Macular Degeneration	Drug: ALS-L1023 Drug: Ranibizumab Other: Placebo	AngioLab, Inc., Daejeon, Daejeon Gwanggyeoksi, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03725501
61 Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD	No Results Available				HEMATOLOGICAL			
					MALIGNANCIES	Other: TOTAL LYMPHOID IRRADIATION	A.O.U. San Giovanni Battista, Torino, Italy	https://ClinicalTrials.gov/show/NCT01081405
62 Total Lymphoid Irradiation and Anti-Thymocyte Globulin in the Allogeneic Hematopoietic Cell Transplantation	No Results Available							
					Graft Versus Host Disease	Drug: Cyclophosphamide Drug: anti-human T-lymphocyte immunoglobulin (ATLG)	Chaim Sheba Medical Center, Ramat Gan, Israel	https://ClinicalTrials.gov/show/NCT03357159
63 Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post	No Results Available				Graft vs Host Disease	Drug: Cyclophosphamide Drug: Anti-Thymocyte Globulin Drug: Conditioning regimen	Saint Antoine Hospital - Hematology Department, Paris, France	https://ClinicalTrials.gov/show/NCT02876679
64 Allogeneic Transplantation Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT	No Results Available	Amyotrophic Lateral Sclerosis Parkinson Disease	Behavioral: Phonetic complexity effects on speech motor performance				University of Kansas Medical Center, Fairway, Kansas, United States University of Missouri-Columbia, Columbia, Missouri, United States	https://ClinicalTrials.gov/show/NCT03613038
65 A Systematic Investigation of Phonetic Complexity Effects on Articulatory Motor Performance in Progressive Dysarthria	No Results Available							
					Leukemia, GVHD, ATG, Transplantation	Drug: anti thymoglobulin	Peking university people's hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT01856803
66 Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis	No Results Available							
					Kidney Transplant Rejection	Drug: Antithymocyte Immunoglobulin (Rabbit) Drug: Interleukin 2 Receptor Antagonist	Doctor Salma Center for Kidney Diseases, Khartoum, Sudan	https://ClinicalTrials.gov/show/NCT03789006
67 Anthymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation	No Results Available							

			Acute Myeloid Leukemia Myelodysplastic Syndromes Myeloproliferative Disorder Chronic Lymphocytic Leukemia B-cell Lymphoma T-cell Lymphoma Non-Hodgkin Lymphoma Hodgkin Lymphoma Ch			Radiation: Total body irradiation (TBI) Drug: Anti-thymocyte globulin (ATG) Drug: Tacrolimus Drug: Mycophenolate mofetil (MMF) Radiation: Total lymphoid irradiation (TLI)	Stanford University School of Medicine, Stanford, California, United States		https://ClinicalTrials.gov/show/NCT03734601
68	Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation	No Results Available							
69	Efficacy and Safety of Rabbit Antithymocyte Globulin 3mg/kg in Kidney Transplant Patients Under Steroid-free and CNI Minimization Maintenance Immunosuppressive Regimen	No Results Available	Thymoglobulin Dose		Drug: Thymoglobulin		Transplant ward of the Hospital do Fortaleza, Fortaleza, Cear�, Brazil		https://ClinicalTrials.gov/show/NCT03082820
70	Cytosan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia	No Results Available	Fanconi Anemia		Biological: Anti-Thymocyte Globulin Drug: Cyclophosphamide Drug: Fluorabine Procedure: Hematopoietic Stem Cell Transplantation Drug: Methyprednisolone Drug: Filgrastim Drug: Cyclosporine Drug: Mycophenolate Mofetil		Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States		https://ClinicalTrials.gov/show/NCT00630253
71	Music Intervention in the Treatment of Sleep Disorders for Depressed Patients	No Results Available	Insomnia Depression		Other: Music intervention		Sanatorium Kilchberg AG, Kilchberg, ZH, Switzerland		https://ClinicalTrials.gov/show/NCT02376686
72	ECOG BMI for Motor and Speech Control	No Results Available	ALS SCI - Spinal Cord Injury Stroke Multiple Sclerosis Muscular Dystrophies		Device: PMT/Blackrock Combination Device		University of California San Francisco, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT03698149
73	Horse ATG in Patients With Aplastic Anemia (AA) or Low/Int-1 Risk Myelodysplastic Syndrome (WDS)	No Results Available	Leukemia		Drug: hATG Drug: Cyclosporine Drug: Methyprednisolone Drug: Pegfilgrastim Drug: Filgrastim		University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT01624805
74	Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy	No Results Available	Autoimmune Disease		Biological: Anti-Thymocyte Globulin Procedure: Autologous Hematopoietic Stem Cell Transplantation Drug: Carmustine Drug: Cytarabine Drug: Etoposide Other: Laboratory Biomarker Analysis Drug: Melphalan Procedure: Peripheral Blood Stem Cell Transplantation Drug: Prednisone Procedure: Syngeneic Bone Marrow Transplantation		Colorado Blood Cancer Institute, Denver, Colorado, United States Fred Hutchinson Cancer Consortium, Seattle, Washington, United States Swedish Medical Center-First Hill, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT00716066
75	Neurologic Stem Cell Treatment Study	No Results Available	Disorders Nervous System Diseases Neurodegenerative Diseases Neurological Disorders Stroke Traumatic Brain Injury Cerebral Ischemia Cerebral Stroke Cerebral Hemorrhage Parkinson Multiple System Degeneration MSA - Multiple System Atrophy Prognosis		Procedure: Intravenous BMSC Procedure: Intranasal BMSC		The Healing Institute, Margate, Florida, United States Euro-Arabian Hospital, Dubai, Sharjah, United Arab Emirates		https://ClinicalTrials.gov/show/NCT02795052
76	Low Dose ATG Plus Low Dose PTcy as GVHD Prophylaxis in Haplo-HSCT	No Results Available	Host-disease Prophylaxis		Drug: ATG		Shanghai First People's HOSPITAL, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT03395860
77	Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation	No Results Available	Kidney Transplant Infection		Drug: Sirolimus Drug: Everolimus Drug: Mycophenolic acid		Hospital do Rim, S�o Paulo, Sao Paulo, Brazil		https://ClinicalTrials.gov/show/NCT03468478

78	Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients	No Results Available	Kidney Transplant Rejection Kidney Transplant; Complications	Drug: Basiliximab Drug: Thymoglobulin	Umae Hospital Especialidades 14 Adolfo Ruiz Cortines, Veracruz, Mexico	https://ClinicalTrials.gov/show/NCT03006419
79	Posaconazole Prophylaxis During ATG Treatment for HMD5/AA Patients Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs	No Results Available	Aplastic Anemia Myelo dysplastic Syndromes Fungal Infection	Drug: Posaconazole	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03318159
80	Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation	No Results Available	ESRD	Drug: Immune Tolerance	Stanford University School of Medicine, Stanford, California, United States	https://ClinicalTrials.gov/show/NCT01165762
81	Phase IIIa Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (HATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome	No Results Available	Immune Tolerance	Procedure: Immune tolerance after kidney transplant Drug: Donor blood stem cells and T cells	Stanford University Medical Center, Palo Alto, California, United States	https://ClinicalTrials.gov/show/NCT03292445
82	Phase IIIa Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (HATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome	No Results Available	Aplastic Anemia Hypoplastic Myelodysplastic Syndrome	Drug: BL-8040 Drug: horse anti-thymocyte globulin (HATG) Drug: Methyprednisolone Drug: Cyclosporine	MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT02462252
83	Phase II of Non-myceloablative Allogeneic Transplantation Using TLI & ATG in Patients w/ Cutaneous T Cell Lymphoma	No Results Available	Mycoses Sezary Syndrome Lymphoma, T-Cell, Cutaneous Bone Marrow Transplant Failure Lymphoma, Non-Hodgkin Cutaneous T-cell Lymphoma	Drug: anti-thymocyte globulin Drug: cyclosporine	Stanford University School of Medicine, Stanford, California, United States	https://ClinicalTrials.gov/show/NCT00896493
84	Scleroderma Treatment With Autologous Transplant (STAT) Study	No Results Available	Biological: Anti-Thymocyte Globulin Procedure: Autologous Hematopoietic Stem Cell Transplantation Drug: Cyclophosphamide Biological: Filgrastim Other: Laboratory Biomarker Analysis Drug: Mycophenolate Mofetil Procedure: Peripheral Blood Stem Cell Transplantation Drug: Plerixafor Other: Quality-of-Life Assessment Other: Questionnaire Administration	City of Hope Comprehensive Cancer Center, Duarte, California, United States UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States University of Colorado, Denver, Colorado, United States Colorado Blood Cancer Institute, Denver, Colorado, United States Boston Medical Center, Boston, Massachusetts, United States Boston University School of Medicine, Boston, Massachusetts, United States University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States Hospital for Special Surgery, New York, New York, United States Weill Medical College of Cornell University, New York, New York, United States Duke University Medical Center, Durham, North Carolina, United States MD Anderson Cancer Center, Houston, Texas, United States The University of Texas Health Science Center, Houston, Houston, Texas, United States Seattle Children's Hospital, Seattle, Washington, United States Fred Hutchinson/University of Washington Cancer Consortium, Seattle, Washington, United States University of Calgary, Calgary, Alberta, Canada Rockyview General Hospital, Calgary, Alberta, Canada	https://ClinicalTrials.gov/show/NCT01413100	
85	Transplantation for Refractory Systemic Lupus Erythematosus (ASSIST)	No Results Available	Systemic Lupus Erythematosus	Procedure: Immunoablation and Autologous Hematopoietic Stem Cell Transplantation	Universitätsmedizin Charité, Berlin, Germany Universitätsklinikum Düsseldorf, Düsseldorf, Germany Universitätsklinikum Essen, Essen, Germany Universitätsklinikum Heidelberg, Heidelberg, Germany Universitätsklinikum Köln, Köln, Germany Universitätsklinikum Mainz, Mainz, Germany Universitätsklinikum Tübingen, Tübingen, Germany Universitätsklinikum Wärszburg, Würzburg, Germany	https://ClinicalTrials.gov/show/NCT00750971
86	BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia or Zoledronic Acid or Methyprednisolone for Active Charcot's Neuroarthropathy of Foot in Patients With Diabetes Mellitus	No Results Available	Tetraplegia Spinal Cord Injuries Amyotrophic Lateral Sclerosis Brain Stem Infarctions Locked in Syndrome Muscular Dystrophy	Device: Placement of the BrainGate2 sensor(s) into the motor-related cortex	Stanford University School of Medicine, Stanford, California, United States Massachusetts General Hospital, Boston, Massachusetts, United States Case Western Reserve University, Cleveland, Ohio, United States Providence VA Medical Center, Providence, Rhode Island, United States	https://ClinicalTrials.gov/show/NCT00912041
87	Single Dose rATG for Renal Allograft Rejection	No Results Available	Charcot Arthropathy Diabetes Mellitus	Drug: Zoledronic Acid Drug: Methyprednisolone Drug: Placebos	Department of Endocrinology, PGIMER, Chandigarh, India	https://ClinicalTrials.gov/show/NCT03289338
88	Single Dose rATG for Renal Allograft Rejection	No Results Available	Acute (Cellular) Renal Allograft Rejection	Drug: rATG	Houston Methodist Hospital, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT02102854
89	HATG+C5A vs HATG+C5A+Eltrombopag for SAA	No Results Available	Severe Aplastic Anemia	Drug: HATG Drug: C5A Drug: Eltrombopag	Hopital Jean Minjoz, Besancon, France Hôpital Haut-Léonard, Bordeaux, France Hôpital Huriez, Lille, France Centre Hospitalier Lyon-Sud, Lyon, France Institut Paoli Calmettes, Marseille, France St. Louis Hospital, Paris, France Pontchaillou Hospital, Rennes, France Hôpital Purpan, Toulouse, France Uniklinik RWTH Aachen, Aachen, Germany Universitätsklinikum Essen, Essen, Germany Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany Hannover Medical School, Hannover, Germany University of Ulm, Ulm, Germany Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy Istituto G. Gaslini children's Hospital, Genova, Italy San Martino Hospital, Genova, Italy Fondazione IRCCS Ca Granda Ospedale, Milan, Italy Ospedale San Raffaele, Milan, Italy Federico II Medical School, Naples, Italy La Sapienza University Hospital, Rome, Italy Policlinico Gemelli, Rome, Italy AOU Città della Salute e della Scienza di Torino, Turin, Italy UMC, Amsterdam, Netherlands UMCG, Groningen, Netherlands Leiden University Medical Center, Leiden, Netherlands UMCU, Utrecht, Netherlands Hospital Universitari Germans Trias i Pujol, Badalona, Spain Institut Català d'Oncologia - Hospital Duran i Reynals, Barcelona, Spain Hospital Clinico San Carlos, Madrid, Spain Hospital Virgen de la Victoria, Malaga, Spain Donostia Hospital, San Sebastian, Spain Hospital La Fe, Valencia, Spain University Hospital Basel, Basel, Switzerland University Hospital Bern, Bern, Switzerland University Hospital Zürich, Zürich, Switzerland City Hospital, Belfast, United Kingdom St. James Hospital, Leeds, United Kingdom King's College Hospital, London, United Kingdom St. Bartholomew's Hospital, London, United Kingdom City Hospital, Nottingham, United Kingdom	https://ClinicalTrials.gov/show/NCT02099747
90	Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization	No Results Available	Staphylococcus Aureus	Biological: NDV-3A Biological: Placebo	Fort Benning, Fort Benning, Georgia, United States	https://ClinicalTrials.gov/show/NCT03455309

Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)	No Results Available	Severe Aplastic Anemia	Drug: Antithymocyte Globulin (ATG) [Drug: Fludarabine] [Drug: Cyclophosphamide] [Radiation: Total Body Irradiation (TBI)] [Procedure: Haplo HSCT] [Drug: Tacrolimus] [Drug: Mycophenolate mofetil (MMF)] [Drug: G-CSF]	City of Hope National Medical Center, Duarte, California, United States Children's Hospital of Los Angeles, Los Angeles, California, United States Stanford Hospital and Clinics, Stanford, California, United States Children's National Medical Center, Washington, District of Columbia, United States University of Florida College of Medicine, Gainesville, Florida, United States Miami Children's Hospital, Miami, Florida, United States All Children's Hospital, Saint Petersburg, Florida, United States H. Lee Moffitt Cancer Center, Tampa, Florida, United States Northside Hospital, Atlanta, Georgia, United States Indiana University Medical Center/Riley Hospital for Children, Indianapolis, Indiana, United States University of Louisville/Kosair Children's Hospital, Louisville, Kentucky, United States Johns Hopkins University, Baltimore, Maryland, United States University of Michigan Medical Center, Ann Arbor, Michigan, United States Karmanos Cancer Institute/Children's Hospital of Michigan, Detroit, Michigan, United States Children's Mercy Hospital and Clinics, Kansas City, Missouri, United States Washington University/Barnes Jewish Hospital, Saint Louis, Missouri, United States Hackensack University Medical Center, Hackensack, New Jersey, United States Roswell Park Cancer Institute, Buffalo, New York, United States Duke University Medical Center, Durham, North Carolina, United States Oregon Health and Science University, Portland, Oregon, United States Penn State College of Medicine/The Milton S. Eshelby Medical Center, Hershey, Pennsylvania, United States University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States University of Texas/MD Anderson Cancer Center, Houston, Texas, United States Texas Transplant Institute, San Antonio, Texas, United States Fred Hutchinson Cancer Research Center, Seattle, Washington, United States Children's Hospital of Wisconsin/Midwest Children's Cancer, Milwaukee, Wisconsin, United States	https://ClinicalTrials.gov/show/NCT02918292
PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease	No Results Available	Hematopoietic Stem Cell Transplantation	Drug: ATG [Drug: CTX] [Drug: Mycophenolate Mofetil]	Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China Guangzhou First People's Hospital, Guangzhou, Guangdong, China Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China Xiangya Hospital, Central South University, Changsha, Hunan, China Chenzhou First People's Hospital, Chenzhou, Hunan, China Peking University People's Hospital, Beijing, China	https://ClinicalTrials.gov/show/NCT03689465
Cord Blood (CB) Ex-vivo Mesenchymal Stem Cell (MSC) Expansion + Fluocytlation	No Results Available	Hematopoietic Lymphoid Cancer	Drug: Busulfan [Drug: Rituximab] [Drug: ATG] [Drug: Fludarabine] [Drug: Clofarabine] [Radiation: Total Body Irradiation] [Procedure: Cord Blood Transplant] [Drug: Mycophenolate mofetil] [Drug: Tacrolimus] [Drug: Filgrastim-snda] [Drug: Melphalan] [Drug: Cyclophosphamide] [Drug: Mesna]	University of Texas MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT03096782
Personalized Natural Killer (NK) Cell Therapy in Cord Blood Transplantation (CBT)	No Results Available	Leukemia Lymphoma Myeloma Myeloproliferative Diseases	Drug: Busulfan [Drug: Fludarabine] [Drug: Clofarabine] [Drug: Rabbit ATG] [Radiation: Total Body Irradiation (TBI)] [Procedure: Cord Blood Infusions] [Drug: Rituximab] [Drug: Cyclophosphamide] [Procedure: Natural Killer Cell Infusion] [Drug: Melphalan] [Drug: Mesna]	University of Texas MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT02727803
Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies	No Results Available	Leukemia	Drug: Busulfan [Drug: Fludarabine] [Procedure: Alloreactive NK infusion] [Drug: Interleukin-2] [Procedure: Stem Cell Infusion] [Drug: G-CSF] [Drug: Tacrolimus] [Drug: Methotrexate]	University of Texas MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT01823198
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies	No Results Available	Lymphoma Leukemia	Drug: CMC-544 [Drug: Fludarabine] [Drug: Bendamustine] [Drug: Rituximab] [Procedure: Allogeneic Stem Cell Transplantation] [Drug: Thymoglobulin] [Drug: Tacrolimus] [Drug: Methotrexate] [Drug: G-CSF]	University of Texas MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT01664910
Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas	No Results Available	Lymphoma	Drug: Gemcitabine [Drug: Clofarabine] [Drug: Busulfan] [Procedure: Stem Cell Infusion] [Drug: Anti-Thymocyte Globulin] [Drug: Rituximab] [Drug: Filgrastim] [Drug: Tacrolimus] [Drug: Mycophenolate Mofetil]	University of Texas MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT01701986